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1. Summary 
Acetylation is a very critical posttranslational modification in vivo. Targeting lysine 
residues of various proteins crucially modulates protein functions and interactions. The 
inhibitors of histone deacetylases are promising anticancer drugs – currently in clinical 
testing. We could show that the treatment of cells with these histone deacetylase inhibitors 
is able to modulate cell fate by enhancing conditions that trigger apoptosis by two distinct 
mechanisms. 
Firstly, VPA and co-treatment with the chemotherapeutic agent HU induce expression 
of the pro-apoptotic BH3-only protein BIM. The enhanced BIM expression arises from an 
increase in transcription of the BIM gene in an AP1-dependent manner. This effect occurs in 
cultured cells and in primary head and neck cancer cells from patients. We observed that the 
effect of apoptosis induction following treatment is mainly dependent on the level of BIM 
protein. This suggests that this therapy might be useful in the clinic. 
Secondly, incubation of cancer cells with various histone deacetylase inhibitors 
reduces expression of the class III deacetylase SIRT1. SIRT1 carries out various cellular 
functions including stress responses and metabolic regulation. During stress conditions, 
SIRT1 expression is enhanced favouring cell survival by inhibiting apoptosis. We could show 
for the first time that inhibitors of the classical protein deacetylases (class I, II and IV), that 
do not target class III enzyme activity, unexpectedly target the class III deacetylase SIRT1 by 
decreasing its protein levels. The reduced SIRT1 protein amount upon inhibitor treatment is 
due to changes in SIRT1 mRNA stability. The mRNA binding protein HuR is responsible for 
this effect. Histone deacetylase inhibitor treatment reduces the cytosolic amount of HuR. 
Additionally, its binding affinity for SIRT1 mRNA decreases significantly leading to SIRT1 
mRNA decay. Furthermore, we identified three novel phosphorylation sites within HuR upon 
inhibitor treatment. Conceivably, these trigger the changed characteristics of HuR towards 
SIRT1 mRNA. The loss of SIRT1 upon histone deacetylase inhibitor treatment leads to 
enhanced sensitivity of cell towards apoptotic stimuli. 
Enhancing conditions of hyperacetylation in cancer cells triggers an adaptation of the 
cellular proteome favouring cell death and sensitivity of cancer cells towards further 
therapeutics. In sum this work provides valuable information for the treatment of cancer 
cells with histone deacetylase inhibitors in combination with other chemotherapeutics. 
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2. Zusammenfassung 
Als posttranslationale Modifikation spielt die Acetylierung in vivo eine entscheidende Rolle. Die 
Neutralisierung positiver geladener Lysinreste verschiedenster Proteine kann deren Funktion sowie 
die Interaktion mit anderen Proteinen entscheidend beeinflussen. Die Inhibitoren der 
Proteindeacetylasen sind vielversprechende Chemotherapeutika die sich momentan in klinischen 
Studien befinden. Wir konnten zeigen, dass die Behandlung von Krebszellen mit diesen Hemmstoffen 
im Stande ist, den apoptotischen Zelltod durch zwei verschiedene Mechanismen zu verstärken. 
Zum einen induziert der Deacetylaseinhibitor VPA zusammen mit dem Chemotherapeutikum 
HU die Transkription und letztendlich die Expression des pro-apoptotischen Proteins BIM. Dieser 
Effekt ist sowohl in kultivierten Zellen als auch in primären Kopf und Hals-Tumorzellen von Patienten 
nachweisbar. Die apoptoseinduzierende Wirkung der Inhibitorgabe ist vorwiegend von der Menge 
des zellulären BIM Proteins abhängig. Dies gibt Hinweise auf die klinische Bedeutung dieser Therapie. 
Ebenso reduziert die Inkubation mit verschiedenen Histondeacetylaseinhibitoren die 
Expression der Klasse III Deacetylase SIRT1 in verschiedenen Krebszelllinien. SIRT1 moduliert viele 
verschiedene Zellfunktionen einschließlich Apoptose und Stoffwechsel. Unter Stress wird die SIRT1 
Expression erhöht und damit das Zellüberleben durch eine Hemmung der Apoptose gesichert. Wir 
konnten zum ersten Mal zeigen, dass Inhibitoren der klassischen Proteindeacetylasen (Klasse I, II und 
IV), welche nicht die Aktivität der Klasse III beeinflussen, dennoch die Klasse III Deacetylase SIRT1 ins 
Visier nehmen durch eine Verminderung der SIRT1 Proteinmenge. Die inhibitorinduzierte Reduktion 
der SIRT1 Proteinlevel ist auf eine Änderung der SIRT1 mRNA-Stabilität zurückzuführen. Hierfür 
scheint das mRNA-bindende Protein HuR verantwortlich zu sein. Eine Histondeacetylaseinhibitor-
Behandlung reduziert den cytosolischen Anteil von HuR. Der SIRT1 mRNA Abbau wird 
höchstwahrscheinlich durch den Verlust der Bindungsaffinität von HuR gegenüber der SIRT1 mRNA 
ausgelöst. Zusätzlich identifizierten wir drei bisher unbeschriebene hemmstoffinduzierte 
Phosphorylierungsstellen innerhalb von HuR. Es ist denkbar, dass diese Veränderungen die HuR-
Charakteristika in Bezug auf die SIRT1 mRNA bedingen. Der Verlust von SIRT1 nach 
Inhibitorbehandlung erhöht die Zellsensitivität gegenüber apoptoseauslösenden Bedingungen. 
Die Induktion der Hyperacetylierung in Krebszellen moduliert das zelluläre Proteom 
dahingehend, dass es Apoptose fördert und Krebszellen gegenüber weiteren Einflüssen sensibilisiert. 
Zusammenfassend bietet diese Arbeit wertvolle Grundlagen für die erfolgreiche Behandlung von 
Krebszellen mit Histondeacetylase-Inhibitoren in Kombination mit anderen Chemotherapeutika. 
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3. INTRODUCTION 
3.1. Acetylation as an important posttranslational modification 
The classical 20 amino acids are the building blocks of every eukaryotic protein. They 
cover a wide variety of chemical characteristics providing the basis for different structures. 
Protein structures depend on hydrogen bonds, van der Waals forces, ionic and hydrophobic 
interactions. The resulting secondary, tertiary and quaternary structures define the 
functionality of all cellular proteins.  
Protein functions are modulated by protein amounts 
and the abundance of co-factors as well as by 
posttranslational modifications. For example, serine or 
threonine residues are phosphorylated by kinases. 
Furthermore, lysine residues can be modified by 
acetylation, (mono-, di- and tri-) methylation, 
ubiquitination, sumoylation and neddylation (see Figure 1). 
These sometimes competing modifications alter the 
structure of the lysine moiety. At physiological pH, 
unmodified lysine residues are protonated and positively 
charged. The addition of acetyl groups neutralises the 
charge and also creates a novel surface for protein 
interactions. In the past, critics stated that only a limited or 
specialized number of proteins become acetylated and that 
biologically important acetylation sites of low abundance 
remain undetected because of a large background of non-
acetylated proteins (Choudhary et al., 2009). Now, more 
robust techniques open new possibilities to identify protein 
targets for acetylation. One approach is to purify acetylated proteins by an acetylation-
specific antibody and to further identify acetylated peptides by mass spectrometry (Kim et 
al., 2006). Recently, Choudhary et al. identified more than 3600 acetylation sites in 1750 
proteins. This approach raised the number of known acetylated proteins extremely. In 
comparison this the size of the phosphoproteome and suggests that acetylation can similarly 
Figure 1 Lysine modifications. 
Lysine residues are subject to 
posttranslational modifications with 
varying functional consequences. 
Switching between modifications 
allows to alter protein function. 
(Spange et al., 2009) 
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affect protein characteristics (Choudhary et al., 2009; Cohen and Yao, 2004; Olsen et al., 
2006 Yang, 2008 #78).  
Histones condense DNA in the nucleus. Since these 
proteins were the first identified acetylated proteins, 
acetylation was only considered in the context of histone 
modification and transcriptional control. Indeed, acetylating 
und deacetylating enzymes are important transcriptional co-
activators and co-repressors (Xu et al., 1999). Nonetheless, 
the discovery of an increasing number of acetylated non-
histone proteins and the finding that acetylation-modifying 
enzymes exert crucial functions outside of the nucleus, 
revealed much broader regulatory potentials for reversible 
acetylation. Depending on the cellular compartment (nucleus, 
cytosol and mitochondria), motifs for acetylation differ 
extremely (Choudhary et al., 2009). The classic motif for 
acetylation is the conserved LxxLL motif whereby adjacent 
lysine residues are targeted. The reason for this could be a 
different subset of acetylases and deacetylases recognising 
different sets of substrates. 
Figure 3: Domain architecture of 
acetylated proteins.  
blue bars = protein families and domains 
that are significantly overrepresented; 
red bars = underrepresented domains in 
the acetylome as compared with those in 
the entire proteome; yellow + orange 
striped bars = cytoplasmic domains 
(Choudhary et al., 2009). 
 
 
 
 
 
Figure 2 Acetylation motifs in different 
subcellular compartments Sequence 
logo plots represent normalized amino 
acid frequencies for ±6 amino acids 
from the lysine acetylation site (Olsen 
et al., 2006). 
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Additionally, the architecture of acetylated proteins shows that certain domains are 
overrepresented in acetylated proteins (Choudhary et al., 2009) (see Figure 3). These 
acetylation events might be important for the assembly of multiprotein machineries and for 
specific cellular functions. Figure 3 indicates that proteins containing RNA recognition motifs 
show a prevalence for acetylation.  
The regulatory power of the acetylome is further amplified through its crosstalk with 
other modifications, including phosphorylation of serine, threonine or tyrosine residues (S/T-
P) and other lysine-based modifications (K-X), where X can be ubiquitination, methylation, 
neddylation, or sumoylation (Norris et al., 2009). Several networks, relying on acetylation, 
phosphorylation and others, interact with each other (see figure 2). Taken together, all this 
demonstrates that complex networks of posttranslational modifications can modulate 
protein functions. This observation raises the question how these modifications interact with 
each other and form dynamic programmes regulating cellular fate. However, there is no 
unified consequence of protein acetylation. The outcome is always context-dependent and 
needs to be elucidated for every single protein. Therefore, the impact of acetylation can only 
be deciphered experimentally. 
 
Figure 4 The acetylome undergoes dynamic 
changes in response to cell signalling, 
stress, metabolic demands, and HDAC 
inhibitor (HDACi) treatment (Norris et al., 
2009). 
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3.1.1 Protein acetylases and –deacetylases 
The dynamics of protein acetylation are regulated by the opposing enzymatic activities 
of protein acetylases (HATs) and protein deacetylases (HDACs). Due to their first identified 
substrates, the protein deacetylases are also named histone deacetylases. The more correct 
term would be lysine or protein deacetylase. Since the discovery of the first HAT enzyme, the 
yeast Hat1 (Kleff et al., 1995), a lot of attention has been drawn to these enzymes. HATs are 
evolutionarily conserved from yeast to man and form multiple subunit complexes (Kimura et 
al., 2005). In mammals, over 30 HATs display distinct substrate specificities for histones and 
non-histone proteins. HATs mainly exerting transcription-related acetylation are grouped 
into five families: GNAT, MYST, p300/CBP, basal/general transcription factors and nuclear 
receptor cofactors (Roth et al., 2001). CBP and p300 are the most intensively studied HATs 
and are often found within the same complexes. Apparently, p300 seems to have the 
broadest spectrum of substrates which includes histones as well as non-histone proteins 
(Kimura et al., 2005).  
The deacetylase super family is much more homogenous then the HAT family. HDACs 
are grouped into two distinct families. The “classical family” of zinc-dependent HDACs is 
structurally related to the yeast Hda1/Rpd3 proteins (de Ruijter et al., 2003). The second 
family, the sirtuins, consists of the NAD+-dependent yeast Sir2 homologues (Haigis and 
Guarente, 2006). Histone deacetylases are further grouped into four classes according to 
their phylogenetic conservation (Gregoretti et al., 2004). Class I, II and IV HDACs are 
members of the classical HDAC family. Class I HDACs (HDAC1, HDAC2, HDAC3 and HDAC8) 
are orthologues of the yeast Rpd3 enzyme. The yeast Hda1 homologues represent the 
mammalian class II HDACs that can be subdivided into class IIa (HDAC4, HDAC5, HDAC7 and 
HDAC9) and class IIb (HDAC6 and HDAC10). Class IIa HDACs does not seem to exert HDAC 
activity (Fischle et al., 2002). It is suggested that any HDAC activity associated with these 
proteins reflects co-purification of class I HDACs. The main difference between those two 
subgroups relies on their catalytic centre. Whereas class I possesses a Tyr moiety, class IIa 
harbours a His residue at the corresponding site. The important role for this moiety is 
demonstrated by the fact that an amino acid substitution in the catalytic centre of class IIa 
HDACs unleashed a ~1000 fold increase in class IIa catalytic activity compared to their wild 
type counterparts (Lahm et al., 2007). HDAC11 shares equal sequence conservation with 
Introduction 
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Rpd3 and Hda1, and is therefore grouped as the currently solitary member into class IV (Gao 
et al., 2002). Homologues of yeast Sir2, SIRTs, represent the class III deacetylases, which are 
termed sirtuins in mammals (SIRT1 to 7) (Yang and Seto, 2008). An overview of the domain 
structures of all mammalian protein deacetylases is shown in Figure 5. 
 
 
Figure 5: Members of the histone deacetylase superfamily and inhibitors 
The classical HDACs in class I, II and IV and the sirtuins (class III) all contain a deacetylase domain (red). The size of the 
protein, denoted in amino acids, is stated next to the protein name. Known inhibitors for single HDAC and HDAC 
subgroups are depicted at the right side (Lichtman M., 2005). 
 
3.1.2 Protein deacetylases as chemotherapeutic targets 
The impact of acetylation on critical regulators of cell signalling and cell fate is 
enormous. Many diseases show abnormal gene expression. These changes may be corrected 
by targeting the enzymes that catalyse acetylation/deacetylation processes  
Hence, this predestines HDACs and HATs, which dynamically target the acetylome, as 
drug targets in cancer and neurodegenerative diseases, such as Parkinson’s and Alzheimer’s 
disease. Currently, more than 100 clinical trials assess the efficacy of HDACi in a clinical 
setting (Bolden et al., 2006; Garber, 2007; Kazantsev and Thompson, 2008; Müller and 
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Krämer, 2010; Xu et al., 2007). The HDACi suberoylanilide hydroxamic acid (SAHA) is in 
clinical use against the cutaneous T cell lymphoma (CTCL). Of note, drugs used successfully in 
therapeutic settings for different diseases proved to have HDACi activity. For example, 
valproic acid (VPA), used in the treatment of epilepsy, bipolar disorder, and less 
commonly major depression is able to inhibit class I and IIa HDACs. Moreover, Methotrexate, 
which is used for treating human cancers, inhibits HDAC1 and 2 as well as overall HDAC 
activity, increasing histone acetylation (Yang et al., 2010). 
How HDACi achieve therapeutic effects is an area of ongoing research. The ability to 
identify "acetylation targets" of HDACi could potentially provide a window into the 
understanding of acetylation events relevant to therapeutic activity. In many cases the 
relevance of these drugs in the fight against cancer still awaits the results of phase III trials. 
Moreover, HDAC inhibitors are potent reprogramming agents for the generation of 
pluripotent stem cells (Huangfu et al., 2008).  
3.2 SIRT1  
Our metabolism eventually degrades fatty acids, carbohydrates and proteins to a 
single and versatile intermediate, acetyl-CoA. This same intermediate is also used during the 
modification of proteins at their lysine residues known to regulate gene expression. 
Therefore, acetylation and NAD+-dependent deacetylation emerged as directly connecting 
the intracellular energy state and cellular fate (Finkel et al., 2009). The NAD+-dependent 
sirtuin deacetylases are homologs of the Sir2 gene in S. cerevisiae. In sum, the activity of the 
sirtuin family is linked to the metabolic state of the cell.  
Among the homologs of the yeast Sir2 protein, SIRT1 is the best-characterised member 
in humans. The seven human sirtuins are distributed in the whole cell with SIRT1, 6 and 7 
being in the nucleus, SIRT2 in the cytosol and SIRT3, 4 and 5 in the mitochondria (Michishita 
et al., 2005). While the classical HDACs only perform deacetylating reactions, some members 
of the sirtuin family (SIRT1, 2, 4 and 6) can use NAD+ to ADP-ribosylate target proteins. The 
ADP-ribosylation activity of several sirtuins is >1000-fold lower than their deacetylation 
activity, therefore the physiological relevance of the ADP-ribosylation activity is not clear (Du 
et al., 2009). An overview of localisation, substrates and functions of different sirtuins can be 
seen in Table 1 
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Table 1: Overview: localisation, substrates and proposed function of the human sirtuins (based on Frojdo et al., 2008; 
Haigis and Sinclair, 2010; Kong et al., 2009; Lavu et al., 2008) 
3.2.1 SIRT1 functions 
SIRT1 can deacetylate proteins in the presence of its cofactor nicotinamide adenine 
dinucleotide (NAD+). Hereby, it catalyzes the conversion of NAD+ and acetylated lysine to 
nicotinamide, 2'-O-acetyl-ADP-ribose (OAADPr) and the deacetylated lysine (see Figure 6). Of 
note, it is the only sirtuin in the nucleus with a reasonable deacetylase activity (Michishita et 
al., 2005). 
Next to its histone targets (mainly histone H3(K9 & K14), histone H4(K16) (Imai et al., 
2000) and the linker histone H1 (Vaquero et al., 2004)) SIRT1 deacetylates many non-histone 
proteins (see Table1 for details) (Lavu et al., 2008). Through its multitude of intracellular 
targets, SIRT1 regulates epigenetic gene silencing, DNA repair and recombination, apoptosis, 
cell cycle and senescence, microtubule organisation as well as fat and glucose metabolism.  
In sum, SIRT1 activities provide stress resistance and cell survival, which in turn could 
play crucial roles in processes like neuroprotection, inflammation, and longevity as well as in 
cancer development (Anekonda and Reddy, 2006; Baur et al., 2006; Labinskyy et al., 2006; 
Michan and Sinclair, 2007; Saunders and Verdin, 2007).  
  Localisation Substrates Function 
SIRT1 Nucleus/ 
Cytoplasm 
histones H1/H3/H4, p53, FOXO proteins, 
NFκB, KU70, MyoD, CBP, COUP-TF, CTIP2, 
NCoR, p300, BCL6, BCL11A, PGC1α, 
MEF2D, eNOS, ACS1, E2F1, AR, p73, 
SMAD7, NBS1, RB, TLE1, IRS2, LXR, AROS, 
HIC1, SUV39H1, WRN, DBC1, TORC2, 
AceCS1, HIV-Tat, HSF-1, NBS1, PCAF, 
PPARγ, TAF I68 
stress regulation, genome 
integrity, DNA repair, longevity, 
senescence, apoptosis, 
metabolism, inflammation, 
neuroprotection 
SIRT2 Cytoplasm, 
Nucleus 
histone H4, α-Tubulin cell cycle, genome integrity 
SIRT3 Mitochondria histone H4, AceCS2 Acetyl-Co-synthesis, 
thermogenesis, longevity 
SIRT4 Mitochondria GDH insulin secretion 
SIRT5 Mitochondria N/A N/A 
SIRT6 Nucleus DNA-Pol β DNA repair 
SIRT7 Nucleoli RNA-Pol I Ribosomal RNA-transcription 
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Figure 6: Proposed enzymatic mechanism of SIRT1 deacetylase activity  
Acetyl-lysine substrate and NAD+ bind to SIRT1 - forming a ternary complex. After binding, the reaction proceeds and 
releases nicotinamide. The O-alkylamidate intermediate is then hydrolyzed through multiple steps to form a product 
complex from which deacetylated-lysine product and O-acetyl-ADP-ribose are released. (Smith and Denu, 2006) 
 
In yeast, the Sir2 protein links the energy status of the cell directly to longevity. One 
hypothesis of ageing mechanisms in yeast suggests that extrachromosomal ribosomal DNA 
circles accumulating in the mother cell by inadvertent recombination cause senescence. 
Increased SIRT1 activity in turn suppresses recombination of rDNA by compacting its 
chromatin structure (Guarente, 2000). Therefore, caloric restriction (CR) can interfere with 
senescence via increasing Sir2 activity by an altered NAD+/NADH ratio.  
In mammals, SIRT1 is also thought to play a role in CR-associated longevity. Activated 
SIRT1 modulates many aspects of glucose and lipid homeostasis by deacetylating key 
metabolic molecules like PPARγ, PGC-1α, IRS-2, CRTC2, UCP-2, AceCS1, STAT3 and TORC2, 
showing its pivotal role in the regulation of metabolism (see Figure 7). The deacetylation of 
PGC1α by SIRT1 activates its transcriptional activity and thus induces the expression of 
target genes involved in gluconeogenesis and fatty acid oxidation. Deacetylation of FOXO1 
also increases its transcriptional activity and promotes the expression of gluconeogenic 
genes in the liver, of insulin in the pancreas, and of adiponectin in adipose tissues preventing 
illnesses like diabetes mellitus. Therefore, SIRT1 is often linked to the positive effects of 
restricted calorie intake not only due to its NAD+-dependency. Hence, its action is associated 
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with extending lifespan and improving health and survival (Baur et al., 2006; Cohen et al., 
2004b; Lavu et al., 2008; Yu and Auwerx, 2009).  
Besides its metabolic functions, SIRT1 triggers cell survival under stress conditions by 
multiple targets. SIRT1 is the main deacetylase of p53. In its deacetylated state the ability of 
p53 to trans-activate target genes (e.g. p21, Bax) is attenuated (Luo et al., 2001; Vaziri et al., 
2001). 
 
Figure 7 SIRT1 affects  
inflammatory responses, insulin 
secretion, hepatic metabolism of 
glucose and lipids, adipogenesis and 
adiponectin secretion, mitochondrial 
homeostasis and ROS levels, the 
insulin signalling pathway, and 
myogenesis (Liang et al., 2009).  
 
In addition to p53, p73 is a SIRT1 target, both proteins mediate the cellular response to 
genotoxic stress and thus SIRT1 is a critical regulator of cells exposed to environmental and 
chemotherapeutic stimuli (Yang et al., 2007). SIRT1-mediated deacetylation of the DNA 
repair-associated Ku70 activates DNA repair processes and inhibits Bax-induced apoptosis 
(Cohen et al., 2004b). Moreover, SIRT1 deacetylates several proteins of the FOXO (FOXO1, 
3a, 4 and 6) transcription factor family. Non-acetylated FOXO proteins are no longer active. 
Consequently, a downregulation of FOXO transcriptional targets like the pro-apoptotic BIM 
and an upregulation of the stress response gene GADD45 occurs in cells (Brunet et al., 2004). 
Promoting cell survival by these various mechanisms favours a central role of SIRT1 as stress 
regulator. 
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3.2.2 SIRT1 and cancer 
The role of SIRT1 in cancer is discussed controversially. It enables cells to survive 
stressful conditions by the modulation of signalling pathways promoting apoptosis or 
autophagy. Some kinds of cancer seem to depend on high SIRT1 levels favouring cell growth 
and survival. Conceivably, a wide variety of solid tumours and leukaemias exhibit increased 
SIRT1 expression compared to healthy tissue (Bradbury et al., 2005; Chang et al., 2009; Chen 
et al., 2005; Hida et al., 2007; Jung-Hynes et al., 2009; Kuzmichev et al., 2005; Lim, 2006; 
Mariadason, 2008). Overexpression of this protein can be relevant for oncogenesis and 
chemotherapeutic responses. For example, a glioblastoma-derived cell line overexpresses 
SIRT1 and a knockdown of SIRT1 in these cells effectively enhanced radiosensitivity and 
apoptosis in vivo and in vitro. Additionally, other hallmarks of cancer cells decreased, 
including cell migration ability, tumour volume and colony formation resulting in enhanced 
survival of mice bearing the tumour (Chang et al., 2009). Another common hallmark of 
human cancers notably is the loss of histone H4 Lys16 acetylation, whereby SIRT1 is the 
major deacetylase of H4 Lys16 (Fraga et al., 2005). Therefore, enhanced SIRT1 activity can be 
linked to the loss of site-specific deacetylation (Hajji et al., 2010).  
On the other hand, enhanced SIRT1 expression showed a promoting effect on tumour 
development and maintenance in a β-catenin-driven mouse model (Firestein et al., 2008). In 
another tumour cell model a strong expression of SIRT1 is associated with a deregulation of 
pRb1 signalling that promotes cell growth and inhibits apoptosis (Hida et al., 2007; Wang et 
al., 2006). Moreover, SIRT1 overexpression epigenetically silences tumour suppressor genes, 
like E-cadherin, SFRP1/2, CRB1 and MLH1. As a consequence SIRT1 inhibition induces re-
expression of the stated genes without changing their promoter DNA methylation status 
(Pruitt et al., 2006). SIRT1 even affects the multidrug resistance of tumours. SIRT1 also 
regulates the expression of the multidrug resistance 1 (MDR1) gene. Thereby, it can promote 
chemo-resistance linked to poor prognosis (Chu et al., 2005). Overexpressed SIRT1 
additionally seems to increase the expression of telomerase, which extends chromosome 
ends and thereby blocks cellular senescence (Lin and Elledge, 2003). 
SIRT1 is suitable as a therapeutic target because it can affect multiple critical pathways 
causally linked to human diseases. Both inhibitors and activators of SIRT1 could be of benefit 
for patients depending on the individual disease and perhaps also on its specific stage. 
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Targeting SIRT1 activity can be seen as a double-edged sword – to lose or overexpress SIRT1 
under normal conditions is unfavourable. Under pathological conditions, SIRT1 activators are 
favourable in the therapy of metabolic diseases. Small molecule inhibitors of SIRT1 are rated 
as novel anti-cancer agents, especially by inducing senescence-like growth arrest and a 
strong pro-apoptotic effect in cancer cells (Heltweg et al., 2006; Lara et al., 2009; Mai et al., 
2005; Olaharski et al., 2005).  
3.3 SIRT1 regulation 
As a key regulator of cellular signalling, SIRT1 is tightly controlled. In recent years, a 
complex regulatory network controlling SIRT1 actions emerged. Various stress-signalling 
pathways regulate SIRT1 at multiple steps including transcription, mRNA stability, 
translation, posttranslational modifications and recruitment of binding partners as well as 
cofactors.  
3.3.1 Transcriptional regulation of SIRT1 
The expression of the SIRT1 gene is controlled by various external stimuli, including 
upregulation via starvation, caloric restriction, oxidative stress and DNA damage or 
downregulation by hypoxia. The SIRT1 promoter comprises a small CpG island (350 bp) and 
numerous transcription factor binding sites. Additionally, SIRT1 regulates its own 
transcription. Known transcriptional regulators of the SIRT1 promoter include p53, E2F1, 
FOXO3A and the HIC1–CtBP repressor complex. SIRT1 associates with all of these factors and 
regulates their activity via deacetylation resulting in a feedback mechanism.  
The tumour suppressor p53 functions as a repressor for the SIRT1 promoter. In the 
absence of nutrients, SIRT1 transcription is induced through nuclear translocation of 
FOXO3a, which interacts with p53 and thereby inhibits the suppressive activity of p53 
(Nemoto et al., 2004; Zschoernig and Mahlknecht, 2008). The transcription factor HIC1 
(hypermethylated in cancer 1) represses SIRT1 expression via SIRT1-HIC1 complexes. In 
cancer cells as well as during ageing the HIC1 promoter is hypermethylated and thereby 
epigenetically silenced. Loss of HIC1 might promote tumourigenesis by upregulation of SIRT1 
(Bzduch and Behulova, 1992; Chen et al., 2005; Lim, 2007; Milner, 2009) and might be causal 
or the aberrantly high promoter activity of SIRT1 in tumour cells (Okazaki et al., 2010; 
Zschoernig and Mahlknecht, 2008) (see Figure 8). 
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3.3.2 Posttranslational regulation of SIRT1 
The posttranslational regulation of SIRT1 involves modifications of SIRT1 as well as 
SIRT1 binding factors that modulate its activity.  
Regulation of SIRT1 enzymatic activity can intrinsically be achieved by phosphorylation 
as well as sumoylation. The three JNK1-targeted phosphorylation sites S27, S47 and T530 
increase nuclear localization of SIRT1 and its enzymatic activity towards histones (Nasrin et 
al., 2009). Elevated SIRT1 protein levels in cancer cells have recently been attributed to 
SIRT1 protein stability. This is correlated with stress-induced JNK2-dependent SIRT1 
phosphorylation at S27 (Ford et al., 2008). SIRT1 protein stability may also play a role in the 
progressive loss of SIRT1 associated with aging. Comparing mouse embryonic fibroblasts 
(MEFs) of different passages indicates that SIRT1 protein levels, but not SIRT1 mRNA, 
decrease rapidly with increasing cell passages (Sasaki et al., 2006). Immortalisation of these 
cells restored the level of SIRT1 protein to that of early passage MEFs. It could be speculated 
that the phosphorylation status of SIRT1 differs in these cells resulting in a more stable 
SIRT1. Additionally, CK2-dependent phosphorylation of S154, S649, S651 and S683 increases 
SIRT1 binding affinity towards its targets (Kang et al., 2009). So far, no functional role for 
other CK2-targeted sites (S659 & S661) could be detected (Zschoernig and Mahlknecht, 
2009). Alongside SIRT1 phosphorylation, the C-terminal K734 is subject to modification with 
small ubiquitin-related modifier (SUMO). Sumoylation increases SIRT1 activity. When this 
lysine is replaced with an arginine, SIRT1 deacetylase activity towards acetylated p53 and 
p73 is almost completely abolished. DNA damage and oxidative stress promote 
desumoylation of SIRT1 by SENP1 and thereby decrease SIRT1 activity (Yang et al., 2007). 
SIRT1 binding proteins can modulate its enzymatic activity. Recently, DBC1 (deleted in 
breast cancer 1) has been identified as a specific negative SIRT1 regulator. DNA damage and 
oxidative stress-induced binding of DBC1 to SIRT1 suppresses its action and favours p53 
acetylation (Zschoernig and Mahlknecht, 2008). Complementary, an active regulator of SIRT1 
protein (AROS) has been found to directly bind the SIRT1 N-terminus and increase its 
enzymatic activity towards p53 (Kim et al., 2007; Verdin, 2007). So far, it is not known how 
the combination or differential regulation of DBC1 and AROS affects SIRT1 activity. Taken 
together, SIRT1 regulation is complex and protein levels do not necessarily represent SIRT1 
protein activity. 
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3.3.3 Small molecule modulators of SIRT1 
As mentioned above, SIRT1 activity is highly dependent on NAD+-cofactor availability. 
During conditions of caloric excess NAD+-levels can be depleted resulting in inactive SIRT1. 
The same situation can be generated by a strong induction of NAD+ competing enzymes like 
the DNA repair-associated PARP. A massive induction of DNA damage strongly activates 
PARP and depletes NAD+-levels and can therefore inhibit SIRT1 functions and promote cell 
death (Pillai et al., 2005).  
Small molecule activators as well as inhibitors of SIRT1 are considered as therapeutics 
in different disease states. The most prominent SIRT1 activator is the polyphenol resveratrol 
(Howitz et al., 2003). The favourable effects of resveratrol in mammals are attributed to 
increased SIRT1 activity including increased lifespan, protection from obesity in mice placed 
on a high-calorie diet with increased insulin sensitivity and protection from metabolic 
diseases (Baur et al., 2006; Lagouge et al., 2006). Recent results indicate that resveratrol 
indirectly activates SIRT1 (Pacholec et al., 2010; Tang, 2010). Other small molecule activators 
like quercetin, piceatannol are interesting drugs for metabolic diseases showing positive 
effects on glucose homeostasis and insulin sensitivity in obesity mouse models (Guarente, 
2006; Liang et al., 2009). 
On the other hand, SIRT1 inhibitors are more likely to be beneficial in malignant 
disorders. They could mainly be useful for the treatment of cancers by increasing p53 activity 
which induces apoptosis and stops the formation of tumours. Tenovin-6, a SIRT1 and SIRT2 
specific inhibitor, increases p53 acetylation and has been shown to decrease tumour growth 
in vivo as a single agent – potentially providing new therapeutic options (Lain et al., 2008). 
3.3.4 Posttranscriptional regulation of SIRT1  
3.3.4.1 mRNA binding proteins 
The first hint that posttranscriptional regulation is crucial for the control of SIRT1 came 
from the finding that the AU-rich element-binding protein HuR stabilises SIRT1 mRNA. So far, 
no further mRNA binding proteins are known to regulate the SIRT1 mRNA level. The mainly 
nuclear HuR binds to and protects the 3´UTR of SIRT1 mRNA from degradation. Multiple HuR 
binding sites can often be found within one mRNA. Targeting c-fos, c-myc, cox-2, TNF-α, GM-
CSF, β-catenin, eotaxin, p27, cyclin A, cyclin B1, cyclin D1, p21, p27, p53 and SIRT1 mRNA, 
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HuR has been suggested to critically affect cell proliferation, tumourigenesis, senescence and 
stress responses (Abdelmohsen et al., 2007a; Abdelmohsen et al., 2007b). While under 
certain conditions HuR binds closely to one mRNA, it dissociates from another resulting in 
complete destabilization of the transcript (Abdelmohsen et al., 2007b; Wilusz and Wilusz, 
2007).  
An siRNA mediated knockdown of HuR resulted in a complete loss of SIRT1 protein 
(Abdelmohsen et al., 2007b). Therefore, regulation and modulation of HuR function are 
closely related to SIRT1 expression levels. Remarkably, the conformation of HuR’s three RNA 
recognition motifs (RRMs), HuR localisation as well as its phosphorylation state critically 
affect SIRT1 mRNA stability (Abdelmohsen et al., 2007b; Kim et al., 2008a; Wilusz and 
Wilusz, 2007) (see Figure 8).  
Oxidative stress activates checkpoint kinase Chk2 through phosphorylation and 
promotes HuR phosphorylation at S88, S100 and T118. In turn, this results in dissociation of 
the HuR–SIRT1-mRNA complex. Decreased levels of HuR and increased levels of Chk2 
synergize to decrease SIRT1 mRNA and protein levels during senescence (Abdelmohsen et 
al., 2007b). Furthermore, the cell cycle-dependent Cdk1 phosphorylates nuclear HuR at 
S202, leading to its nuclear retention by binding to 14-3-3 proteins. Hence, SIRT1 mRNA 
stability decreases in the G2/M-phase (Kim et al., 2008a).  
3.3.4.2 micro RNAs 
Next to proteins, the role of miRNAs in the regulatory network of mRNA fate attracts 
an increasing number of researchers. These small regulatory RNAs primarily bind within the 
3´UTR of mRNAs. Their grade of complementarity is responsible for the suppressing effect. 
High similarity causes siRNA-like mRNA degradation whereas low sequence similarity inhibits 
translation. 
Several miRNAs targeting the 3´-UTR of SIRT1 mRNA are identified so far: the strongly 
p53-dependent miR-34a (Yamakuchi et al., 2008); the hypoxia related regulator miR-199a 
(Rane et al., 2009); the ageing associated miR-217 (19786632); the nutrition related miR-132 
(Strum et al., 2009); miR-200b/c (Tryndyak et al., 2010) and miR-449a (Lize et al., 2010) (see 
Figure 8). 
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Figure 8: complex regulation of SIRT1 activity 
The promoter of SIRT1 is regulated by various transcription factors including SIRT1 itsself, HIC1, p53 and FOXO3A. 
Additionally, SIRT1 mRNA is regulated by the RNA binding protein HuR and diverse microRNAs. Finally, SIRT protein activity 
is regulated positively and negatively by interacting proteins such as AROS and DBC1 or posttranslational modifications like 
SUMO. 
3.4 BIM 
Another crucial factor in the regulation of apoptosis and consequently in the survival 
of tumour cells is the Bcl-2 protein family member BIM (B cell lymphoma 2 interacting 
mediator of cell death). Defective apoptosis not only promotes tumourigenesis, but also can 
confound chemotherapeutic response. The tumour suppressor BIM has been shown to 
determine cancer cell sensitivity in vivo. 
BIM contains a Bcl-2 homology domain 3 (BH3) characteristic for the BH3 only 
proteins. Like the other members of the Bcl-2 family it forms hetero- and homodimers to act 
as an apoptotic regulator. BIM appears to act as a 'death ligand' which can only neutralize 
certain members of the pro-survival Bcl-2 sub-family (O'Connor et al., 1998). 
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3.4.1 BIM function 
BIM acts as an apoptotic activator dimerised with other Bcl-2 members (e.g. Bcl2, 
Bcl2L1/Bcl-XL, and Mcl1). In healthy unstressed cells BIM binds to microtubules via the LC8 
dynein light chain. Upon stress signalling BIM participates in the permeabilisation of the 
outer mitochondrial membrane. 
 
 
Hereby, pro-apoptotic content is released into the cytoplasm where it activates the 
downstream apoptotic machinery (see Figure 9) (Hendrickson et al., 2008; Youle and 
Strasser, 2008). The intrinsic apoptotic pathway starts with BH3-only protein induction or 
their posttranslational activation resulting in an inhibition of Bcl-2 family members. In turn, 
this activates Bax and Bak activation which promotes apoptosis. Interestingly, some BH3-
only proteins (e.g. BIM, Puma) directly activate Bax and/or Bak. Once activated Bax and Bak 
promote cytochrome c release, which leads to the assembly of Apaf1 into the apoptosome. 
Hereby, caspase 9 becomes activated to cleave and thereby activate downstream 
executioner caspases like caspase 3. Caspases cleave multiple substrates, activate DNases 
and orchestrate the programmed cell death. The extrinsic apoptotic pathway can bypass the 
Figure 9 apoptosis induction 
Apoptosis can be induced by cell 
surface receptors, (Fas, or TNFR1) 
(extrinsic pathway), or by various 
stress/genotoxic agents (intrinsic 
pathway) resulting in the activation of 
caspases (Youle and Strasser, 2008).  
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mitochondrial step and activate caspase 8 directly, which also leads to caspase 3 activation 
(Youle and Strasser, 2008). 
Several drugs, especially chemotherapeutics, target apoptotic pathways or trigger 
apoptosis indirectly to kill cancer cells efficiently. In these cells, growth factor signalling like 
the epidermal growth factor (EGF) pathway is often deregulated. Oncogenic kinase 
mutations affecting the MAPK pathway and the PI3K/Akt pathway can result in a cancerous 
behaviour of cells. Upon induction of this pathway the downstream activation of ERK1/2 
leads to a phosphorylation of numerous cytoplasmic and nuclear substrates involved in cell 
survival and proliferation. ERK-mediated phosphorylation of c-myc, ELK1, and other 
transcription factors favours the expression of growth promoting genes (Wang et al., 2007). 
ERK-mediated phosphorylation of Bcl-2 proteins can inhibit 
apoptosis. 
EGFR inhibitors such as the kinase inhibitor Gefitinib trigger 
apoptosis by inhibition of the downstream Ras-ERK pathway. 
Consequently, BIM is up-regulated, targeting all its pro-survival 
relatives. The apoptotic affect can be further enhanced by the 
addition of the BH3 mimetic ABT-737, which also targets Bcl-2 
and Bcl-XL, enabling Bax to permeabilise the mitochondrial 
membrane. The potential benefit of simultaneously inhibiting 
oncogenic kinases and inhibiting Bcl-2 action is most promising in 
the therapy of solid tumours (Hendrickson et al., 2008). The 
inhibition of BCR-ABL by Imatinib has similar effects (see Figure 
10). The activity of BIM is predominantly regulated by its protein 
level. As mentioned above, Ras signalling inhibits BIM expression 
(Cragg et al., 2007). 
 
Figure 10 Targeting of the BH3 only 
protein BIM by anticancer drugs 
(Cragg et al., 2007). 
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proliferation and immune functions. Here, we summarise the complex effects of dynamic 
alterations in the cellular acetylome on physiologically relevant pathways. 
PMID: 18804549 
 
The International Journal of Biochemistry & Cell Biology 41 (2009) 185–198
Contents lists available at ScienceDirect
The International Journal of Biochemistry
& Cell Biology
journa l homepage: www.e lsev ier .com/ locate /b ioce l
Review
Acetylation of non-histone proteins modulates cellular signalling at multiple
levels
Stephanie Spangea,b, Tobias Wagnerb, Thorsten Heinzelb,∗, Oliver H. Krämerb,∗
a Leibniz Institute for Age Research – Fritz Lipmann Institute, Beutenbergstrasse 11, 07745 Jena, Germany
b Friedrich-Schiller-Universität Jena, Centre for Molecular Biomedicine (CMB), Institute for Biochemistry and Biophysics, Hans-Knöll-Str. 2, 07745 Jena, Germany
a r t i c l e i n f o
Article history:
Available online 2 September 2008
Keywords:
Acetyltransferases (HAT)
Deacetylases (HDAC)
Non-histone targets
Posttranscriptional regulation
a b s t r a c t
This review focuses on the posttranslational acetylation of non-histone proteins, which determines vital
regulatory processes. The recruitment of histone acetyltransferases and histone deacetylases to the tran-
scriptionalmachinery is a key element in thedynamic regulation of genes controlling cellular proliferation
and differentiation. A steadily growing number of identiﬁed acetylated non-histone proteins demonstrate
that reversible lysine acetylation affects mRNA stability, and the localisation, interaction, degradation and
function of proteins. Interestingly, most non-histone proteins targeted by acetylation are relevant for
tumourigenesis, cancer cell proliferation and immune functions. Therefore inhibitors of histone deacety-
lases are considered as candidate drugs for cancer therapy. Histone deacetylase inhibitors alter histonePosttranslational regulation
acetylation and chromatin structure, which modulates gene expression, as well as promoting the acety-
lation of non-histone proteins. Here, we summarise the complex effects of dynamic alterations in the
cellular acetylome on physiologically relevant pathways.
© 2008 Elsevier Ltd. All rights reserved.
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. Histone acetylation
Eukaryotic DNA, histones and histone-like proteins are assem-
led into nucleosomes. Histones, the main protein component of
hromatin, not merely play a role in packaging DNA. The tails and
he globular domains of histones can be modiﬁed by acetylation,
hosphorylation, methylation, ubiquitination, sumoylation, and
ess commonly by citrullination and ADP-ribosylation. These post-
ranslational modiﬁcations can alter DNA-histone interactions or
he binding of proteins, such as transcription factors, to chromatin.
istone hyperacetylation provides a more open chromatin struc-
ure correlating with gene transcription (Durrin et al., 1991). This is
ue to reduced ionic interactions of the positively charged histone
ails with the negatively charged DNA backbone and reduced inter-
ucleosomal interactions. Additionally,modiﬁed histones generate
peciﬁc binding sites for protein interactions, for example with
ranscription factors and histone acetyltransferases (HATs). Bind-
ng of HATs to acetylated lysine moieties via bromodomains can
rovide a feed-forwardmechanism for acetylation. Still, the recruit-
ent of additional factors is required to initiate transcription (Kuo
t al., 1998). Via such mechanisms, various proteins with gene acti-
ating and gene silencing activity can be recruited to individual
romoters.
The term “histone code” has been coined for the combinato-
ial diversity of posttranslational histone modiﬁcations (Fischle et
l., 2003; Strahl and Allis, 2000). However, in recent discussions
he inﬂuence of histone acetylation on transcriptional activation –
ncluding the “histone code”-theory – loses weight in explaining
ranscriptional activation. From this point of view, a single acetyla-
ion event may either directly govern processes like transcription,
eplication and DNA repair mechanisms, or might alternatively
e integrated within the overall chromatin context. Because his-
one acetylation itself directly modulates the chromatin structure,
t is hard to discriminate between acetylation as a “code” signal
or transcriptional initiation and direct effects towards chromatin
tructure (Turner, 2007). HDACi treatment induces global protein
cetylation, but changes the expression of only 2–10% of human
enes signiﬁcantly, with almost equal numbers of genes upregu-
ated and downregulated (Daly and Shirazi-Beechey, 2006; Gray
t al., 2004). Promoters can be both, induced (e.g., p21) and sup-
ressed (e.g., SRC1) following HDACi treatment, although ChIP
nalysis revealed a similar histone acetylation pattern (Ellis et
m
p
h
c
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l., 2008). Hence, histone hyperacetylation is not a reliable pre-
ictor of gene activity. Moreover, histone deacetylase inhibitor
HDACi)-mediated histone hyperacetylation has been reported to
ffect non-transcribed peripheral chromatin stronger than central
uchromatin, which in some cases even responded with histone
ypoacetylation (Rada-Iglesias et al., 2007).
. Histone deacetylases (HDACs) and histone deacetylase
nhibitors
.1. HDACs and SIRTs
HATs catalyse the transfer of an acetyl group from acetyl-CoA
o the -NH2 group of the amino acid side chain of lysine residues.
cetylation of lysine residues at the -NH2 is highly dynamic. The
rst deacetylase activitywas identiﬁedback in the1960s (Inoueand
ujimoto, 1969), soon after the discovery of histone acetylation and
ts potential role in the regulation of gene expression (Allfrey et al.,
964; Phillips, 1963). Since histoneswere the ﬁrst identiﬁed targets
f deacetylases, these enzymes were termed histone deacetylases.
he large and continuously growing number of non-histone tar-
ets undoubtedly demonstrates that histones are only some of the
any substrates of HATs and HDACs. Therefore, referring to HDACs
ndHATs as lysinedeacetylases/acetylases (KDACs/KATs) or protein
eacetylases/acetylases (PDACs/PATs) appears to be more precise.
owever, throughout this review we will continue to use the tradi-
ional term HDAC.
HDACs can be grouped into two distinct families. The “classi-
al family” of zinc-dependent HDACs are structurally related to the
east Hda1/Rpd3 proteins (de Ruijter et al., 2003), and the sec-
nd one consists of the NAD+-dependent yeast Sir2 homologues
Haigis and Guarente, 2006). Histone deacetylases are further
rouped into four classes according to their phylogenetic con-
ervation (Gregoretti et al., 2004). Class I, II and IV HDACs are
he classical HDAC family. Homologues of yeast Sir2, SIRTs, rep-
esent the class III deacetylases, also commonly termed sirtuins in
ammals. Class I HDACs (HDAC1, HDAC2, HDAC3 and HDAC8) are
roteins orthologous to the yeast Rpd3 enzyme. The yeast Hda1
omologues of mammalian class II HDACs can be subdivided into
lass IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and class IIb (HDAC6
nd HDAC10). HDAC11 shares equal sequence conservation with
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pd3 and Hda1, and is therefore grouped as a currently solitary
ember into class IV. Class III HDACs represent a phylogenetically
onserved group with seven members in man (SIRT1 to 7) (Gao et
l., 2002; Yang and Seto, 2008).
Class I HDACs consist of 350–500 amino acid residues (≈50kDa)
nd are ubiquitously expressed. Besides their deacetylase (DAC)
omain, spanning approximately 300 residues, they carry a small
-terminal part that is often subject to posttranslational mod-
ﬁcations, like phosphorylation, ubiquitination and sumoylation
de Ruijter et al., 2003; Krämer et al., 2001; Yang and Seto,
008). Class II HDACs are considerably larger, consisting of about
000 residues. The class IIa deacetylases possess an Hda1-like
atalytic domain in the C-terminus and additional N-terminal
xtensions, which harbour multiple domains and regulatory sites.
he class IIb deacetylases HDAC6 and HDAC10 have an N-terminal
atalytic domain (Yang and Seto, 2008). In contrast to other
eacetylases, HDAC6 further contains a C-terminally located sec-
nd functional DAC domain. Most classical histone deacetylases
orm large high molecular weight complexes of up to 1–2MDa
Yang and Seto, 2008). These complexes contain multiple corepres-
ors harbouring chromatin remodelling activities and the ability
o bind sequence speciﬁc transcription factors (Grozinger and
chreiber, 2002).Whilst classical HDACs can be found in the cytosol
nd in the nucleus, no localisation to mitochondria has been
escribed so far (de Ruijter et al., 2003; Yang and Gregoire, 2005;
ang and Seto, 2008).
Sirtuins make use of a different mechanism of catalysis. Instead
f using an electrophilic Zn2+ ion to directly hydrolyse the amide
ond with water, they transfer the acetyl group to the cosubstrate
AD+ yielding two products, nicotinamide and 2′-O-acetyl-ADP-
ibose (Denu, 2005). This reaction depends on the NAD+/NADH
atio. Metabolism thus may provide a mechanism to regulate
IRTs. Moreover, some SIRTs catalyse ADP-ribosylation (Frye, 1999;
ichan and Sinclair, 2007). The seven human SIRT paralogs are
biquitously expressed (Michishita et al., 2005). SIRT1, 6 and 7 are
uclear proteins with differential subnuclear distribution. SIRT6
s linked with heterochromatic regions and SIRT7 found in nucle-
li. Although SIRT1 is mainly found in the nucleoplasm, it neither
ccurs in heterochromatin nor in nucleoli. SIRT1 also carries out
ome cytoplasmic functions (Jin et al., 2007), SIRT2 localises to
he cytoplasm, and SIRT3, 4 and 5 are mitochondrial proteins
Michishita et al., 2005).
Due to its interactions with several transcription factors, SIRT1
s involved in multiple regulatory processes. These typically are
poptotic and stress responses, linked to a variety of diseases
ncluding cancer (Michan and Sinclair, 2007). SIRT1 furthermore
ffects neuroprotection, tumour suppression, inﬂammation, and
ongevity (Anekonda, 2006; Baur et al., 2006; Labinskyy et al.,
006; Saunders and Verdin, 2007). SIRT3, 4, and 5 are reg-
lators of mitochondrial processes, metabolism, and longevity
Guarente, 2008).
.2. HDACi
Of note, the discovery of HDAC inhibitors (HDACi) preceded
he discovery of HDACs. Sodium butyrate was the ﬁrst com-
ound identiﬁed to induce histone acetylation (Riggs et al., 1977).
ater, Trichostatin A (TSA), a fungal antibiotic (Yoshida et al.,
990), valproic acid (VPA), already used in treatment of epilep-
ic diseases (Göttlicher et al., 2001), and several other compounds
ere identiﬁed as HDACi. These agents fall into diverse structural
lasses: Hydroxamic acid derivatives, carboxylates, benzamides,
lectrophilic ketones, cyclic peptides and a few substances not
ssignable to these groups. Apharmacophoricmodel for the actions
f HDACi has been suggested (Miller et al., 2003).
3
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Since epigenetic changes critically contribute to cancer onset
nd progression, HDACi were soon considered as promising anti-
ancer drugs (Bolden et al., 2006; Krämer et al., 2001; Warrell et
l., 1998; Yoo and Jones, 2006). Indeed, at the cellular level HDACi
an induce differentiation, cell cycle arrest, senescence, apoptosis,
eactive oxygen species (ROS)-production and mitotic cell death. In
ivo, HDACi were found to reduce tumour invasiveness, angiogene-
is andmetastasis. An additional very promising effect of HDACi for
ancer therapy is their selective toxicity against tumour cells com-
ared tonormal cells (Boldenetal., 2006;Minucci andPelicci, 2006;
u et al., 2007). However, inhibiting deacetylation not only affects
hromatin structure.HDACiequallypromote theacetylationofnon-
istone proteins (Caron et al., 2005; Glozak et al., 2005), which can
etermine the interactions, localisation, and stability of these pro-
eins. Whilst there are attempts to reveal aberrant gene expression
atterns in tumours, less information is available for differences in
he acetylation patterns between normal and cancer cells and the
ffect of HDACi. The fact that HATs and HDACs are deregulated in
arious cancers (Bolden et al., 2006; Das and Kundu, 2005) gives a
lear hint that anomalous acetylation takes place, which might be
orrected by therapeutic HDACi treatment.
Isoform-speciﬁc inhibition of HDACs remains a challenging
ask (Khan et al., 2008). TSA inhibits all HDACs roughly to the
ame extent. Other pan-HDACi are suberoylanilide hydroxamic
cid (SAHA), LAQ-824 and LBH-589. A class I-selective inhibitor
s VPA (Göttlicher et al., 2001), whilst MS-275 and depsipeptide
re selective towards only a subset of class I HDACs (Khan et al.,
008). HDAC6-speciﬁc HDACi also exist, e.g., tubacin (Haggarty
t al., 2003). Additional isoform-selective HDACi are available or
nder development. Such compounds will not only provide inter-
sting new tools for molecular biology, but might also represent
ew candidate drugs for cancer treatment. It is, however, contro-
ersially discussed whether strictly isoform-speciﬁc HDACi would
ave therapeutic beneﬁts (Karagiannis and El-Osta, 2007).
.3. SIRT inhibitors (SIRTi) and sirtuin activating compounds
STACs)
Because of the need for NAD+ as a cosubstrate carba-NAD+
nd nicotinamide are non-competitive inhibitors of SIRT proteins
Denu, 2005; Grubisha et al., 2005; Schmidt et al., 2004). How-
ver, the large number of other NAD+-dependent enzymes could
voke side effects of such agents (Belenky et al., 2007; Grubisha
t al., 2005). By chemical genetic screening, compound libraries
f small organic molecules were analysed for inhibition of Sir2 in
east (Bedalov et al., 2001;Grozinger et al., 2001). Sirtinol and split-
micin were found to be efﬁcient SIRTi in eukaryotic cells (Araki et
l., 2004; Bedalov et al., 2001; Fulco et al., 2003; Yeung et al., 2004).
part from inhibitors, activators of SIRTs (STACs) have also been
dentiﬁed. The best characterised and most potent one is resver-
trol. This plant polyphenol increases lifespan in several animal
odels, an effect also observed upon overexpression of Sir2 or its
rthologs (Howitz et al., 2003; Wood et al., 2004). In vivo, artiﬁcial
ctivation of sirtuins equally mimics caloric restriction, which is
inked to positive effects on physiological condition and longevity
Baur et al., 2006).
. Histone acetyltransferases (HATs) and histone
cetyltransferase inhibitors (HATi).1. HATs
Since thediscovery of theﬁrstHAT enzyme, the yeastHat1 (Kleff
t al., 1995), a lot of attention has been drawn to these enzymes.
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(Kouzarides, 2000). Acetylation apparently shows a broader sub-
strate spectrum than phosphorylation, and far fewer acetylases
than kinases have been described. Intriguingly, no acetylation cas-
cades have been identiﬁed to date.88 S. Spange et al. / The International Journal o
ATs are evolutionarily conserved from yeast to man and form
ultiple subunit complexes (Kimura et al., 2005). Unlike HDACs,
ATs are more diverse in structure and function (Yang, 2004). In
ammals, over 30 HATs display distinct substrate speciﬁcities for
istones and non-histone proteins. HATs do not acetylate lysine
oieties randomly. Crystal structure analysis identiﬁed a potential
ecognition motif, in which glycine is followed by an acetylatable
ysine (GKxxP) (Bannister et al., 2000; Rojas et al., 1999). How-
ver, this motif has serious limitations in predicting non-histone
rotein acetylation. For example, a proteomic survey identiﬁed
ifferent sets of preferentially acetylated amino acid stretches in
ammalian proteins. Nuclear non-histoneproteins frequently pos-
ess an asparagine in the −1 position and a histidine in the +1
osition, whilst histones show a tendency for a lysine or acetylated
ysine in ±4 positions. The subset of acetylated mitochondrial pro-
eins additionally has histidine or tyrosine at the +1 position. These
ariations could be due to the localisation of target-speciﬁc HATs
Kim et al., 2006), and cytoplasmic proteins do not demonstrate a
trictly conserved acetylation consensus motif at all.
In contrast to HDACs, the HAT classiﬁcation is less clear. They
re grouped into two general classes: A- and B-type HATs, of which
-type HATs mainly carry out transcription-related acetylation.
hese are further grouped intoﬁve families:GNAT,MYST, p300/CBP,
asal/general transcription factors and nuclear receptor cofac-
ors (Roth et al., 2001). Nuclear A-type HATs are chieﬂy found in
onserved, cooperatively acting high-molecular-weight complexes
Grant and Berger, 1999). The cytoplasmic B-typeHATs acetylate de
ovo synthesised free histones, promoting their nuclear localisa-
ion and deposition onto newly synthesised DNA (Allis et al., 1985;
uiz-Carrillo et al., 1975).ManyHATs showadistinct patternof sub-
trate speciﬁcity, even towards histones, depending on the subunit
omposition of HAT complexes and the speciﬁc recruitment to the
arget sites of acetylation (Waterborg, 2002). HAT complexes also
ffect chromosome decondensation, DNA-damage repair and the
cetylation of non-histone targets (Lee and Workman, 2007). Many
ATs possess an evolutionarily conserved protein module specif-
cally recognising acetyl-lysines—the bromodomain which directs
hromatin associated proteins to acetylated histones (Dhalluin et
l., 1999; Lee and Workman, 2007).
The most intensively studied HATs are CBP and p300. Both
ontain a bromodomain and are often found within the same
omplexes. Apparently, p300 seems to have the broadest sub-
trate acceptance for histones and non-histone proteins (Kimura
t al., 2005). The GNAT family (Gcn5 related N-acetyltransferases)
ncludes Gcn5 and PCAF (p300/CBP associated factor), which are
mportant for transcriptional initiation. Elp3 is involved in tran-
criptional elongation andHat1 inhistonedeposition and telomeric
ilencing (Grant, 2001). Members of the MYST family serve as cat-
lytic subunits in Tip60, HBO1 and MOZ/MORF complexes (Lee
nd Workman, 2007). There are additional enzymes that carry an
cetyl transferase activity. Because of their lower sequence similar-
ty they cannot be grouped into any of these families. Numerous
ATs furthermore undergo functionally relevant auto-acetylation
Thompson et al., 2004).
.2. HATi
Comparatively little attention has been drawn to inhibitors of
cetyltransferases (HATi), as HATs are rarely considered as drug
argets. A reason for this could be thepromisinguse ofHDACi in var-
ous diseases like leukaemia and other haematological disorders.
urrently, only a small numberofHATi is known. Synthetic peptide-
oA conjugates showed HAT inhibitor potential (Lys-CoA for p300
nd H3-CoA-20 for PCAF) (Lau et al., 2000), but they lack cell per-
eability. The cell permeable polyphenol curcumin was shown to
F
i
aemistry & Cell Biology 41 (2009) 185–198
peciﬁcally inhibit p300 activity in the micromolar range. Other
aturally occurring compounds like anacardic acid and garcinol are
on-speciﬁc inhibitorsofp300/CBPandPCAF (Balasubramanyamet
l., 2003). Furthermore, the quinoline derivative MC1626 (Smith et
l., 2007) and isothiazolones (Stimson et al., 2005) act as inhibitors
f Gcn5, PCAF and p300, respectively.
. Non-histone targets of HDACs and HATs—the acetylome
Lysine side chains can be acetylated, methylated (mono-, di-
r trimethylation), ubiquitinated (mono- or polyubiquitination),
umoylated and ADP-ribosylated (Merrick and Duraisingh, 2007).
hese rivalling and reversible posttranslational modiﬁcations are
egulated by a complex interplay of different enzymes. Reversible
cetylation of lysine -amino groups crucially modulates protein
unction und cellular networks (Fig. 1). In eukaryotic cells, acety-
ation is among the most common covalent modiﬁcations and
anks similar to the important master switch phosphorylationig. 1. Lysine modiﬁcations. Lysine residues are subject to posttranslational mod-
ﬁcations with varying functional consequences. Switching between modiﬁcations
llows to alter protein function.
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Hundreds of proteins are known to be modiﬁed by acetyla-
ion. Surely, there exist many more acetylated proteins than those
dentiﬁed until now, and acetylation can change protein character-
stics and functions enormously. In general, acetylation changes the
lectrostatic state of lysine from positive to neutral and increases
he size of the amino acid side chain. Acetylation can equally
ffect enzymatic activities, as acetylated lysines exhibit slightly
ifferent preferences for secondary structures than unacetylated
ysines. Different covalent modiﬁcations can furthermore compete
or the same lysines important for signalling or the subcellular
ocalisation of a protein (Kim et al., 2006). Additionally, the acety-
ation of lysines can create new docking sites for protein–protein
nteractions, for example via recognition by the bromodomain.
ence, acetylation can determine protein function at multiple
evels.
Protein acetylation patterns appear to be very organ speciﬁc
Iwabata et al., 2005). To identify acetylated proteins, in several
tudies lysine-acetylated peptides and proteins were immunop-
riﬁed, and investigated by 2D gel electrophoresis and HPLC/MS
nalysis (Iwabata et al., 2005; Kim et al., 2006; Xie et al., 2007).
ore than 60 transcription factors and many other proteins
nvolved in DNA repair and replication, metabolism, cytoskeletal
ynamics, apoptosis, nuclear import, protein folding and cel-
ular signalling were found to be acetylated (Cohen and Yao,
004; Kouzarides, 2000; Sterner and Berger, 2000; Yang and
regoire, 2007). Since 277 lysine acetylation sites were identiﬁed
n 133 mitochondrial proteins, acetylation is also a very abun-
ant posttranslational modiﬁcation in mitochondria (Kim et al.,
006). In sum, these modiﬁed proteins are called the acetylome
see Table 1).
a
5
s
able 1
elected acetylated proteins
iological implication Proteins affected by acetylation
rotein stability Acetylation increases stability A
p53, p73, Smad7, c-Myc, Runx3, AR, H2A.z, E2F1,
NF-E4, ER81, SREBP1a, HNF6, BACE1
NA binding Increased DNA binding D
p53, SRY, STAT3, GATA transcription factors, E2F1,
p50 (NFB), Er, p65 (NFB), c-Myb, MyoD, HNF-4,
AML1, BETA2, NF-E2, KLF13, TAL1/SCL, TAF(I)68, AP
endonuclease
F
ene expression Transcriptional activation T
p53, HMG-A1, STAT3, AR, ER (basal), GATA
transcription factors, EKLF, MyoD, E2F1, p65(NFB),
GR, p73, PGC1, MEF2D, GCMa, PLAG1, PLAGL2,
Bcl-6, -Catenin, KLF5, Sp1, BETA2, Cart1, RIP140,
TAF(I)68
F
rotein interactions Enhanced D
STAT3, AR, EKLF, Importin A, STAT1, TFIIB,
-Tubulin, actin, cortactin
ocalisation Ac→nucleus A
PCAF, SRY, CtBP2, POP-1, HNF-4, PCNA
Sub-nuclear
WRN, PCNA
RNA stability Increased D
p21, Brm
nzymatic activity Enhanced D
p300, ATM
itochondrial proteins ACS (Ac-CoA-Synthetase), Sod1/2, Proﬁlin I, Thioredoxin; m
iral proteins E1A, S-HDAg, L-HDAg, HIV Tat, SV40 T-Ag
elected non-histone proteins and functional consequences of their acetylation (Arányi e
lozak et al., 2005; Ito et al., 2007; Rössig et al., 2002; Sadoul et al., 2008; Xu et al., 2007;emistry & Cell Biology 41 (2009) 185–198 189
. Acetylation regulates multiple processes from gene
xpression to protein activity
Acetylation can affect signalling pathways and thereby alter cell
ate and function.mRNA splicing,mRNA transport, mRNA integrity,
ranslation, protein activity, protein localisation, protein stability
nd interactions are regulated by acetylation. Hence, acetylation
an interferewithevery stepof regulatoryprocesses fromsignalling
o transcription to protein degradation.
.1. Signalling and transcription
The process of gene expression has been closely linked to
cetylation. In addition to histone acetylation, the acetylation of
on-histone proteins is important. For example, acetylation of
ranscription factors within their DNA-binding domain has been
escribed. In the cases of E2F1, YY1 and many more, this results
n altered DNA binding afﬁnity (Lamonica et al., 2006; Martinez-
albas et al., 2000). However, acetylation can equally inhibit the
NA binding of transcription factors, providing an explanation
hy HDACi do not generally increase gene expression. Not all
roteins are regulated by acetylation of the protein itself. For exam-
le, HDAC6-mediated Hsp90 deacetylation enables activation of
he glucocorticoid receptor by ligands (Kovacs et al., 2005). The
ollowing examples demonstrate the complex consequences of
cetylationoncellular signalling and their effects on transcriptional
ctivity.
.1.1. STAT proteins
Mammalian STATs are a family of transcription factors con-
isting of seven members. These are STAT1, STAT2, STAT3, STAT4,
cetylation decreases stability
GATA1, HIF-1, pRb, SV40 T-Ag
ecreased DNA binding
YY1, HMG-A1, HMG-N2, p65 (NFB), DEK, KLF13,
en-1
ranscriptional inactivation
Er (ligand-bound), HIF-1, STAT1, FOXO1,
OXO4, RIP140
ecreased
p65(RelA), Ku70, Hsp90
c→ cytosol
c-Abl, p300, PAP
ecreased
Tyrosinhydrolase (Th), eNOS
ecreased
PTEN, HDAC1, Mdm2, ACS, Neil2, Pol
ultiple components of metabolic and oxidative phosphorylation machinery
t al., 2007; Cohen and Yao, 2004; Das and Kundu, 2005; Dokmanovic et al., 2007;
Yamamichi et al., 2005; Yang and Gregoire, 2007; Zhang and Dent, 2005).
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TAT5A, STAT5B and STAT6. Speciﬁc cytokines and growth factors
ctivate JAK kinases. These phosphorylate STATs, which induces
heir translocation into the nucleus. STATs are known to activate
enes containing GAS or ISRE response elements in their promot-
rs, thereby modulating biological processes like cell proliferation,
urvival, apoptosis and differentiation. STAT-mediated effects are
ightly regulated by negative feedback loops. Only tyrosine dephos-
horylation inactivates STATs directly (Mertens and Darnell, 2007).
STAT6 was the ﬁrst STAT protein shown to undergo acetylation
nd its acetylation correlateswith the transcription of reticulocyte-
ype 15-lipoxygenase-1 (Shankaranarayanan et al., 2001). STAT1
an be acetylated by CBP within its DNA binding domain (Krämer
t al., 2006). Acetylation of STAT1 might negatively regulate its
unctions, as overexpression of HDAC1, HDAC2, or HDAC3 enhances
TAT1-dependent gene expression upon cytokine stimulation, and
nhibition of HDACs with HDACi or speciﬁc siRNAs blocks the
xpression of IFN-responsive genes (Chang et al., 2004; Klampfer
t al., 2004; Nusinzon and Horvath, 2003). Acetylated STAT1 fur-
hermore binds to the NF-B subunit p65 which decreases p65
NA binding, nuclear localisation and expression of anti-apoptotic
F-B target genes in transformed cells. Via thismechanism, acety-
ation of STAT1 K410 and K413 regulates NF-B activity and thus
ltimately apoptosis (Krämer et al., 2006) (Fig. 2B). Acetylated
TAT2 was reported to act as an adaptor for STAT1 and the con-
ormation of the STAT1/Ac-STAT2 heterodimer might be critical
or binding to the IFN receptor 2 or the interferon regulatory
actor IRF9 (Tang et al., 2007). This ﬁnding is, however, hard to rec-
ncile with several studies clearly showing that the STAT1/STAT2
ependent activation of genes is strongly suppressed upon HDAC
nhibition (Chang et al., 2004; Klampfer et al., 2004; Nusinzon and
orvath, 2003). The cytokine-dependent acetylation of STAT3 by
300/CBPmay facilitate STAT3dimerisation, resulting inDNAbind-
ng and transcriptional activation of STAT3 target genes (Yuan et al.,
005) involved in cell growth and cell survival, like cyclinD1, bcl-xL,
nd c-myc (Wang et al., 2005; Yuan et al., 2005) (Fig. 2C). How-
ver, suchaﬁnding contrasts thewell-establishedanti-proliferative
unctions of HDACi, and the mechanistic details and physiolog-
cal relevance of STAT3 acetylation are discussed controversially
O’Shea et al., 2005).
.1.2. NF-B
The inducible transcription factor NF-B plays a central role in
mmune responses, inﬂammation, cell survival, differentiation and
roliferation. TheNF-B/Rel family consists of p50, p52, p65 (RelA),
-Rel and RelB, which form homo- or heterodimers (Xiao, 2004).
hep50/p65heterodimer is themost frequently foundcombination
n mammals. Inactive NF-B complexes are retained in the cyto-
lasm by the IB inhibitor. The activation of the IB kinase (IKK)
esults in IB phosphorylation triggering its ubiquitination and
roteasomal degradation. Free NF-B translocates to the nucleus
here it binds to target sequences. This promotes or inhibits tran-
cription through coactivator or corepressor recruitment (Hayden
nd Ghosh, 2008).
Posttranslational modiﬁcations of NF-B dimers have been
hown to alter their interactions with co-activators. Phosphory-
ated p65 preferentially interacts with p300/CBP, resulting in p65
cetylation at multiple sites. Acetylation of K221 and K310 is associ-
ted with an increased transcription of NF-B target genes (Chen
nd Greene, 2004), and is required for the full activity of p65 (Chen
t al., 2002). This is also supported by the observation that SIRT1
riven deacetylation of p65 K310 inhibits transcription of NF-B
arget genes (Yeung et al., 2004). Likewise, HDAC1 and HDAC3
eacetylate p65 at either K221 or K310, resulting in the inhibition of
F-B. The p300-mediated acetylation of K314 and K315 in p65 had
o obvious effect on NF-B DNA binding or localisation. However,
M
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icroarray analysis identiﬁed a speciﬁc set of genes differently reg-
lated by TNF treatment when comparing wild type and K314 and
315 mutant p65 (Buerki et al., 2008). Additionally, K122 and K123
cetylation reduces p65 DNA binding afﬁnity accompanied with
ncreased IB interaction and nuclear export (Kiernan et al., 2003).
ite-speciﬁc p300-mediated acetylation of p65 thus regulates the
peciﬁcity of NF-B dependent gene expression (Greene and Chen,
004; Kiernan et al., 2003) (Fig. 2A). The situation appears less
omplicated for p50. Acetylation of p50 (K431, K440 and K441) pro-
otes higher DNA binding afﬁnity towards NF-B target sequences
orrelating with increased p300 recruitment and transcriptional
ctivation (Deng and Wu, 2003; Deng et al., 2003).
NF-B is deregulated in a large number of diseases. HDACi and
IRTi application should result inNF-Bhyperacetylation andmod-
lation of NF-B target gene expression. Indeed, HDACi have been
hown to repress NF-B signalling and expression of several NF-
B target genes (Huang et al., 1997; Inan et al., 2000; Krämer et
l., 2001). Others though showed that HDACi enhanced NF-B-
ependent gene expression in the presence of TNF (Adam et al.,
003; Ashburner et al., 2001; Quivy et al., 2002; Vanden Berghe et
l., 1999), or even that a HATi induced the repression of NF-B tar-
et genes (Sung et al., 2008). A possible caveat to assess the in vivo
elevance of p65 acetylation is that this modiﬁcation could only be
etected upon overexpression of a HAT protein in certain studies
Chen and Greene, 2003). Hence, there is debate on which lysine in
F-B p65 is actually acetylated under physiological conditions.
.1.3. p53
The tumour suppressor p53 is a key player in cellular signalling
nd stress responses. This transcription factor can both, positively
r negatively regulate the expression of genes contributing to cell
ycle arrest, senescence and apoptosis (Vousden and Lane, 2007).
he phosphorylation and acetylation status of p53 has a major
mpact on its functions,withphosphorylationof p53 stimulating its
cetylation (Sakaguchi et al., 1998). The p53 protein can be acety-
ated by distinct acetyltransferases at different lysines: K120, K164,
320, K370, K372, K373, K381, K382 and K386 (Li et al., 2007; Tang et
l., 2008). The resulting effects on p53 activity are still discussed
ontroversially (Zhao et al., 2006). Especially for C-terminal acety-
ation of p53 there is dispute whether or not acetylation increases
NA binding (Espinosa and Emerson, 2001; Gu and Roeder, 1997;
akaguchi et al., 1998). Lately, mutation at major acetylation sites
K120, K164 and in the C terminus) was shown to result in a com-
lete loss of p53 activity towards p21 transcription, whereas single
ite mutations were compensated by acetylation at the remaining
unctional residues (Tang et al., 2008). Acetylation of K120 mediated
y Tip60 and hMOF seems to be important for the expression of
enes favouring apoptosis after DNA damage. Here, the acetylated
ysine contributes to coactivator recruitment (Sykes et al., 2006;
ang et al., 2006). Acetylation of K320 and polyubiquitination of
53 apparently stimulates transcription (Knights et al., 2006; Le
am et al., 2006). Additionally, p53 acetylated at K382 recruits CBP
ia its bromodomain to further activate transcription, suggesting
hat p53 acetylation increases its DNA binding afﬁnity followed by
ranscriptional activation of its target genes (Mujtaba et al., 2004).
As p53 acetylation might favour DNA binding and transcrip-
ional activation (Fig. 2C), this mechanism has likewise been
uggested for the transcription factors SRY (Thevenet et al., 2004),
ATA factors (Boyes et al., 1998;Hayakawa et al., 2004; Yamagata et
l., 2000), E2F1 (Martinez-Balbas et al., 2000; Marzio et al., 2000),
yoD (Sartorelli et al., 1999) and many others.
.1.4. FOXO transcription factors
Acetylation has equally been found to inhibit gene expression.
or example, acetylation can disrupt DNA binding and transcrip-
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Fig. 2. Effects of acetylation on signalling, transcription and posttranscriptional events. (A) p300/CBP-mediated site-speciﬁc acetylation of p65 or p50 has a major impact
on the transcriptional activity of NF-B in vitro. Acetylation of p65 (K218, K221 and K310) or p50 (K431, K440 and K441) activates transcription. The acetylation of p65 on K122
and K123 inhibits its DNA binding, favours IB binding and results in the cytoplasmic accumulation of NF-B. Acetylation of p65 on K314 and K315 regulates a speciﬁc set
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he transcriptional activity of NF-B. (C) Acetylation of transcription factors can aff
e.g., HNF-4) and thereby transcriptional activity. (D) HDACi alters the cellular ace
ranslation. Additionally HDACi have been shown to alter mRNA stability.
ional activation by the FOXO transcription factors, as well as for
Y1 (Yao et al., 2001), and the ligand-bound, activated ER (Wang
t al., 2001) (for additional proteins see Table 1).
The mammalian family of FOXO proteins (FOXO1, 3, 4, and
) belongs to the forkhead family of transcription factors. In
he absence of insulin or growth factors, the FOXO proteins are
ocated in the nucleus triggering gene expression to regulate
tress resistance, metabolism, cell cycle arrest and apoptosis. Upon
nsulin/growth factor stimulation, the Akt kinase phosphorylates
he FOXO proteins, resulting in nuclear export and inhibition of
OXO action (Carter and Brunet, 2007). Besides phosphorylation,
cetylation of FOXO proteins functions as a second pathway of
egative control (Calnan and Brunet, 2008). The p300/CBP- and
CAF-mediated acetylation diminishes the DNA binding ability of
OXO proteins, in turn reducing their activity (Calnan and Brunet,
008). In response to oxidative stress SIRT1mediates deacetylation
f FOXO1. However, it is not that clear whether this deacetyla-
ion automatically leads to FOXO activation, as FOXO acetylation
an have diverse effects towards different promoters (Daitoku et
l., 2004; Fukuoka et al., 2003; van der Heide and Smidt, 2005).
onetheless SIRT1-mediated FOXO deacetylation can promote cel-ular survival and increase lifespan (van der Horst et al., 2004).
nder conditions of caloric restriction, higher NAD+-levels could
ncrease SIRT1 activity towards FOXO, and the resultingmodulation
f FOXO functions may contribute to Sir2 family mediated lifespan
xtension.
a
c
t
b
alting complex dissociates from DNA, translocates into the cytoplasm and inhibits
merisation (e.g., STAT3), DNA binding afﬁnity (e.g., p53) or subcellular localisation
n state of various proteins including factors needed for pre-mRNA processing or
.2. Posttranscriptional regulation
Posttranscriptional control is mainly mediated by cis-acting
NA elements located in the 5′- and 3′-untranslated regions of
RNAs (5′-UTRs and 3′-UTRs) that can be targeted by trans-acting
NA binding proteins (Grzybowska et al., 2001; Pesole et al., 2001).
he control of mRNA stability is often under-rated as a mechanism
n regulation of gene expression. In fact, the initiation of transcrip-
ion is just one side of themedal. The other side includes pre-mRNA
rocessing, mRNA transport, mRNA stability and ﬁnally transla-
ion. In the end, transcriptional activation not necessarily results
n increased protein levels. It is estimated that about 50% of the
hanges in gene expression actually are alterations in mRNA sta-
ility rather than “direct” transcriptional control (Cheadle et al.,
005). Actions of HDACi towards such posttranscriptional control
echanisms have not been the focus of research so far (Fig. 2D).
.2.1. Pre-mRNA processing
Acetylation has been suggested to have an impact on pre-mRNA
rocessing, including RNA splicing as well as 5′- and 3′-processing.
nterestingly, the heterogeneous ribonucleoprotein A1, which has
potential role in splicing by binding to unprocessed pre-mRNA,
an be acetylated (Kimet al., 2006).Moreover, an impact of acetyla-
ion on proteins involved in RNA cleavage and polyadenylation has
een described for CFIm25, a component required for 3′ RNA cleav-
ge and polyadenylation, as well as poly-(A)-polymerase (PAP), a
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Fig. 3. Interplay of acetylation and other protein modiﬁcations. (A) Posttransla-
tional modiﬁcations can target the same lysine residue, as exempliﬁed for the
SUMO-Acetylation switch (SAS) occurring on MEF2A. (B) Ubiquitination and acety-
lation differentially regulate proteasomal degradation, as ubiquitin conjugation
at p53 lysines is blocked by acetylation. Other examples are Smad7, p73 and c-
Myc. (C) Protein acetylation leads to enhanced degradation, for example of HIF-1.
(D) The HDACi-mediated transcriptional upregulation of E2 and/or E3 enzymes of
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olyadenylating enzyme involved in pre-mRNA 3′-end process-
ng. Actually, acetylation decreased interactions between PAP and
he CFIm complex, and PAP acetylation disrupts its binding to
he importin-/ complex, resulting in cytosolic accumulation
Shimazu et al., 2007).
.2.2. Acetylation-mediated regulation of mRNA stability and
ranslation
The endothelial nitric oxide synthase (eNOS) generates nitric
xide, a key second messenger in inﬂammatory diseases. Side
ffects of this free radical are cytotoxic effects through lipid, DNA
nd protein damage. The majority of the literature favours a pro-
umourigenic role of eNOS, which is in contrast to its potential
nti-tumourigenic functions (Ying and Hofseth, 2007). TSA evokes
NOS promoter activity and causes a constant transcript rate in
uclear run-on experiments. The HDACi-mediated reduction of the
alf-life of eNOS mRNA is nevertheless sufﬁcient to decrease eNOS
rotein levels. Consequently, an HDACi-mediated decrease in eNOS
evels interferes with endothelial cell function (Rössig et al., 2002).
urthermore, theHDACi TSAhas been shown to decrease themRNA
tability of DNA methyltransferase-1 and -3B (Januchowski et al.,
007; Xiong et al., 2005), which results in a signiﬁcant reduction
f de novo DNA methylation. HDACi can additionally decrease the
xpression of estrogen receptor  (De los Santos et al., 2007) and
yrosine hydroxylase (Arányi et al., 2007) by modulation of mRNA
tability. The mechanisms behind these effects on mRNA stabil-
ty remain to be identiﬁed. Perhaps, dynamic protein acetylation
ffects mRNA turn-over via an RNase and/or mRNA stabilising fac-
ors, which usually bind to the 3′-UTR ofmRNA (Arányi et al., 2007).
MicroRNAs are non-coding RNAs that regulate mRNA stability
y RNA interference. The HDACi LAQ-824 rapidly alters the lev-
ls of 40% of >60 different assessed miRNA species. This ﬁnding
lso supports the idea thatHDACi canmodulate posttranscriptional
rocesses (Scott et al., 2006). The functional consequence of altered
iRNAexpressionuponHDACi treatment remains tobeunderstood
n detail.
Until now, no major impact of protein acetylation on trans-
ational control has been described. Remarkably though, two
ranslation factors (EF1 and eIF-5A) can be targeted by acetylation
nd this may regulate translation (Kim et al., 2006).
.3. Protein modiﬁcation and stability
.3.1. Acetylation switches
Various posttranslational modiﬁcations target lysine residues,
aising the possibility of modiﬁcation-based switches. The tar-
eted replacement of one modiﬁcation by another allows
he functional adaptation of proteins. Alternative acetyla-
ion/ubiquitination determines protein stability, whereas rivalling
cetylation/sumoylation likely affects protein activity,with sumoy-
ation of transcription factors being often linked to transcriptional
epression (Geiss-Friedlander and Melchior, 2007). Accordingly,
cetylation switches at the KxE SUMO consensus sites have
een reported for the transcription factor Sp3 (Sapetschnig et al.,
002), theHIC1 tumour suppressor (Stankovic-Valentinet al., 2007)
nd the HAT p300 (Bouras et al., 2005). The phosphorylation-
egulated sumoylation–acetylation switch (SAS) occurring on the
ranscription factor MEF2A has been well characterised (Fig. 3A).
n MEF2A, K403xExxSP is a phosphorylation-dependent sumoy-
ation motif (PDSM) where phosphorylation of the serine residue
riggers sumoylation of the lysine residue. Ca2+-dependent dephos-
horylation at S408 by calcineurin causes loss of sumoylation,
llowing acetylation, which inhibits postsynaptic differentiation
Shalizi et al., 2006).
b
s
e
c
ahe ubiquitin-proteasome pathway acts in concert to speciﬁcally induce protein
egradation, e.g., of HDAC2, and of the leukaemia fusion proteins AML1-ETO, and
ML-RAR. (E) HDACi can lead to Hsp90 hyperacetylation, which correlates with
sp90 target protein degradation in the cytosol.
.3.2. Acetylation can prevent ubiquitination and proteasomal
egradation
Acetylation regulates protein stability in a sophisticated man-
er and by surprisingly diverse mechanisms (Fig. 3) (Sadoul et al.,
008). Acetylation of lysines can block ubiquitination at the same
esidue thereby preventing proteasomal degradation. Thiswas ﬁrst
uggested for p53, which is tightly controlled by the Mdm2 E3 lig-
se driving proteasomal degradation of p53. PCAF and p300/CBP
atalyse acetylation of C-terminal p53 lysine residues (K320, K370,
372, K373, K381 and K382), which overlap with ubiquitination sites
Fig. 3B) (Ito et al., 2002). Acetylation abrogates complex formation
etween p53 and Mdm2, whereas an unacetylatable p53 mutant
trongly interacts with Mdm2 resulting in p53 degradation (Tang
t al., 2008). In an overexpression system, Mdm2 formed an HDAC1
ontaining complex binding to p53. Recruitment of HDAC1 (Juan et
l., 2000; Luo et al., 2000) might thereby link two enzymatic activ-
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ties promoting p53 degradation (Ito et al., 2002). It is nonetheless
ery surprising that positive regulation of p53 levels by HDACi has
ot been reported, yet. This could be due to the fact that the HDACi-
nsensitive SIRT1 likely represents the major p53 deacetylase (Luo
t al., 2001). Accordingly, SIRTi lead to p53 hyperacetylation. The
ombined effect of HDACs and SIRTs on p53 stability remains to be
nalysed.
Similar acetylation–ubiquitination mechanisms are described
or the p53homologp73 (Bernassola et al., 2004), Smad7 (Grönroos
t al., 2002; Kume et al., 2007; Simonsson et al., 2005), Runx3 (Jin et
l., 2004) and c-Myc (Vervoorts et al., 2003). Numerous HATs (CBP,
ip60, Gcn5 andPCAF)were reported to acetylate c-Myc atmultiple
ysines, preventing its ubiquitination and proteasomal degradation
Patel et al., 2004; Vervoorts et al., 2003). In contrast, p300 depen-
ent acetylation of c-Myc resulted in enhanced degradation (Faiola
t al., 2005). These results indicate that acetylation of different
ysines affects targets in divergent ways (Table 1).
.3.3. Acetylation can increase proteasomal degradation
Acetylation of proteins can equally promote enhanced degrada-
ion (Fig. 3C). Acetylation of the important angiogenesis regulator
IF-1 at K532 by ARD1 was reported to induce its degradation
Jeong et al., 2002). HIF-1 is steadily ubiquitinated by the E3 ligase
VHL and degraded by the proteasome under normoxic conditions
Lee et al., 2004). HIF-1 acetylation facilitates interaction with
VHL and its degradation (Jeong et al., 2002). Although hypoxia
sually induces stabilisation of HIF-1, HDACi lead to the desta-
ilisation of HIF-1 protein levels even under hypoxic conditions
Jeong et al., 2002). In addition, the metastasis-associated protein
TA1 forms a complexwithHDAC1 that is able to bind, deacetylate
nd stabilise HIF-1 (Yoo et al., 2006). However, other studies link
n HDACi-mediated HIF-1 decrease to pVHL- and proteasome-
ndependent degradation (Kong et al., 2006) or to class II HDACs
Qian et al., 2006), likely suggesting multiple pathways regulating
IF-1 stability (Bilton et al., 2006). The transcription factor GATA1
Fig. 3E) (Hernandez-Hernandez et al., 2006) and pRb (Leduc et al.,
006) are other proteins preferentially degraded after acetylation
Table 1).
.3.4. Acetylation can lead to non-proteasomal degradation
Non-proteasomal degradation is also affected by acetylation.
or example, the acetylation status of the SV40 large T-Ag is con-
rolled by CBP, HDAC1, HDAC3 and SIRT1, and HDACi enhance
proteasome-independent degradation of T-Ag (Shimazu et al.,
006). Also, acetylation of HNF-6 increases its half-life, whereas
n unacetylatable mutant is degraded non-proteasomally (Rausa
t al., 2004).
.3.5. HDACi can inﬂuence protein stability by regulation of the
biquitination machinery
The expression of various enzymes required for proteasomal
egradation pathways is affected by acetylation. This mechanism
asﬁrst identiﬁed for anHDAC itself.HDAC2 is selectivelydegraded
pon treatment with VPA (Hrzenjak et al., 2006; Krämer et al.,
003; Tou et al., 2004). Ubc8 and RLIM are the E2 and E3 enzymes
or ubiquitination of HDAC2, and VPA induces expression of Ubc8.
SA, a general class I and II HDACi, also enhances Ubc8 expression,
ut additionally triggers degradation of RLIM. Therefore, the overall
evels of HDAC2 remain constant in the presence of such an HDACi
Krämer et al., 2003). Notably, HDAC2 is suggested both as a phar-
acodynamicmarker and as a target of VPA as a cancer therapeutic
Atmaca et al., 2007; Bug et al., 2005; Heinzel and Krämer, in press).
The oncogenic fusion proteins AML1-ETO and PML-RAR crit-
cally contribute to leukaemia. Notably, HDACi treatment also
avours their proteasomal degradation (Fig. 3D) (Krämer et al.,
f
i
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008b; Yang et al., 2007), which is equally linked to increased Ubc8
evels (Krämer et al., 2008b). In addition to relieving misdirected
ranscriptional repression by direct inhibition of HDACs, targeting
eukaemia fusion proteins for proteasomal degradation (Fig. 3D)
anhencebeconsideredasapromising therapeutic strategyagainst
cute myeloid and promyelocytic leukaemias.
Correct folding of proteins by chaperones, especiallyHsp90, also
as a major impact on protein stability. HDACi that inhibit HDAC6
nduce Hsp90 hyperacetylation (Aoyagi and Archer, 2005; Bali et
l., 2005; Scroggins et al., 2007), and degradation of several Hsp90
lient proteins. Among the proteins described to be downregulated
y HDACi via the HDAC6-Hsp90 axis (Fig. 3F) are several (proto-)
ncogenes like the leukaemia fusion protein Bcr-Abl (George et al.,
005; Nimmanapalli et al., 2003), the Flt3 kinase (Bali et al., 2004),
he c-Raf kinase (Yu et al., 2002), and the receptor tyrosine kinase
rbB2 (Fuino et al., 2003). However, combinatory treatment with
DACi and an Hsp90 inhibitor results in synergistically enhanced
rotein degradation, suggesting that both agents act on at least par-
ially distinct pathways (George et al., 2005). In addition, Hsp90
cetylation and reduced complex formation between Hsp90 and
ts client proteins after depletion of HDAC6 hardly evokes desta-
ilisation of these client proteins (Bali et al., 2005). Even more
urprisingly, expressionof anacetylation-mimickingHsp90mutant
oes not show notable effects on the stability of its target proteins
Scroggins et al., 2007).
.3.6. Acetylation as a folding control mechanism in the
ndoplasmatic reticulum
Acetylation at seven lysine residues of the beta-site amyloid
recursor protein (APP) cleavage enzyme (BACE1) seems to pro-
ide folding control through its ER-Golgi transition. Non-acetylated
ACE1 is cleared out of the ER by proteasome-independent degra-
ation, exclusively allowing acetylated BACE1 to translocate to the
olgi apparatus (Costantini et al., 2007). This ﬁnding not only
emonstrates a new function for acetylation, but could also give
nsights to the role of APP and BACE1 in Alzheimer disease.
.4. Acetylation and regulation of the cell cycle and circadian
hythms
.4.1. Acetylation and cell cycle control
HDACi-mediated acetylation events can affect the cell cycle by
ndirect or direct modulation of p21, retinoblastoma protein (pRb)
nd E2F transcription factors.
p21 (WAF1, CDKN1) is a potent cyclin-dependent kinase
nhibitor that belongs to the Cip/Kip family of Cdk inhibitors. Its
xpression is tightly controlled at the transcriptional level by p53.
nder stress conditions, like DNA damage, p53 induces p21, which
esults in growth arrest. One of the major beneﬁts of HDACi in can-
er therapy was suggested to be p21 upregulation resulting in cell
ycle arrest or apoptosis (Ocker andSchneider-Stock, 2007).HDACi-
nduced p21 expression is thought to be independent of p53, but
ependent on Sp1/Sp3 and other factors, e.g., ATM (Ju and Muller,
003) or c-Myc (Li andWu, 2004). Nevertheless, p21 inductionmay
lso prevent apoptosis by inhibition of caspase activation (Heinzel
nd Krämer, in press; Krämer et al., 2008a; Suzuki et al., 1999).
ranscriptional activation does not seem to be the only mechanism
esponsible for the HDACi-mediated increase in p21 protein levels.
he inﬂuence of mRNA stability on p21 expression is an estab-
ished concept, traced back to the binding of Hu proteins or other
actors targeting the 3′-UTR. This stabilises p21 mRNA, resulting
n increased p21 expression (Kim et al., 2005; Yang et al., 2004;
ano et al., 2005). Indeed, posttranscriptional regulation of p21 by
utyrate has been described and different HDACi increased p21
RNA stability depending on de novo protein synthesis in HepG2
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ells. The underlying mechanism, however, is still unclear (Hirsch
nd Bonham, 2004).
E2F proteins and pRb represent decisive regulators of cell cycle
ontrol andprogression. E2F1binds topRb inacell-cycledependent
anner, which prevents interactions of E2F1 with the transcrip-
ional machinery. Growth factor-induced phosphorylation of pRb
y cyclin-dependent kinases releases E2F1. Free E2F1 facilitates the
1/S transition and S-phase by expression of its target genes (Sun
t al., 2007). HDACi have been shown to interfere with E2F1 activ-
ty by downregulation of different cyclins, c-Myc and Cdc25A and
pregulation of p21 (Abramova et al., 2006). On the other hand,
2F1 is acetylated at three lysines by p300, which stabilises the E2F
rotein and increases its speciﬁc DNA binding (Ianari et al., 2004;
artinez-Balbas et al., 2000). Acetylation of these lysines evokes
he accumulation of ubiquitinated, though stable E2F1 (Galbiati et
l., 2005).
pRb itself recruits mSin3 and HDACs to counteract the expres-
ion of cyclins A and E, which evokes cycle arrest (Zhang et
l., 2000). Equally, acetylation of pRb on K873 and K874 hampers
ts cyclin E-Cdk2 dependent phosphorylation and the following
nsufﬁcient pRb phosphorylation leads to cell cycle arrest. This
s proposed to regulate differentiation-speciﬁc functions of pRb
Nguyen et al., 2004), which could provide a different explana-
ion for the HDACi-induced growth arrest of cells: Hyperacetylated
Rb would continue to block E2F1 and thereby prevent cell cycle
rogression.
.4.2. Acetylation and circadian function
Mammalian CLOCK and BMAL1 are transcription factors con-
ected to the circadian system (Kondratov et al., 2003). The
ircadian rhythm dictates a daily periodicity of approximately 24h
n the biochemical, physiological or behavioural processes ofmam-
als. Polymorphisms in the CLOCK gene are associated with sleep
isorders (Pirovano et al., 2005). CLOCK and BMAL1 form a het-
rodimer that binds to E-box enhancer elements, for example in
he promoter of the PER1 gene (Motzkus et al., 2007). Recently,
LOCK has been shown to have intrinsic HAT activity. Beside effects
n chromatin structure, CLOCK acetylates BMAL1 at K537. Further,
MAL1undergoes rhythmic acetylation in themouse liver, correlat-
ngwith thedownregulationofCLOCK-controlledgenes. This seems
o be mediated by acetylated BMAL1, which recruits CRY1 that
n turn accomplishes transcriptional repression (Hirayama et al.,
007). Therefore, CLOCK-induced acetylation of its binding partner
nd the resulting repression of CLOCK target genes could contribute
o a circadian auto-regulatory feedback loop,whichmaybeaffected
y HDACi.
.5. Acetylation affects metabolism and mitochondria
Unexpectedly, about 20% of mitochondrial proteins were shown
o be acetylated (277 acetylation sites in 133 proteins). The lysine
cetylation recognition motif differs between mitochondrial and
uclear or cytosolic proteins (Kimet al., 2006) and the largenumber
f acetylated mitochondrial proteins could regulate metabolism.
IRT3, 4 and5 are the only knowndeacetylases inmitochondria and
heir activity might be controlled by the cellular NAD+/NADH ratio
Grubisha et al., 2005). The cosubstrates for such acetylation and
eacetylation reactions, acetyl-CoA and NAD+, are the key indica-
ors of the cellular energy state. This suggests a possible regulatory
echanism in which the energy state of the cell can control theellular acetylome or acetylation states of mitochondrial proteins.
n addition, the acetylation of the metabolically central cytoplas-
ic acetyl-coenzyme A synthetase (ACS) within its catalytic centre
t K609 decreases its enzymatic activity (Starai et al., 2002). There-
ore, sirtuins could regulate the cellular metabolism in response to
a
i
I
a
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utrient availability and exhibit a function as a metabolic master
witch (Schwer and Verdin, 2008). Hence acetylation can provide
tight control and response to metabolic changes.
.6. Viral proteins
Many viral proteins can be targeted by acetylation (Table 1).
ecause the viral genome encodes only a very limited number of
roteins, their acetylation could have a major impact on virus–host
nteractions.
.6.1. HIV Tat
The HIV transactivator protein Tat plays a critical role in HIV
eplication by binding the leader RNA (TAR sequence) of the viral
enome. Tat is acetylated by p300 at K50 and K51 in its RNA binding
egion (Ott et al., 1999), and by PCAF at K28 in its activator domain
Kiernan et al., 1999). Acetylation of Tat byp300decreases the bind-
ng afﬁnity between Tat and TAR sequences. This releases Tat and
hereby enhances transcription from the LTR by promoting elon-
ation (Kiernan et al., 1999). Deacetylation of Tat by SIRT1 allows
ts rapid recycling to TAR, which is critical for the repeated repli-
ation of the viral genome. Cycles of Tat acetylation by p300 and
eacetylation by SIRT1 appear to regulate viral transcription. SIRT1
herefore acts as a coactivator during Tat transactivation (Pagans
t al., 2005). HATi could inhibit Tat acetylation in the ﬁrst place
Balasubramanyam et al., 2004), next to speciﬁc inhibitors of SIRT1
hat could abolish Tat acetylation and deacetylation cycles required
or HIV replication. HDACi are furthermore discussed as agents tar-
eting latent viral reservoirs (Mai, 2007).
.6.2. E1A
The adenoviral transforming protein E1A is acetylated by
300/CBP and PCAF at K239. Acetylation of E1A inhibits p300/CBP-
ependent transcription by interacting with and speciﬁcally
nhibiting p300 activity (Deng et al., 2005). In its acetylated state,
1A can also bind to the carboxyl-terminal binding protein (CtBP)
Molloy et al., 2006). As a consequence, viral diseases can modu-
ate global HAT activity, resulting in abnormal cellular signalling
nd gene expression. Furthermore, acetylation impairs the ability
f E1A to bind importin-3, resulting in cytosolic localisation. The
ytoplasmic fraction of acetylated E1A may in turn affect multiple
ytoplasmic processes (Madison et al., 2002).
. Conclusion
Aberrant lysine acetylation has been reported inmalignant cells
Yang, 2004), and HATs and HDACs are closely linked to severe
iseases such as cancer, neurodegeneration, cardiovascular disor-
ers, inﬂammatory lung diseases, as well as to ageing (Blander
nd Guarente, 2004; Carrozza et al., 2003; Heinzel and Krämer, in
ress; Ito et al., 2007; McKinsey and Olson, 2004; Saha and Pahan,
006). The previous view that HDACi modulate gene expression
ainly by histone acetylation appears to be too narrow. The grow-
ng number of identiﬁed acetylatable targets beyond chromatin
rovides a whole new world of regulatory mechanisms. Further-
ore, switches between acetylation and other posttranslational
odiﬁcations at the same lysine residue play a critical role. The
unctional consequences of acetylation can be almost as variable
s their targets. It is not possible to predict the effect of acety-
ation of proteins at multiple sites without experimental testing,
nd the number of identiﬁed acetylated proteins up to date surely
s below the actual number representing the in vivo acetylome.
n vitro approaches have to be interpreted keeping in mind that
cetyltransferases and deacetylases act primarily in protein com-
lexes. These containmultiple subunits and cofactors that crucially
f Bioch
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ontrol substrate speciﬁcity and enzymatic activity that can hardly
e reconstituted in vitro. However, despite technical challenges,
cetylation research draws attention to the highly interesting ﬁeld
f posttranslational modiﬁcations and their critical impact on cel-
ular functions. HDACi could possibly correct aberrant acetylation
atterns and ameliorate disease states. In the future, acetylation
f non-histone targets should be considered as a crucial molecular
echanism of tumour-selective HDACi therapy.
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Abstract 
The histone deacetylase (HDAC) enzyme family controls eukaryotic transcription, cell 
proliferation and apoptosis. The evolutionary conserved class III HDAC SIRT1 critically 
controls various cellular functions promoting resistance to apoptotic stimuli. The 
dysregulation of HDAC activity is linked to oncogenesis and increased survival rates of 
tumour cells. Identifying mechanisms regulating HDACs is therefore of utmost importance for 
cancer research. Here, we show that histone deacetylase inhibitors (HDACi) decrease 
expression of SIRT1 at the mRNA and protein levels. We demonstrate acetylation-dependent 
posttranscriptional regulation of SIRT1 via the RNA binding protein HuR, which controls the 
stability of SIRT1 mRNA. HDACi evoke nuclear translocation and posttranslational 
modification of HuR. Subsequently, the affinity of HuR for SIRT1 mRNA is altered favouring 
SIRT1 mRNA degradation. We identify an unexpected link between class I/II HDAC 
inhibitors, which do not block the activity of the class III enzyme SIRT1, and reduced SIRT1 
expression. Thus, HDACi indirectly target this epigenetic regulator via posttranscriptional 
regulation. This finding reveals novel mechanistic insights into the control of protein 
expression by HDACi. 
Keywords: acetylation, histone deacetylase inhibitor, protein deacetylase SIRT1, HUR, 
mRNA stability, phosphorylation 
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Introduction  
HDACs are important regulators of gene expression and cellular signalling. According to their 
size and cofactor usage, the HDAC family is grouped into four classes (Bolden et al., 2006). 
Transcriptionally active chromatin is hyperacetylated. Silent chromatin is hypoacetylated, 
which results in a more condensed form. Consequently, access of the transcriptional 
machinery to DNA target sequences is impaired (Kouzarides, 2007). Nevertheless, inhibiting 
HDACs does not simply result in a net increase in gene expression (Spange et al., 2009). 
Moreover, acetylation of lysine residues can modulate the interaction, localisation, stability 
and enzymatic activity of histones and non-histone proteins. Remarkably, acetylation is in 
scope and consequences comparable to the phosphorylation of proteins (Norris et al., 2009; 
Spange et al., 2009). 
Class III HDACs, also termed sirtuins, are NAD+-dependent-enzymes linked to metabolism, 
ageing, apoptosis, differentiation and stress responses in several species (Finkel et al., 
2009). SIRT1 is often linked to positive effects of calorie restriction. It targets a variety of 
cellular substrates like p53, FOXO proteins, NFκB-p65, NCOR, histones H1 and H4, KU70, 
p300, BCL11A, PGC1α, eNOS, E2F1, AR, p73, SMAD7, RB, SUV39H1, COUP-TF (Lavu et 
al., 2008; Liu et al., 2009). Its multitude of intracellular targets mediate stress resistance and 
cell survival which in turn are connected to metabolic control, inflammation and longevity as 
well as cancer development (Donmez and Guarente). Thus, the activity of SIRT1 has been 
implicated in improved organismic health and survival (Baur et al., 2006). Enhanced SIRT1 
expression also showed beneficial effects on tumour development and maintenance in a β-
catenin-driven mouse model of colon cancer (Firestein et al., 2008).  
Although SIRT1 activators are considered for therapy of metabolic diseases, SIRT1 
overexpression or unbalanced activation is linked to cancer by increasing cell survival and 
stress resistance of cancer cells (Jiang, 2008; Lavu et al., 2008). For example, SIRT1 can 
inhibit p53 function by deacetylation (Tang et al., 2008). Furthermore, high SIRT1 levels can 
Manuscript 2_3 
 
inhibit apoptosis by targeting FoxO1 (Jung-Hynes and Ahmad, 2009), E2F1 (Wang et al., 
2006) and p73 (Dai et al., 2007). Moreover, loss of acetylation at Lys16 of histone H4 is a 
hallmark of human cancer pointing to an enhanced SIRT1 activity or a decreased activity of 
the acetyltransferase hMOF (Hajji et al., 2010). A wide variety of cancer tissues, from solid 
tumours to leukaemia, exhibit increased SIRT1 expression compared to healthy tissue (Hida 
et al., 2007). According to the multi-hit model of cancer development, SIRT1 seems to be a 
tumour growth promoter once other critical molecular changes have taken place. Of note, 
sirtuin inhibitors like salermide show a strong cancer-specific proapoptotic effect (Lara et al., 
2009). 
Dysregulated protein acetylation is a frequent feature of human cancers and can result in  
unbalanced cell cycle control and aberrant gene expression. Therefore, enzymes regulating 
the acetylation status represent attractive targets for cancer therapy. Pan-HDAC inhibitors 
like Trichostatin A (TSA), LBH589 or LAQ824, inhibit all classical HDACs (class I, II and IV), 
whereas other HDACi like valproic acid (VPA) or sodium butyrate inhibit a subgroup of these 
deacetylases. Therapeutic effects of HDACi include induction of differentiation, cell cycle 
arrest, senescence, apoptosis and mitotic cell death (Minucci and Pelicci, 2006).  
Due to their evolutionary origin, the class III HDACs – the sirtuins – have a different catalytic 
mechanism that cannot be inhibited by the classical HDACi. Nevertheless, we were 
interested in potential indirect effects of classical, chemotherapeutically active HDACi on 
SIRT1. Here we show that HDACi decrease SIRT1 protein level dramatically. Our data 
indicate that, this reduction is due to altered posttranscriptional regulation of SIRT1 mRNA 
and posttranslational modification of its binding partner HuR. HDACi modulate the cellular 
distribution and binding affinity of HuR favouring cytosolic mRNA decay of SIRT1 transcripts. 
We propose a novel mechanism by which HDACi affect sirtuins and achieve a more 
vulnerable cancer cell condition via reduced expression of SIRT1 in a therapeutic setting. 
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Results  
HDACi decrease SIRT1 protein levels 
HDACi block the catalytic activity of class I/II HDACs and promote the proteasomal 
degradation of the class I enzyme HDAC2 (Krämer et al., 2003). We observed that 
incubation of cells with HDACi like TSA, VPA or butyrate also reduced the protein levels of 
the class III deacetylase SIRT1 drastically (Fig. 1A). Fig. 1B shows that this effect was time-
dependent and reproducible in several different tumour cells. The SIRT1 loss was already 
noticeable after 24 hours, which is consistent with previously published findings (Hajji et al., 
2010; Kyrylenko et al., 2003). Under these conditions, HDACi did not lead to degradation of 
the housekeeping protein tubulin (Fig. 1A, B).  
Given that HDACi are able to increase proteasomal degradation of proteins (Buchwald et al., 
2009; Krämer et al., 2003), we tested whether inhibitors of the 26S proteasome (Lactacystin 
and ALLN) can prevent the decrease of SIRT1 levels upon HDACi treatment. Since co-
treatment with proteasome inhibitors could not counteract the HDACi-induced SIRT1 
reduction (Fig. 1C), we could rule out an HDACi-dependent proteasomal degradation of 
SIRT1.  
Additionally, HDACi can induce apoptosis of cancer cells (Bolden et al., 2006) and SIRT1 is 
a target of caspase-1, -3, -8 and -9 (Ohsawa and Miura, 2006). Therefore, we blocked 
caspase activity with the pan-caspase inhibitor Z-VAD-FMK and analysed SIRT1 protein 
levels. Since this compound permitted detection of a weak signal for SIRT1 in cells treated 
with HDACi, apoptosis appeared as a minor cause of SIRT1 degradation (Fig. 1D). Thus, 
proteasomal degradation and caspases do not contribute significantly to attenuation of 
SIRT1 in cells exposed to HDACi. 
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HDACi target SIRT1 at the posttranscriptional level 
These findings argue for a regulation of SIRT1 at the mRNA level. Indeed, we noticed that 
HDACi reduced SIRT1 mRNA levels (Fig. 2A). This result is consistent with published data 
(Kyrylenko et al., 2003) and suggests that HDACi reduce SIRT1 protein expression by 
affecting SIRT1 mRNA levels.  
Based on these results, we analysed the putative regulation of the SIRT1 promoter by 
HDACi. We tested different SIRT1 promoter fragments towards their activity after HDACi 
treatment in the pGL3-luciferase reporter system. For this purpose, we subcloned fragments 
of the SIRT1 core promoter (1000 bp (A) to 100 bp (F)) containing the transcription start site 
(Fig. 2 B upper panel). These constructs showed a higher basal transcriptional activity 
compared to the pGL3vector containing only the SV40 promoter. Inclusion of the 5´UTR 
resulted in increased overall promoter activity. Unexpectedly, all SIRT1 promoter fragments 
independent of the presence of the 5´UTR showed increased luciferase activity after 
incubation with HDACi (Fig. 2 B). RNA controls from the same cells, run in parallel, however 
showed a decrease in endogenous SIRT1 mRNA levels (data not shown).  
A nuclear run-on assay (NRO) revealed an almost unchanged frequency of transcriptional 
initiation of the endogenous SIRT1 promoter in vivo, while SIRT1 mRNA levels declined (Fig. 
2C). The lack of induction of SIRT1 promoter activity in the NRO as compared to the 
luciferase assay is likely due to the use of the whole promoter context in the NRO versus 
small, non-chromatinised promoter fragments in the reporter assay. The fact that SIRT1 
mRNA expression does not decrease in either case indicates that the loss of SIRT1 may 
depend on the regulation of mRNA stability.  
Having excluded impaired transcriptional induction of the SIRT1 gene, we tested whether 
HDACi reduce the half-life of SIRT1 mRNA. After blocking RNA synthesis with the RNA 
polymerase II inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), we analysed 
the stability of SIRT1 mRNA by quantitative real time-PCR of DRB and HDACi/DRB co-
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treated cells. The SIRT1 mRNA stability was unaltered with DRB alone or in combination 
with butyrate at two and four hours after treatment (Fig. 2D). By blocking protein synthesis 
with cycloheximide (CHX) we determined that de novo protein synthesis is not necessary for 
the effects of HDACi on SIRT1 (Fig. 2E). We therefore conclude that the effect of HDACi on 
SIRT1 expression is direct and does not require de novo synthesis of proteins or RNAs. 
HDACi alter the subcellular localisation of HuR 
The AU-rich element binding protein HuR (ELAV) crucially regulates the stability of the 
SIRT1 mRNA. It binds at several sites within the 1.8 kb 3´-UTR of the SIRT1 mRNA and 
favours SIRT1 expression by enhancing SIRT1 mRNA stability (Abdelmohsen et al., 2007b). 
The conformation of its three RNA recognition motifs (RRMs), its localisation as well as its 
phosphorylation state critically determine HuR’s effects on mRNA stability (Abdelmohsen et 
al., 2007b; Kim et al., 2008). HuR binds to newly synthesised mRNA in the nucleus and is 
co-exported into the cytosol. Cytosolic HuR protects mRNA from degradation and maintains 
translation. We hence speculated that HDACi might reduce SIRT1 mRNA levels by affecting 
this protein. Fluorescence microscopy and Western Blot experiments revealed that HDACi 
treatment reduced the cytosolic amount of HuR, while overall HuR levels remained stable 
(Fig. 3 A & B).  
Although an impact of HDACi treatment on HuR localisation has also been reported by 
others (Pryzbylkowski et al., 2008; Wang et al., 2004), the overall change in HuR localisation 
appears insufficient to fully account for the SIRT1 mRNA loss in cells incubated with HDACi. 
Moreover, the typical NaAsO2-induced cytosolic accumulation of RNA degrading P-bodies 
(Fig. 3 A lower panel) is not seen in HDACi-treated cells, which disfavours a general 
induction of the cytosolic mRNA decay machinery by such agents.  
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HDACi alter the mRNA binding ability and phosphorylation state of HuR 
Modulation of the HuR affinity for SIRT1 mRNA would be a more specific mechanism, than a 
change in HuR localisation. By an RNP-IP approach we tested whether HDACi affect the 
SIRT1 mRNA binding capacity of HuR. As a positive control for reduced HuR binding affinity 
towards SIRT1 mRNA we treated cells with H2O2, which induced Chk2-dependent 
phosphorylation of HuR resulting in dissociation of the HuR-SIRT1 mRNA-complex 
(Abdelmohsen et al., 2007b). After a 24 hour incubation period with HDACi, specific binding 
of HuR to SIRT1 mRNA was no longer detectable (Fig. 4 A). Thus, this effect is linked to the 
HDACi-induced SIRT1 loss upon HDACi treatment.  
Mechanisms affecting the binding affinity of HuR for its target mRNAs can be modulated by 
HuR binding factors or by posttranslational modifications. These observations, together with 
the stable levels of HuR in HDACi-treated cells, suggest an HDACi-induced posttranslational 
modification of HuR. Lysine acetylation is an obvious candidate for an HDACi-induced 
posttranslational modification of HuR. However, immunoprecipitation and Western blotting 
revealed no acetylation of HuR (data not shown).  
Since phosphorylation of HuR influences its SIRT1 mRNA binding affinity strongly, we 
analysed immunoprecipitated HuR by mass spectrometry. This analysis revealed that 
HuR(S202) was phosphorylated in control cells, whereas treated cells showed no 
phosphorylation at this site. Additional sites critical for the HuR-RNA binding affinity are the 
Chk2 (checkpoint kinase-2)-dependent phosphorylation sites HuR(S88, S100, T118). HuR 
phosphorylated at these sites displayed reduced SIRT1 mRNA affinity following oxidative 
stress (Abdelmohsen et al., 2007b). No phosphorylation was detectable at these sites, even 
though the corresponding peptides were traceable. This suggests a Chk2-independent 
mechanism that lowers HuR-SIRT1 mRNA binding affinity. Additionally, our mass 
spectrometry approach identified three novel HDAC-responsive HuR phosphorylation sites, 
at HuR(S41, S142, S197) (Fig. 4B).  
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Effects of HDACi on cancer cells partially depend on attenuation of SIRT1 
Given that SIRT1 favours cancer cell survival, loss of SIRT1 upon HDACi treatment could 
provide therapeutic benefits. To test whether SIRT1 is relevant for anti-proliferative effects of 
HDACi we overexpressed SIRT1 in Hela cells and treated them with TSA to block all 
classical HDACs. The ectopic SIRT1 expression vector did not include the 3´UTR of SIRT1. 
Consequently, it could not be targeted posttranscriptionally. Ectopic SIRT1 expression 
promoted cell growth in comparison to the control (Fig. 5A). In addition to higher proliferation 
rates, SIRT1 overexpression favoured cell viability upon TSA treatment. The effect of SIRT1 
overexpression was most prominent after a 72 hour incubation period. Hence, SIRT1 loss 
upon HDACi treatment could in part account for the therapeutic impact of HDACi therapy. 
 
Discussion 
Alteration of mRNA stability by HDACi affects gene expression 
The proper regulation of deacetylases appears to be critical for the maintenance of 
homeostasis. Accordingly, dysregulated HDAC activity has been found in certain severe 
human malignancies (Bolden et al., 2006; Krämer, 2009). HDACs are known to crucially 
regulate eukaryotic gene expression via deacetylation of histones and other proteins 
targeting transcription. Their inhibition by HDACi alters the expression of 2–10% of human 
genes significantly, with almost equal numbers of genes up- and down-regulated (Müller and 
Krämer, 2010). On the other hand, approximately 50% of inducible changes in gene 
expression are caused by alterations in mRNA stability rather than “direct” transcriptional 
control (Cheadle et al., 2005). It is unknown to which extent posttranscriptional mechanisms 
change gene expression in response to HDACi.  
As a key regulator of cellular signalling, SIRT1 is tightly controlled. Recently, a complex 
network regulating SIRT1 transcription, mRNA stability, posttranslational modifications, co-
factors and binding proteins has been identified. When analysing the effect of HDACi on 
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mRNA stability we found that while SIRT1 mRNA half-life is drastically reduced by DRB, it 
cannot be further decreased by HDACi co-treatment (Fig. 2D). This finding suggests that 
SIRT1 mRNA destabilisation by HDACi is established at later time points. Alternatively, the 
DRB-blocked RNA synthesis may override HDACi-induced effects on SIRT1. HDACi as well 
as DRB may act on the same targets, which excludes additive effects. It is equally possible 
that further RNA-dependent destabilising pathways are needed to enhance SIRT1 mRNA 
degradation (Rössig et al., 2002). Of note, effects of HDACi on posttranscriptional control 
mechanisms just recently became a topic of interest. Our report adds SIRT1 to the few 
proteins like eNOS, p21, ERα, BRM, GATA3, Claudin-1, DNMT-1, -3B that are 
posttranscriptionally regulated by HDACi (Spange et al., 2009). 
HDACi can alter SIRT1 mRNA stability via modulation of HuR 
3´-UTR binding proteins modulate mRNA stability. HuR has been suggested to critically 
affect cell proliferation, tumourigenesis, senescence and stress responses by targeting c-
FOS, c-MYC, COX-2, Tnf-α, GM-CSF, β-catenin, eotaxin, p27, cyclin A, cyclin B1, cyclin D1, 
p21, p27, p53 and SIRT1 mRNA (Abdelmohsen et al., 2007a; Abdelmohsen et al., 2007b). 
While under certain conditions HuR binds tightly to some mRNAs, it dissociates from others 
resulting in complete destabilisation of the transcript (Abdelmohsen et al., 2007b). HuR 
posttranscriptionally regulates SIRT1 expression levels critically, which is evidenced by the 
fact that an siRNA-mediated knock-down of HuR results in a complete loss of SIRT1 protein 
expression. This observation furthermore shows that SIRT1 mRNA is subject to high 
turnover rates (Abdelmohsen et al., 2007a). 
Here, we reveal the novel finding that HDACi evoke dissociation of HuR from SIRT1 mRNA 
and consequently its decay. Thus, we not only provide a new member to the handful of 
proteins controlled posttranscriptionally by HDACi (Spange et al., 2009), our findings even 
suggest a mechanism responsible for this process. 
We also considered that different transport mechanisms as well as binding partners were 
found to affect the cellular distribution of the mainly nuclear HuR protein. Our findings are 
consistent with reports showing a decrease of cytoplasmic HuR levels in cells exposed to 
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HDACi alone or in combination with aza-cytidine (Pryzbylkowski et al., 2008; Wang et al., 
2004). AMP-activated protein kinase (AMPK) might be involved in the HDACi-dependent 
regulation of SIRT1 by HuR. Upon activation of AMPK, p300 becomes phosphorylated which 
in turn triggers acetylation of importin-α1. In this case, acetylation favours binding to its 
nuclear import factor importin-β. Additionally, AMPK phosphorylates importin-α1 creating a 
binding site for HuR. The formed complex containing importin-β/importin-α1/HuR 
translocates into the nucleus. HDACi enhance acetylation of importin-α1, promoting importin-
β binding (Bannister et al., 2000). Basal activity of AMPK without further activation may be 
sufficient to phosphorylate a certain cytosolic HuR fraction, which in turn translocates to the 
nucleus. Ultimately, these points argue for an HDACi-induced shift in the cellular HuR 
distribution independent of AMPK activation.  
In addition to localisation, phosphorylation of HuR interferes with its binding capacity for 
mRNAs (Abdelmohsen et al., 2007b). Phosphorylation of HuR(S202) enhances nuclear 
retention and promotes association of target transcripts with HuR (Abdelmohsen et al., 
2007a). This site is targeted by the cell-cycle dependent kinase 1 (CDK1) favouring nuclear 
localisation and retention of HuR during the G2/M-Phase (Kim et al., 2008). Phosphorylation 
at HuR(S202) was hence observed only in asynchronously growing control cells in different 
cell cycle stages, e.g. with activated CDK1 in the G2/M-phase (Fig. 4B). HDACi like butyrate 
or VPA induce G1-cell cycle arrest via induction of p21 preventing CDK1 activity (Krämer et 
al., 2008). This could explain why there is no detectable HuR(S202) phosphorylation in 
HDACi-treated cells. Therefore, the HDACi effect is independent of the G2/M-induced 
phosphorylation at HuR(S202). 
Regarding SIRT1 mRNA the additional HDACi-induced phosphorylation of HuR(S41, S142) 
(Fig. 4B), located within the RNA binding domains (RRM), may be responsible for the 
reduced binding affinity. Moreover, phosphorylation of HuR(S197), which is positioned close 
to HuR(S202), could interfere with mRNA binding as well as the subcellular localisation of 
HuR. Our results add a new layer to the understanding how HuR regulates SIRT1 mRNA 
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stability in response to protein acetylation. HDACi critically influence HuR phosphorylation 
and mRNA stability of SIRT1. Similar regulatory processes might apply to other enzymes and 
modulators.  
HDACi-mediated SIRT1 loss and cancer sensitivity 
Accumulating evidence supports a tumour-promoting role for SIRT1 (Ford et al., 2005). Since 
SIRT1 knockout mice show no elevated tumour rates after induction of skin papillomas, 
SIRT1 does not act like a classical oncogene. Simple overexpression of SIRT1 does equally 
not per se lead to tumourigenesis (Lavu et al., 2008). Nevertheless, tumour tissues very 
often show elevated SIRT1 levels (Stunkel et al., 2007), which correlates with poor survival 
prognosis of cancer patients (Jang et al., 2008). Deacetylation of the tumour suppressors 
p53, p73 and Ku70 likely contributes to such tumour-promoting functions of SIRT1 (Cohen et 
al., 2004; Luo et al., 2001).  
Congruent with such findings, tumour suppressor proteins including p53, HIC1 and DBC1 
repress SIRT1. During ageing and cancer development, the HIC1 promoter can undergo 
hypermethylation and epigenetic silencing. Consequently, SIRT1 expression is expected to 
rise in ageing tissues, where it might increase the survival of damaged cells and cancer risk 
(Campisi and Yaswen, 2009).  Indeed, inhibition of SIRT1 as well as its siRNA-mediated 
knock-down impairs the growth of multiple cancer cell lines (Kamel et al., 2006; Stunkel et 
al., 2007) as well as tumours (Kojima et al., 2008).  
Classical HDACi do not block the catalytic activity of class III HDACs (Müller and Krämer, 
2010). We could nonetheless demonstrate that these inhibitors have a strong effect on 
SIRT1 expression levels in different cancer cell lines. Hence, decreased expression of SIRT1 
may contribute to the anti-tumourigenic effects of HDACi (Hajji et al., 2010). Transient or 
persistent attenuation of SIRT1 decreases the stress resistance of transformed cells, which 
may explain why HDACi are more effective in killing cancer cells when combined with 
chemotherapeutic drugs inducing cellular stress (Hajji et al., 2010; Müller and Krämer, 2010). 
Hence, the view on whether HDACi target class III HDACs requires a novel definition.  
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Materials and methods 
Cell Culture, Transfections, Luciferase assay and Proliferation 
All cells (293T, Hela, NB4, U3A, P19, 2F and Cos7) were maintained in RPMI medium 
supplemented with 10% FCS (PAA), 1% penicillin/streptomycin. All cell lines were cultured at 
37°C in a 5% CO2 atmosphere. 293T cells were seeded at 2.5*10
4/24-Well and transfected 
with 0.025 µg pGL3 derived promoter vectors using PEI (Sigma). Luciferase assays were 
carried out as described with SIRT1 promoter constructs (Göttlicher et al., 2001). Hela cells 
were transfected using SIRT1 plasmid and Turbofect (Fermentas). The SIRT1 expression 
vector has been described before (Narala et al., 2008). Cell viability was determined by using 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT, Sigma) and was 
represented as percentage of the cell viability of untreated cultures. 
Drugs and chemicals: 
The HDACi and other inhibitors were purchased as indicated: sodium butyrate (Merck), 
valproic acid (Sigma) and TSA (Sigma), cycloheximide (CHX, Sigma), Z-VAD-FMK (Z-VAD, 
Bachem), lactacystein (Lac, Santa Cruz), ALLN (Sigma), sodium orthovanadate (Na3VO4), 
sodium fluoride (NaF), sodium pyrophosphate (NaPP, Sigma), 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole (DRB, Sigma), H2O2 (Merck), 4,5 dimethyl-2-yl 2,5-diphenyl 
tetrazolium bromide (MTT) (Sigma), Luciferin (Promega). 
Preparation of cell lysates, immunoprecipitation and immunoblotting  
For Western blot analysis, all NETN lysates were assessed by BCA assay (Thermo) for 
protein concentrations. They were size-fractionated by SDS-PAGE and transferred onto 
PVDF membranes. Antibodies were obtained from Santa Cruz Biotechnology: SIRT1 
sc15404, HuR sc5261; Sigma: Tubulin #T5168; Upstate Biotechnology: HDAC1 05-614. 
After secondary antibody incubation, signals were detected by enhanced 
chemiluminescence. All Western blots were probed for Tubulin to ensure equal sample 
loading. Densitometric analysis of protein bands was performed with 
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Abobe Photoshop software. To define the relative density in each sample, the average grey 
value of the specific protein band was normalised to the signal for Tubulin.  
Real Time PCR 
RNA was isolated using Trizol (PeqLab). 2 µg of RNA were reverse transcribed using using 
oligo-dT primer and RevertAid M-MuLV Reverse Transcriptase (Fermentas). Semi-
quantitative RealTime-PCR (sq-RT-PCR) was performed using the ABsolute QPCR SYBR 
Green Fluorescein Mix (Thermo) with SIRT1 primers ATTGTTATTGGGTCTTCCCTCA (fw) 
and CATCACAGTCTCCAAGAAGCTC (rev). RT-PCR linearity was controlled with GAPDH 
primers TGCACCACCAACTGCTTAGC (fw) and GGCATGGACTGTGGTCATGAG (rev). 
Nuclear run-on assay 
Nuclear run-on assay was performed as described (Hartmann et al., 2009). Radiolabeled 
RNA was hybridized with a Hybond-N nylon membrane (Amersham) containing immobilized 
fragments of GAPDH (1 µg of a 558 bp fragment generated with primers 
ACCACAGTCCATGCCATCAC (fw) and TCCACCACCCTGTTGCTGTA (rev)) and SIRT1 (2 
µg of a 402 bp PCR-fragment generated with primers CTGGGGAAGGAGACAATGG (fw) 
and GCGAGAGTCTCCCGACCT (rev)). Hybridisation was performed overnight at 65°C with 
1 x 106 c.p.m. labeled RNA per sample using 3 ml of the Rapid-hyb buffer (Amersham) 
according to the manufacturer's recommendations. Signals were quantified by 
phosphoimager (Fujifilm). 
RNP-IP 
Immunoprecipitation (IP) of endogenous RNA-protein complexes was performed as 
described (Abdelmohsen et al., 2007b). The RNA isolated from IP material was reverse-
transcribed using oligo-dT primer and RevertAid M-MuLV Reverse Transcriptase 
(Fermentas). RT-PCR was done as described above. 
Immunofluorescence staining and fluorescence microscopy 
Hela cells were fixed using 4% PFA and permeabilised with PBS + 0,25% Triton X-100. After 
blockading, samples were incubated with primary antibody anti-HuR followed by incubation 
with secondary antibody conjugated with Alexa488 (Invitrogen, Karlsruhe Germany). 
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Subsequently, cells were covered with ProLong® Gold antifade reagent (Invitrogen, Karlsruhe 
Germany) containing DAPI. Microscopic analysis was performed with the ApoTome 
deconvolution system® (Carl Zeiss, Göttingen). Images were processed using 
Abobe Photoshop software. 
Mass spectrometry 
HuR was immunoprecipitated from Hela cell lysates with phosphatase inhibitors NaF, 
Na3VO4 and NaPP, and samples were separated by SDS-PAGE. Protein gels were stained 
with Coomassie stain kit (Invitrogen) and appropriate gel sections were subjected to in-gel 
digestion with trypsin as described (Shevchenko et al., 1996) with one modification: reduction 
and oxidation of thiol groups was performed with a mixture of tributylphosphine and 4-
vinylpyridine (Sigma-Aldrich). The trypsin in-gel protein digests were analysed with LC-ESI-
MS equipment consisting of a MDLCÔ chromatography system (GE Healthcare, Munich, 
Germany) online coupled to a Finnigan LTQ mass spectrometer (Thermo Electron 
Corporation, Dreieich, Germany). The HPLC was equipped with a Zorbax 300SB 5 μM, 
5×0.3 mm trapping column and a Zorbax 300SB 5 μM, 150×0.075 mm separation column 
(Agilent, Böblingen, Germany). The separation of peptides on the HPLC occurred by 
applying a linear gradient running from 0% to 47% acetonitrile, followed by a stepwise elution 
with 84% acetonitrile in 0.1% formic acid, each under control of Unicorn software (GE 
Healthcare, Munich, Germany). The LTQ was operated under control of Xcalibur 1.4 
software (Thermo ElectronCorporation, Dreieich, Germany). For processing of the mass 
spectra and the final protein identification the BioWorks 3.2 software (Thermo Electron 
Corporation, Dreieich, Germany) and the National Center for Biotechnology Information 
human protein database were used. Site-specific phosphorylation analysis was performed by 
scanning pSer and pThr for loss of phosphoric acid (neutral loss of 98) in the respective 
MS/MS spectra. 
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Figures: 
 
 
 
Figure 1  HDACi reduce SIRT1 protein levels  
(a) Western Blot analysis of SIRT1 protein level in lysates from Hela cells treated with 3 mM 
butyrate, 3 mM VPA and 100 nM TSA for 24 h. Tubulin was used as loading control. 
(b) Western Blot analysis of SIRT1 protein levels in lysates from various cell lines treated with VPA 
(1.5 mM) for the indicated time periods (8, 24 and 48 h).  
(c) NB4 cells were either co-treated with butyrate (1.5 mM)/ VPA (1.5 mM) and the proteasome 
inhibitors lactacystein (10 μM)/ALLN (1 µg/ml) or with these agents alone for 24 h. Protein levels 
in lysates were analysed by Western blot.  
(d) NB4 cells were co-incubated with butyrate (1.5 mM) or Z-VAD (20 μM) alone or in combination for 
24 h. Protein levels were analysed by Western blot. (D = DMSO, solvent control for Z-VAD)  
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Figure 2  HDACi reduce SIRT1 protein levels by decreasing SIRT1 mRNA stability 
(a) After a 24 h incubation of 293T and NB4 cells, SIRT1 mRNA levels were analysed by sq-RT-PCR 
at different concentrations (1.5; 3 and 5 mM) of butyrate or VPA. mRNA levels measured in 
untreated cells were set as 1. Data were normalised to GAPDH. (means ± SEM., n = 3) 
(b) Analysis of the SIRT1 promoter was carried out with the pGL3 basic luciferase reporter system. A 
series of fragments (from 1000 bp (A) to 100 bp (F); without 5´-UTR or with 5´-UTR (U) were 
subcloned into a promoterless luciferase vector (pGL3 basic) (panel B, upper part). Data were 
normalised to the activity of a co-transfected SV40 β-galactosidase plasmid to ensure 
comparable transfection conditions; negative control: promoterless vector (pGL3 basic), positive 
control: SV40 promoter containing vector (pGL3 Promoter). (means ± SEM., n = 3) 
(c) Transcription rates of SIRT1 and GAPDH in 293T cells treated for 24 h with 5 mM butyrate were 
analysed by NRO. Upper panel, Representative autoradiographies; Lower panel, densitometric 
analysis.  
(d) Hela cells were treated with the mRNA synthesis inhibitor DRB (75 µM) alone or in combination 
with butyrate (3 mM) for 2 and 4 h. SIRT1 mRNA half-life was evaluated by sq-RT-PCR . Data 
were normalised to GAPDH. (means ± SEM., n = 7) 
(e) NB4 cells were incubated for 24 h with the protein synthesis inhibitor cycloheximide (CHX, 1 
μg/ml) in co-treatment with the HDACi butyrate or VPA. 
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Figure 3  HDACi treatment affects HuR subcellular localisation and mRNA binding affinity  
(a) The subcellular localisation of HuR upon HDACi treatment (3 mM butyrate and 100 nM TSA) was 
analysed in Hela cells after 24h by microscopy. P-bodies were induced by incubation with 0.5 mM 
NaAsO2 for 45 minutes. The DNA dye DAPI was used as a control to visualise the nucleus. The 
mainly nuclear HuR complicated the detection and quantification of the cytosolic HuR levels. 
Therefore, the nuclear areas were removed in the right panel to facilitate the detection of cytosolic 
HuR levels.  
(b) After a 24 h incubation of Hela cells with 3 mM butyrate or 3 mM VPA, cytoplasmic and nuclear 
extracts were analysed for the subcellular localisation of HuR (short and long (*) exposure). 
Loading controls for the cytosolic compartment (Tubulin) and for the nuclear compartment 
(HDAC1) were used to ensure proper fractionation. Densitometric analysis of the HuR protein 
bands in the different subcellular compartments is included (lower part). 
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Figure 4  The phosphorylation pattern of HuR changes in response to HDACi treatment 
(a) After incubating 293T cells for 24 h with 3mM butyrate, lysates were subjected to RNP-IP with an 
antibody specific for HuR. The depicted levels of HuR-bound SIRT1 mRNA after HDACi 
treatment represent data from one representative experiment (n=3). H2O2 treatment was used as 
a positive control for the decrease of SIRT1 mRNA binding to HuR. 
(b) Schematic diagram of the HuR domain structure is depicted including published phosphorylation 
sites, the associated kinases and functional consequences. HuR was immunoprecipitated from 
Hela cell lysates after 24 h incubation with 3 mM But, separated by SDS-PAGE and further 
analysed by mass spectrometry. Phosphorylation sites identified by this approach are shown 
underneath the HuR domain structure.  
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Figure 5  SIRT1 increases survival of HDACi-treated cells 
(a) Hela cells were transfected either with control plasmid or pBabe-Ires-Neo-SIRT1-R. Cell survival 
was assessed in response to TSA (50 nM and 100 nM) after 24 h, 48 h and 72 h treatment by 
MTT assay.  
(b) HuR protects and assures expression of SIRT1 mRNA by binding to its 3´-UTR. Under HDACi 
treatment HuR becomes phosphorylated and dissociates from the mRNA. SIRT1 mRNA devoid 
of HuR is prone to degradation by the mRNA decay machinery. 
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Supplementary Figure 1  Mass spectrometric analysis of HuR  
The HuR peptide SLFSSIGEVESAK (AA 38-50) was identified in control and treated lysates of Hela 
cells by MS. The ESI-MS blots (left panels) and an enlarged image detail (right panels) of this 
particular peptide show the fragment ions of the b- and y-series. The further MS/MS analysis was used 
for localisation of a particular phosphorylation event within the peptide. Treated cells show a mass loss 
of 18 at the SLFS peptide ion (b4
+1
) in treated cells. This characteristic neutral loss of the peptide 
confers to a phosphorylation event at Ser41 under HDACi-treatment. The identification of 
phosphorylated peptides was shown exemplarily at this peptide and applied to the other peptides 
accordingly.  
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We show that the histone deacetylase inhibitor valproic acid (VPA) combined with the 
ribonucleotide reductase inhibitor hydroxyurea (HU) efficiently elicit HNSCC cancer cell 
deathVPA/HU enhances expression of the pro-apoptotic BCL-2 family protein BIM through 
transcriptional activation. We provide a molecular rationale for the potent anti-cancer 
activities of this drug combination, which efficiently eliminates HNSCC in murine tumour 
xenografts. 
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ABSTRACT 
Background 
Head and neck squamous cell carcinomas (HNSCC) are characterized by resistance to 
therapy due to the overexpression of anti-apoptotic proteins and the epidermal growth factor 
receptor (EGFR), counteracting improvement of long-term survival. 
 
Methods 
Employing HNSCC cell lines, freshly isolated tumor cells and murine tumor transplantation 
models, we show that the histone deacetylase inhibitor valproic acid (VPA) combined with 
the ribonucleotide reductase inhibitor hydroxyurea (HU) efficiently trigger HNSCC cancer cell 
death. In vitro, VPA/HU treatment is superior in cancer cell killing when compared to cisplatin 
or the EGFR inhibitors cetuximab and gefitinib. VPA/HU enhances expression of the pro-
apoptotic BCL-2 family protein BIM through AP-1 mediated transcriptional activation, 
whereas PUMA and BAX levels are not increased. The pro-apoptic activity of BIM in HNSCC 
was confirmed by ectopic overexpression and RNAi-mediated depletion studies. Also, 
significantly elevated BIM levels (p<0.01) were detectable in the apoptotic tumor centers 
versus proliferating tumor margins in HNSCC patients (n=31), underlining BIM’s clinical 
relevance. Importantly, VPA/HU treatment additionally reduces expression and cell surface 
localization of EGFR. 
 
Conclusion 
We provide a molecular rationale for the potent anti-cancer activies of this drug combination, 
which efficiently eliminates HNSCC in murine tumor xenografts. A major advantage 
promoting clinical studies with VPA/HU is the fact that both agents have already been tested 
in the clinics, whereas other anti-tumor strategies targeting BCL-2 family members have 
unknown toxicity profiles and uncertain clinical efficacy. The VPA/HU combination will be of 
therapeutic interest most likely also for other tumor entities characterized by therapy 
resistance and EGFR activation. 
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INTRODUCTION 
With a worldwide annual incidence of more than 640,000 cases, head and neck cancer is 
the sixth most common malignant neoplasm in humans (1, 2). The majority of head and neck 
squamous cell carcinoma (HNSCC) is induced by chronic exposure to a surplus of 
carcinogens enclosed in all forms of tobacco, synergized by heavy alcohol consumptions 
and/or is associated with oncogenic human papillomaviruses (3, 4). HNSCC is characterized 
by local tumor aggressiveness, high rate of early recurrences and development of second 
primary carcinomas (3). Loco-regional relapse after therapy is the major cause of death 
despite modern disease management strategies (5, 6). Hence, long-term survival rates, 
especially for advanced HNSCC (30-40%), have not improved significantly over the last 
decades (3, 6). Currently, EGFR-targeting agents, such as antibodies or tyrosine kinase 
inhibitors gained major clinical attention (3, 7). Despite encouraging developments, EGFR-
directed therapies are effective only in a relatively small percentage of cancer patients 
underlining the need for additional treatment options (7). 
Therapy resistance favoring recurring or advanced-stage HNSCC mainly results from 
failure of the tumor cells to undergo chemoradiation-induced apoptosis (1, 3). Particularly, 
the intrinsic or mitochondrial pathway of programmed cell death (PCD) plays an important 
role for killing cancer cells in response to various therapies, and is controlled by interactions 
among pro- and anti-apoptotic BCL-2 protein family members (8, 9). Pro-survival proteins like 
BCL-XL and BCL-2 inhibit apoptosis by binding and neutralizing the activities of the pro-
apoptotic multidomain proteins BAX and BAK as well as the BH3 domain-only proteins BIM, 
BIK, NOXA, and PUMA (8-10). 
Overexpression of anti-apoptotic BCL-2 proteins and apoptosis inhibitors like Survivin is 
known for HNSCC and plays a critical role for therapy resistance and overall survival (8, 9, 
11). Consequently, strategies for neutralizing these cytoprotective factors involve shifting the 
cellular balance of anti- versus pro-apoptotic proteins in favor of the latter. As a 
consequence, proteins such as BIM (B cell lymphoma 2 interacting mediator of cell death) 
participate in the formation of a pore that permeabilizes the mitochondrial outer membrane. 
  Manuscript 3_4 
 
   
Pro-apoptotic contents are exposed to the cytoplasm where they engage various aspects of 
the downstream apoptotic machinery (8, 9). Hence, permeabilization of the mitochondrial 
outer membrane is considered the point of commitment to cancer cell death. 
In this respect, histone deacetylase inhibitors (HDACi), such as VPA, have emerged as 
promising chemotherapeutic agents by inducing a wide range of anti-tumoral activities, 
including induction of cell cycle arrest and apoptosis (12). HDACi can correct aberrant 
genomic and non-genomic signaling by chromatin remodeling as well as histone/protein 
modifications (13). The (pre)clinical efficacy of HDACi has been examined in various studies 
(12, 14, 15). Likewise, the ribonucleotide reductase inhibitor hydroxyurea (HU) sensitizes 
tumors to cancer therapy-induced apoptosis and has been used to treat HNSCC (16). 
However, it has not been investigated whether the combination of VPA and HU may be 
applicable for the treatment of HNSCC nor have molecular mechanisms underlying its 
potential anti-tumoral activity been resolved in detail. 
Our study demonstrates for the first time that this drug combination efficiently eliminates 
HNSCC cancer cells by evoking expression of the pro-apoptotic protein BIM and by 
downregulation of EGFR. This potent dual anti-tumoral activity strongly suggests the clinical 
exploitation of this novel drug combination as a strategy to counteract therapy resistance in 
HNSCC. 
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MATERIAL AND METHODS 
Cells, transfections and luciferase assay 
Cultivation of the indicated head and neck cancer and other tumor cell lines has been 
described in detail (17-21) (Supplementary Table SI). Cell lines constitutively expressing 
shRNA directed against BIM or a scrambled control were generated by transfection of pHR-
THT-BIMshRNA-SFFV-eGFP or pHR-THT-scr_shRNA-SFFV-eGFP (22), respectively. Cells 
were selected by addition of puromycin (1 µg/ml; Sigma Aldrich, Munich, Germany). Cells 
were transfected using PEI (Sigma Aldrich, Munich, Germany) or Lipofectamine (Invitrogen, 
Karlsruhe, Germany). Luciferase assays were carried out as stated (19, 23). All reporter 
experiments were performed out in triplicate and repeated thrice. 
Microscopy and image analysis 
Observation, image analysis and quantification of protein localization were performed as 
described (24). DNA/cell nuclei were visualized by Hoechst 33258 staining (Sigma Aldrich, 
Munich, Germany) according to (24). At least 100 fluorescent cells were analyzed in three 
independent experiments. 
Patients, tissue sampling and primary tumor cell isolation 
 Biopsies of patients diagnosed with HNSCC and treated at the Departments of Oral and 
Maxillofacial Surgery and ENT of the University Hospitals in Frankfurt and Mainz were 
analyzed. Tumor specimens were collected from primary tumors of patients who underwent 
surgery. All cases were clinically and histologically diagnosed according to established 
criteria including grading and TNM-classification (Supplementary Table SII). Studies of 
human tissue biopsies were performed according to the requirements of the local ethics 
committee, and informed consent was obtained in accordance with the Declaration of 
Helsinki. For the isolation of primary cancer cells, tumor specimens were cut into small 
pieces and enzymatically digested with collagenase typeI/hyaluronidase (Sigma Aldrich, 
Munich, Germany) in RPMI-1640 (Invitrogen, Karlsruhe, Germany) at 37°C overnight. 
Following digestion, dissociated cells were passed through a cell strainer, and epithelial 
cancer cells separated from stromal cells by MACS® separation using CD326 (EpCAM) 
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MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the 
manufacturer’s recommendations. Cells were propagated for one week as described (25) 
and subjected to analysis.  
Drug treatment and clonogenic survival assay 
Cells were treated with VPA, trichostatin A (T), sodium butyrate (B), HU, or cisplatin 
(Sigma Aldrich, Munich, Germany) as described (15, 25). The EGFR antagonists gefitinib 
(Tocris Bioscience, Ellisville, USA) and cetuximab (ImClone, New York, NY, USA) were 
applied for 48 h. For folony formation assays, 1x103 cells/T25 flask were seeded in triplicate. 
24 h later, cells were treated with the indicated compounds or PBS control and further 
cultivated for 10 days. Drug-containing medium was replaced every day. Cells were fixed 
and stained with Giemsa. Colonies containing >50 cells were counted automatically using a 
colony counter (Oxford Optronics, Oxford, United Kingdom). Data shown are calculated from 
the mean values of three independent experiments. 
Antibodies (Ab) 
Ab were: -PUMA (4976) (NEB Cell Signaling, Frankfurt, Germany); -Survivin (Novus 
NB 500-201; Novus Biologicals, Littleton, CO); anti-ß-Actin (A2066), -BIM (B7929), anti-
alpha-Tubulin (T5168) (Sigma Aldrich, Munich, Germany); -BCL-XL (66461A), -Caspase-8 
(9745), -9 (9501) (Pharmingen); cleaved Caspase-3 (9664) (Cell Signaling); -BAX (sc-
20067), -Caspase-3 (sc-7272/-7148), -EGFR (sc-81449), -ERK1/2 (sc-135900), -
STAT3 (sc-482) (Santa Cruz Biotechnology, Heidelberg, Germany). Appropriate HRP-, Cy3- 
or FITC-conjugated secondary antibodies (Sigma Aldrich, Munich, Germany; Santa Cruz 
Biotechnology, Heidelberg, Germany) were used. 
Protein extraction, immunoblot analysis and immunofluorescence 
Preparation of whole lysates from cells or tissue, co-immunoprecipitations and 
immunoblotting were carried out as described (18, 19). Equal loading of lysates was 
controlled by reprobing blots for Actin or Tubulin as described (19). Immunofluorescence was 
performed as described in detail (19, 24). 
 
  Manuscript 3_7 
 
   
Immunohistochemistry (IHC) 
Tissue samples or transfected cell pellets were formalin fixed, paraffin embedded (FFPE) 
and processed for IHC as described (17, 18). For antigen retrieval, sections were treated in a 
pressure cooker with Tris buffer (10 mM, pH9.0) for BIM or were treated with proteinase K 
(S3020, DakoCytomation, Glostrup, Denmark) for 8 min at room temperature for EGFR 
detection. Sections were incubated with primary Ab ( -BIM, 1:800; -EGFR 1:50) overnight 
at 4°C. For visualization, the EnVision® detection system (Dako GmbH, Hamburg, Germany) 
was applied as described (17). Sections were counterstained with hematoxylin. Negative 
control slides without primary Ab were included for each staining. For quantification, sections 
were scanned at low power to identify areas of positivity and three random fields were 
selected. Expression levels for BIM were scored semi-quantitatively based on staining 
intensity and distribution using the immunoreactive score (IRS) (17). IRS=SI (staining 
intensity) x PP (percentage of positive cells). SI is assigned as 0, negative; 1, weak; 2, 
moderate; 3, strong. PP is defined as 0, negative; 1, <5%; 2, 6–30%; 3, 31–60%; and 4, 
>60% positive cells. 
Measurement of apoptosis, cell cycle and viability 
Assessment of apoptosis was performed by quantifying Caspase-3-dependent hydrolysis 
of a fluorogenic substrate and by immunoblot-based detection of cleaved caspases (19). 
Apoptotic cells were visualized by analyzing mitochondrial integrity using the PromoKine 
Mitochondrial Apoptosis Staining Kit (PromoCell; Heidelberg, Germany), staining of 
fragmented nuclei with Hoechst dye or TUNEL-staining according to (26). Briefly, 200 cells 
from three separate images were inspected and the percentage of apoptotic cells 
determined. Cell viability was calculated employing MTT-assays and the electric sensing 
zone method according to (18, 19). Cell cycle profiles were obtained by FACS-mediated 
analysis of prodidium iodide (PI) stained cells according to (15). 
Xenograft tumors 
FaDu cells (2x106) cells were implanted into both flanks of four-week-old female NMRI 
nu/nu mice (Harlan Winkelmann, Hamburg, Germany) (26) and were allowed to establish for 
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seven days followed by treatment for 14 d. VPA/HU (350 mg/kg, 750 mg/kg body weight) or 
PBS control was administered intraperitoneally (i.p.) everly second day as described (23). 
Mice were randomized into groups (4 mice/group) such that the average tumor volumes 
across the groups were equal. Tumor growth was monitored using calipers to calculate tumor 
volumes according to the formula: length x  width2 x 0.52. Animals were euthanized at the 
end of the study, and the tumors processed for IHC analysis as described (26). All animal 
experiments were approved by the Institutional Animal Care and Use Committees at the 
Universities of Erlangen and Mainz. 
Statistical analysis 
For all experiments stating p-values, a paired Student’s t-test was performed. Unless 
stated otherwise, p-values represent data obtained from three independent experiments 
done in triplicate. p-values <0.05 were considered as significant. 
Plasmids and RNAi 
The expression construct for human BIMEL, pCDNA4/TO-BIMEL, was described (27). For 
expression of a BIMEL-GFP fusion, BIMEL cDNA was PCR amplified and cloned into pc3-GFP 
(pc3BIMEL-GFP) as described (24). pGL3-luciferase reporter constructs containing the BIM 
promoter, MYB, E2F or AP1 binding sites have been described (28). Lentiviral vectors 
constitutively expressing shRNA directed against BIM or a scrambled control, pHR-THT-
BIMshRNA-SFFV-eGFP or pHR-THT-scr_shRNA-SFFV-eGFP, respectively were reported 
(22).
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RESULTS 
VPA and HU synergize in the killing of HNSCC tumor cells and loss of clonogenicity 
Cell lines representing HNSCC from different anatomical sites (Supplementary Table SI) 
were treated with VPA and HU alone and in combination. MTT assays revealed that although 
VPA and HU individually inhibited proliferation in a dose-dependent manner, co-
administration of VPA/HU was most effective (Figure 1A and B; Supplementary Table SI).  
Similar results were obtained using a clonogenic cell survival assay (Figure 1C). FACS 
analysis showed that the VPA/HU combination potently induced apoptosis and confirmed 
that HU induced S-phase arrest (Figure 2A; Supplementary Figure S1A). Induction of cell 
death was already evident using a single dose of 0.3 mM VPA/HU and was not dependent 
on repetitive drug administration (Figure 2A). VPA/HU-induced apoptosis was further 
confirmed by independent experimental approaches. Immunoblot analysis showed enhanced 
cleavage of Caspases-3, -8 and -9 (Figure 2B; Supplementary Figure S1B). Also, increased 
Caspase-3 activity was detectable in lysates from treated cells, which could be counteracted 
by the pan-Caspase inhibitor Z-VAD-FMK (Figure 2B). The observed cleavage of Caspase-9, 
the loss of mitochondrial integrity, and DNA-fragmentation upon treatment strongly imply that 
the intrinsic apoptosis pathway is responsible for VPA/HU induced cell death (Figure 2C; 
Supplementary Figure S1C). Data for representative cell lines are shown. Similar results 
were obtained for other cell lines tested (Supplementary Table SI; data not shown). 
Induction of the pro-apoptotic protein BIM by VPA/HU treatment correlates with cell 
death 
When analyzing the effects of VPA/HU treatment on the levels of pro- and anti-apoptotic 
BCL-2 proteins, we observed increased BIM levels (Figure 3A). Although both drugs slightly 
induced expression of BIM, the effect was most prominent using the VPA/HU combination, 
correlating with enhanced apoptosis. The doses required to induce appreciable Caspase-3 
activation and apoptosis were comparable to those necessary to induce BIM expression 
(Figure 2 and 3A). Notably, this effect was not restricted to VPA as treatment with other 
HU/HDACi combinations, such as with TSA or butyrate, also resulted in BIM induction and 
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cell death (Supplementary Figure S1D; data not shown). Another BH-3-only protein, p53-
upregulated modulator of apoptosis (PUMA), was recently reported to mediate apoptosis 
induced by EGFR inhibitors in HNSCC cells (10). In contrast to the strong induction of BIM 
by VPA/HU, immunoblot analysis revealed no enhanced expression of PUMA, BAX, and 
BCL-2/BCL-xL (Figure 3G and data not shown). Moreover, VPA/HU could induce BIM in p53-
negative PC3 cells, and BIM induction could be verified by independent methods in p53-
mutant FaDu cells (Supplementary Figure S1E, S2A). 
BIM is critical for VPA/HU-induced apoptosis in HNSCC cells 
To demonstrate that enhancing BIM levels triggers apoptosis in HNSCC cell lines, we 
first performed ectopic overexpression studies. Transfection of plasmids encoding a BIMEL-
GFP fusion or untagged BIMEL, the longest BIM isoform (196 amino acids), resulted in 
efficient cell death (Figure 3B and not shown). 
In order to confirm direct relevance of BIM for VPA/HU-induced apoptosis, we used RNAi 
to deplete endogenous BIM. HNSCC cells with attenuated BIM expression displayed 
enhanced proliferation linked to reduced basal apoptosis rates (Figure 3C and data not 
shown). Furthermore, compared to the scrambled-control, cell lines with BIM levels reduced 
by BIM-specific shRNAs showed significantly enhanced resistance to VPA/HU-induced cell 
death, as verified by analyzing Caspase-3 activation, TUNEL-staining and loss of 
mitochondrial integrity (Figure 3D; Supplementary Figure S2B). Collectively, these results 
provide strong evidence that BIM is critical for the VPA/HU-induced killing of HNSCC cells. 
VPA/HU enhances BIM expression via AP1-dependent transcriptional activation 
Increased BIM levels (Figure 3E) could be the result of transcriptional activation (28, 29). 
Transfection of a BIM promoter-containing luciferase reporter revealed that VPA/HU indeed 
stimulated BIM transcription (Figure 3F). To date, several transcription factors have been 
reported to regulate BIM transcription (9, 28). VPA/HU-induced BIM expression was 
observed also in cells bearing inactive p53 (FaDu) or p53-negative cells (PC3) 
(Supplementary Figure S1D and E), and a BIM reporter containing an inactivated MYB-
binding site was still responsive to VPA/HU treatment (Supplementary Figure S2C). 
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Transfection of HNSCC cells with E2F- or c-JUN/FOS (AP1)-dependent reporter constructs 
finally demonstrated the crucial role of AP1 for the VPA/HU-mediated transcriptional 
activation of BIM (Supplementary Figure S2D). Although pharmacological inhibition of ERK 
signaling was critical for BIM expression in B-RAF/K-RAS mutant lung tumor cells (9), 
VPA/HU did not affect ERK levels but still evoked enhanced BIM expression in our cell 
models (Supplementary Figure S2E). 
BIM expression in tumor biopsies from head and neck carcinoma patients 
To show that BIM is expressed also in HNSCC patients, we first visualized BIM 
expression by IHC in tumor biopsies (n=31). Using the immunoreactive score (IRS) (17), 
significantly elevated BIM levels (p<0.001) were observed in cancer cells in the apoptotic 
tumor centers versus proliferating tumor margins (Figure 4A and 4B). Hence, regulated BIM 
expression appears to be relevant for disease progression and outcome. Second, to 
definitely demonstrate that BIM is induced by VPA/HU also in primary tumor cells triggering 
apoptosis, we tested cancer cells freshly isolated from HNSCC patients. Treatment of such 
tumor cells with VPA/HU resulted in enhanced BIM levels and cancer cell death (Figure 4C). 
VPA/HU attenuates expression and cell surface localization of EGFR. The EGF receptor 
is overexpressed in epithelial malignancies and represses BIM expression (9, 30). As EGFR-
targeting strategies are currently tested in the clinics for HNSCC, we investigated the effects 
of VPA/HU treatment on this receptor. Interestingly, immunoblot analysis revealed that the 
combination of VPA/HU efficiently reduced the levels of total and phosphorylated EGFR 
(Figure 5A). To further examine the intracellular localization of EGFR, cells were treated with 
VPA/HU or PBS, FFPE and examined by IHC analysis. This analysis not only confirmed the 
reduction of EGFR levels, but also showed that such treatment attenuated the cell surface 
localization of the receptor and enhanced BIM expression (Figure 5B). As a control, VPA/HU 
treatment appears not to cause a general attenuation of pro-survival proteins, as STAT3 
levels, an important factor for head and neck carcinogenesis (31), were not significantly 
affected (Supplementary Figure S2E). Collectively, these data provide evidence for a hitherto 
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unknown molecular mechanism explaining the potent anti-cancer activity of the VPA/HU 
combination. 
VPA/HU efficiently suppresses HNSCC tumor growth in murine xenotransplantation 
models 
Prior to testing the anti-tumoral activity of VPA/HU in murine models, we first evaluated 
the cell killing activity of VPA/HU and of chemotherapeutic drugs currently used in the clinics. 
In our HNSCC cell culture models, VPA/HU treatment was more effective in triggering cell 
death, when compared to the EGFR inhibitors cetuximab and gefitinib or the DNA-damaging 
agent cisplatin (Supplementary Figure S2F). 
These in vitro-results encouraged us to examine whether VPA/HU treatment also inhibits 
tumor growth in vivo. Using a xenograft model, established FaDu tumors were treated with 
VPA/HU (350 mg/kg, 750 mg/kg body weight) or PBS control i.p. for 14 days. Administration 
of VPA/HU to FaDu tumor-bearing mice significantly inhibited tumor growth (p<0.001) (Figure 
5C). To visualize whether drug treatment also enhanced BIM levels and caused EGFR 
attenuation in vivo, tumors from treated and control animals were analyzed by IHC. 
Enhanced BIM levels and reduced EGFR expression were observed in tumors from VPA/HU 
treated animals compared to those from control mice (Figure 5D). The above data not only 
confirmed the potent anti-cancer activity of the VPA/HU combination in vivo, but also 
demonstrated the in vivo-relevance of the molecular mechanisms identified in our cell culture 
models. 
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DISCUSSION 
Employing comprehensive in vitro and in vivo models we here demonstrate for the first 
time that combining HDACi with a ribonucleotide reductase inhibitor potently kills HNSCC. 
Although such agents have been shown to individually affect tumor cells (16, 32), the 
(pre)clinical anti-tumor activities of the VPA/HU combination as well as the underlying 
molecular mechanisms have not been investigated so far for HNSCC. 
Treatment of malignant cells with HDACi can induce a wide range of anticancer effects 
including apoptosis, cell cycle arrest, differentiation as well as immunomodulatory effects (12, 
33-35). Hence, numerous HDACi have been tested in the clinics or are currently the subject 
of ongoing early-phase clinical trials, including HNSCC (14, 36-38). Since HDACi 
monotherapies seem not to be effective against solid tumors, their full therapeutic potential 
will be best realized through combination with other anticancer agents (15, 34). However, 
most reports do not provide a well-defined molecular rationale for combining an HDACi with 
a given agent. Moreover, the molecular and biological events that underpin any observed 
additive or synergistic combination effects are largely lacking (15, 34). 
In contrast, we here provide convincing evidence that activation of the proapoptotic BH3-
only protein BIM is a key regulator for VPA/HU-induced tumor cell death. This conclusion is 
based on several lines of evidence: First, freshly isolated tumor cells from HNSCC patients 
responded to VPA/HU administered at therapeutically achievable levels with BIM induction 
and apoptosis. These results strongly support an expectable clinical efficacy of VPA/HU 
independent from the fact that permanent tumor cell lines may differ dramatically from 
primary tumor cells at their molecular level (39). Furthermore, VPA/HU induced BIM 
upregulation, induction of apoptosis and loss of the clonogenic potential of HNSCC cell lines 
derived from different anatomical sites. This finding will be clinically relevant as SCC from 
different anatomical regions, like the hypopharynx or the oral cavity, differ drastically in their 
clinical prognosis and response (6). Second, ectopic expression and RNAi experiments 
convincingly demonstrated that BIM is essential for VPA/HU-induced cancer cell death. 
Third, VPA/HU efficiently prevented progression of HNSCC tumors in nude mice correlating 
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with enhanced BIM levels. The tumor growth delay achieved with the combination treatment 
was highly significant compared with the untreated control, without major toxicity. 
BIM-evoked apoptosis can be crucial for epithelial tumor cell death triggered by anti-
cancer therapeutics (9, 40, 41). Consistent with this notion, we found strong induction of the 
intrinsic cell death pathway via mitochondrial Cytochrome C and Caspase-9. Although the 
BH-3-only protein PUMA was recently reported to mediate apoptosis of HNSCC cell lines 
induced by EGFR tyrosine kinase inhibitors (10), VPA/HU-mediated PCD did not require 
induction of the p53 target genes PUMA and BAX. Notably, HNSCC cells with attenuated 
BIM expression even displayed enhanced proliferation. Our finding suggests that lowering 
endogenous pro-apoptotic factors not only increases tumor cell survival but also proliferation 
is potentially relevant for HNSCC therapy response and progression. Although we have 
shown that BIM plays a major role in death signaling, this does not rule out the additional 
participation of other BCL-2 family members and/or other apoptosis inhibitor proteins (1, 10). 
Remaining apoptosis rates of HU/VPA-treated cells with attenuated BIM expression are 
probably mediated via alternative pro-apoptotic proteins and/or the activation of the extrinsic 
death pathway (10, 42). 
As we did not observe increased BCL-2/BCL-xL levels upon VPA/HU treatment 
potentially neutralizing increased BIM expression, it is conceivable to speculate that the 
addition of BH3 mimetics, such as ABT-737, may not further boost tumor cell death. In 
contrast, killing of B-RAF mutant lung tumor cells required BIM induction by inhibition of ERK 
signaling combined with ABT-737, whereas B-RAF wild type cancer cells were even largely 
resistant to this treatment (29). As the frequency of RAF/RAS mutations in HNSCC is rather 
low (43, 44), VPA/HU is thus likely to be clinically more effective when compared to certain 
other attempts to alter BCL-2 family members (9).  
Increased BIM levels could be the result of reduced proteasomal degradation or 
enhanced transcriptional activation (8, 9, 45). We found that VPA and HU activate BIM at the 
transcriptional level. To date, several transcription factors, including p53, E2F, c-JUN/FOS 
(AP1), MYB, RUNX3, and FOXO3A have been reported to regulate BIM transcription (9, 28, 
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46). Our data collectively support a crucial role of AP1 for VPA/HU-mediated transcriptional 
activation of BIM in HNSCC. This finding seems to be of clinical relevance as in contrast to 
p53, which is mutated in the majority of HNSCC (47), the AP1 system is intact in cancer 
patients (48). S-phase-dependent induction of c-JUN could be a mechanism enhancing BIM 
expression (49). Of note, the activity of c-JUN is repressed by the HDAC3-NCoR complex 
(50), which is particularly sensitive to inhibition by VPA (12, 23). Phosphorylation of c-JUN by 
JUN kinase (JNK) permits dissociation of HDAC3 and c-JUN-dependent transcription (50). 
HU has been shown to activate JNK in vivo (51), which thereby could contribute to c-JUN-
dependent BIM induction. Our results do not contradict the reported activation of BIM via E2F 
and MYB, as these data were collected in different cell systems with different stimuli (28). 
HNSCC tumors are often characterized by deregulated EGFR signaling due to receptor 
overexpression, activating receptor mutations and aberrant downstream signaling cascades. 
Survival is secured by the sequential phosphorylation and activation of MEK and ERK 
kinases, leading to stabilization of MCL-1, activation of BCL-2, and degradation of BIM. 
Pharmacogenetic approaches interfering with EGFR signaling trigger apoptosis by 
enhancing BIM expression (9). Importantly, we demonstrate for the first time that VPA/HU 
treatment efficiently reduced not only EGFR levels, but also attenuated its cell surface 
localization in vitro and in tumor xenografts. The underlying mechanisms remain to be 
resolved in detail. These may involve HU-induced replication arrest, known to attenuate 
oncogenic tyrosine kinase signaling (52), and/or the E3 ubiquitin ligase c-CBL, which controls 
EGFR ubiquitination and lysosomal degradation (53).  
A major advantage allowing now to expedite clinical studies using VPA/HU for the 
treatment of HNSCC is the fact that both agents have already been used in the clinics (16, 
37). Thus, one can rely on an extensive knowledge on the therapeutically most effective 
dose and pharmacodynamics of these drugs (32, 38). The safety profiles of HDACi and HU 
have been favorable, especially in comparison to traditional cytotoxic chemotherapy. 
Toxicities common to most HDACi tested as well as to HU, are fatigue, nausea, and diarrhea 
(16, 32, 37, 38, 54). Compared with other anti-tumor strategies targeting BCL-2 family 
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members (29), for which toxicity profiles and clinical efficacy are not yet known, this 
advantage will allow to swiftly translating our findings into the clinical arena. Although recent 
targeting strategies such as antibodies directed against EGFR (cetuximab) or the Vascular 
Endothelial Growth Factor (bevacizumab), have gained major attention, the clinical response 
rates to such therapies are rather low (7, 16). In addition, whereas these agents are 
expensive and often show a suboptimal pharmacodynamic profile, VPA and HU are cheap 
and stable drugs, which can be administered orally (14, 16). Moreover, as the VPA/HU 
combination also attenuates EGFR, it may represent a contingency treatment option for 
patients acquiring resistance to EGFR-targeting approaches (55). Although not examined in 
this study, suffice it to say that the VPA/HU combination may be of therapeutic interest also 
for other tumor entities, characterized by therapy resistance and EGFR overexpression, such 
as colon cancer. 
Despite our pre-existing knowledge and the potent dual anti-tumor activity of VPA/HU 
with tolerable toxicity in mice shown here, it remains now to be demonstrated that this drug 
combination shows therapeutic efficacy without dose-limiting toxicities in the clinic. 
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FIGURES 
 
Fig. 1. VPA and HU synergize in HNSCC cells growth inhibition and loss of clonogenicity. Columns, 
mean; bars, SD from three independent experiments. A) Indicated cell lines were treated with VPA 
(V), hydroxyurea (HU), VPA/HU (1.5 mM each) or PBS (C; set as 1) for 48 h, and proliferation was 
analyzed by the MTT assay. B) Treatment was performed with the indicated drug combinations or 
PBS (C; set as 1). Cell proliferation was assessed with MTT. C) VPA/HU affects clonogenic cell 
survival. Cells were seeded and 24 h later treated with the indicated compounds or PBS. Surviving 
colonies were counted 10 d later and displayed as colony forming units (CFU) relative to the PBS 
control (C; set as 1). 
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Fig. 2. VPA and HU efficiently trigger apoptosis in HNSCC tumor cells. A) Drug-induced apoptosis 
was determined by measuring the sub-G1 population by flow cytometry (PI staining) 48 h post 
treatment. Induction of cell death was already evident using a single dose of VPA/HU (1.5 mM/0.5 
mM) and was not further enhanced by additional drug administration after 24 h (VPA/HU 2X). B) 
VPA/HU treatment (1.5 mM each; 48 h) induced caspases activation sensitive to the pan-Caspase 
inhibitor Z-VAD. Immunoblot analysis demonstrated cleavage of Caspase-3 and -9 (upper panel; 
tubulin, loading control. Apoptosis was quantified by measuring Caspase-3 activity in cell lysates 
(lower panel). C) VPA/HU-induced cell damage shown by analyzing mitochondrial integrity and by 
TUNEL-staining. The VPA/HU combination (1.5 mM each) caused significant mitochondrial damage 
already 24 h post treatment, resulting in loss of dimeric MitoCapture dye staining (upper panel). 
TUNEL-staining revealed VPA/HU-induced DNA-damage indicative of apoptotic cells (lower panel). 
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Fig. 3. VPA/HU-treatment specifically induces the BCL-2 family protein BIM modulating cell 
proliferation and apoptosis. A) Cells were drug treated (1.5 mM; 20 h) and expression levels of the 
indicated proteins were visualized by immunoblot. Actin served to control equal loading of cell lysates. 
B) Cell death induction by ectopic expression of BIMEL-GFP. BIMEL-GFP was visualized 24 h post 
transfection in FaDu cells by direct and indirect immunofluorescence using -BIM Ab. C) 
Downregulation of BIM in HNSCCUM-03T cells stably transfected with BIM- (shBIM) vs scrambled-
shRNA (shCtl) verified by immunoblot. Counting revealed that cells with attenuated endogenous BIM 
levels displayed enhanced proliferation. D) Decreased VPA/HU-induced apoptosis (1.5 mM each, 24 
h) in BIM-depleted cells shown by immunoblot analyses for BIM and cleaved Caspase-3 (left), as well 
as by quantification of enzymatic Caspase-3 activity in cell lysates (right). E) Immunoblot revealed that 
VPA/HU (1.5 mM each) induced BIM in a time-dependent manner. F) VPA/HU-mediated 
transcriptional activation was monitored by analyzing luciferase activity. FaDu cells transfected with a 
BIM reporter were treated with VPA/HU (1.5 mM each). G) In contrast to the strong induction of BIM 
levels by VPA/HU, correlating with Caspase-3 cleavage, no enhanced expression of PUMA and BAX 
was induced by VPA/HU. Actin and Tubulin served as loading controls. Columns, mean; bars, SD 
from three independent experiments. 
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Fig. 4. BIM expression in tumor biopsies from head and neck carcinoma patients. A) Detection of BIM 
in HNSCC tumor centers (TC) vs proliferating tumor margins (TM). Representative example of an oral 
SCC (G2, pT3, pN0) stained with hematoxylin/eosin (HE) (left panel) and immunohistochemical 
visualization of BIM using -BIM Ab (right panel). B) Box plot (with range) for BIM IRS reveals 
enhanced BIM expression in the TC in HNSCC patient biopsies (*p<0.001; n=31). C) Treatment of 
freshly isolated tumor cells from two patients (T1: Hypopharynx, G2, pT3, pN0; T2: oral cavity, G3, 
pT3, pN0) with VPA/HU (1.5/0.5 mM) for 48 h resulted in BIM induction and Caspase-3 activation. 
Indicated proteins were detected by immunoblot analysis. Actin served as loading control. 
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Fig. 5. Effects of VPA/HU on EGFR and suppression of HNSCC tumor growth. A) FaDu cells were 
treated with V, HU, VPA/HU (1.5 mM each) or PBS (C). Expression of proteins indicated was analyzed 
by immunoblotting. Actin served to control equal loading. VPA/HU treatment effectively reduced the 
levels of total and phosphorylated EGFR. B) FaDu cells treated with VPA/HU (1.5 mM each) were 
FFPE and used for IHC analysis employing EGFR- or BIM-specific Ab. Treatment resulted in reduced 
expression and cell surface localization of the EGFR as well as increased BIM levels. C) VPA/HU 
suppressed the growth of FaDu HNSCC xenograft tumors. Growth curve of tumors subjected to 
VPA/HU (i.p., 350 mg/kg and 750 mg/kg body weight) or PBS control. Nude mice were inoculated with 
FaDu tumor cells. When tumors had reached the target size of 0.1 cm
3
, mice were treated once every 
second day for 14 days. *p<0.001, n=4 animals per treatment group, data are mean±SD. D) Enhanced 
BIM and reduced EGFR levels in xenograft tumors at the end of VPA/HU treatment. BIM and EGFR 
expression was visualized by IHC. 
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SUPPLEMENTARY MATERIAL 
 
Fig. S1. A) Effect of VPA/HU treatment (1.5 mM each) on HNSCCUM-03T cells analyzed by flow 
cytometry (PI staining). The increase in the sub-G1 population, indicative of apoptosis, was most 
prominent 48 h post treatment. B) Indicated drug treatment (VPA, HU; 1.5 mM each) of HNSCCUM-
03T cells resulted in cleavage of Caspase-8 and -9 demonstrating activation of PCD demonstrated by 
immunoblot. C) VPA/HU-induced cell damage was shown by analyzing mitochondrial integrity and by 
TUNEL-staining of FaDu cells. VPA/HU treatment (1.5 mM each) caused significant mitochondrial 
damage already 24 h post treatment, resulting in loss of dimeric MitoCapture dye staining. TUNEL-
staining revealed VPA/HU-induced DNA-damage characteristic for apoptotic cells, which was most 
prominent 48 h post treatment. D) The combination of HU with HDACi synergize in BIM-induction. 
FaDu cells were treated with V (1.5 mM), HU (1.5 mM), V/HU (1.5 mM each), trichostatin A (T, 100nM) 
and HU (1.5 mM), sodium butyrate (B, 1.5 mM) and HU (1.5 mM) for 24 h. BIM expression was 
analyzed by immunoblot. Tubulin served as the loading control. E) VPA/HU-treatment results in 
enhanced BIM expression in p53-negative PC3 cells. Cells were treated with V (1.5 mM), HU (1.5 mM) 
or V/HU (1.5 mM each) for 20 h. BIM expression was visualized by immunoblot analysis. Actin served 
as the loading control. 
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Fig. S2. A) VPA/HU-induced (1.5 mM each, 24 h) BIM expression versus PBS control (C) in 
HNSCCUM-03T cells was visualized by indirect immunofluorescence using BIM-specific Ab followed 
by staining with a Cy3-conjugated secondary Ab. B) BIM depletion attenuates VPA/HU-induced 
apoptosis. Decreased VPA/HU-induced apoptosis (1.5 mM each, 24 h) in cells stably expressing BIM- 
(shBIM) vs scrambled-shRNA (shCtl) is shown by TUNEL-staining or by analyzing mitochondrial 
integrity (Mito). C) In contrast to the empty control vector (pGL3), VPA/HU treatment resulted in 
transcriptional activation of the BIM-reporter as well as of a reporter containing a BIM promoter with an 
inactivated MYB-binding site (BIM-MYB
mut
). D) VPA/HU promotes AP1-dependent transcriptional 
activation of the BIM promoter. FaDu cells transfected with the indicated reporter constructs were 
treated with VPA/HU (+; 1.5 mM each, 6 h) or PBS control (-). Transcriptional activation was 
monitored by quantifying luciferase activity (RLU). Columns, mean; bars, SD from three independent 
experiments. E) Time-dependent effects of VPA/HU-treatment on survival pathways in FaDu cells. 
Expression of the indicated proteins was visualized by immunoblot. Actin was used to monitor equal 
loading of cell lysates. In contrast to the strong reduction of EGFR levels, no significant effect on ERK 
or STAT3 levels were detectable. F) Evaluation of the cytotoxic activity of VPA/HU and 
chemotherapeutic drugs. FaDu cells were treated with PBS (C, set at 100%), cetuximab (10 mg/ml), 
gefitinib (20 M), cisplatin (10 M) or VPA/HU (1.5 mM each) for 48 h and the numbers of viable cells 
counted. Columns, mean; bars, SD from three independent experiments. 
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Supplementary Table SI 
Anatomical origin, EGFR status, VPA/HU-induced BIM expression and apoptosis of cell lines 
used in the study. 
 
A 
HNSCC cell line / 
anatomical origin 
EGFR 
expression 
VPA/HU-induced 
BIM expression Apoptosis* 
    
Naso-/Oropharynx    
    
Nasopharynx    
Detroit 562 high + ++ 
Tonsils    
UMB-SCC-864 high + + 
UMB-SCC-969 high + + 
Tongue    
HNSCCUM-02T high + ++ 
SCC-4 (CRL-1624) high + ++ 
    
Hypo-/Laryngopharynx    
    
Hypoharynx    
FaDu high + + 
Piriform sinus    
HNSCCUM-03T 
 
high + ++ 
Larynx    
UM-SCC-5 high + ++ 
UM-SCC-10B high + ++ 
UM-SCC-24 high + ++ 
UM-SCC-33 high + ++ 
    
B 
Cancer cell line / 
anatomical origin 
EGFR 
expression 
VPA/HU-induced 
BIM expression Apoptosis* 
    
Prostate    
    
PC3 (B-Raf WT) high + ++ 
    
Lung    
    
A549 (B-Raf/K-RAS mut) high + ++ 
    
 
*Cell viability was calculated employing MTT-assays. 
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Supplementary Table SII 
Tumor stages and clinical characteristics of 31 HNSCC patients examined by IHC analysis. n.k.: not 
known; M: male; F: female. 
A 
Case 
Staging 
Grading Age Sex 
pT pN 
      
1 T2 N2 G2 47 M 
2 T4 N2 G2 68 M 
3 T4 N1 G2 46 M 
4 T1 N2 G3 57 M 
5 T2 N3 G2 56 M 
6 T2 N1 G3 50 M 
7 n.k. n.k. n.k. n.k. n.k. 
8 T3 N1 G2 48 M 
9 T3 N2a G2 58 M 
10 T3 N2 G2 56 M 
11 T2 N3 G2 57 M 
12 T2 N2 G3 56 M 
13 T4 N3 G3 56 M 
14 T2 N2 G2 47 F 
15 T2 N1 G2 58 F 
16 T3 N2 G2 58 F 
17 T3 N2 G2 72 M 
18 T3 N1 G2 49 M 
19 T4 N2c G3 66 M 
20 T2 N2b G2 53 M 
21 T4 N2 G2 51 M 
22 T3 N1 G2 47 M 
23 T3 N2 G2 56 M 
24 T4 N1 G2 42 F 
25 T4 N3 G3 56 M 
26 T3 N2 G2 49 M 
27 T3 N1 G2 58 M 
28 T1 N2 G3 57 M 
29 T2 N3 G2 57 M 
30 T2 N2 G2 47 M 
31 T4 N2 G2 80 M 
      
B 
 
Parameter  
Anatomical site  
Naso -/Oro - 
pharynx (N) 
Hypo -/Laryngo - 
pharynx (N) 
   
pT1/2 10 2 
pT3/4 12 6 
N0/1 5 3 
N2/3 17 5 
G1 0 0 
G2 17 6 
G3 4 2 
 22 8 
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4. Discussion 
4.1 Acetylation as a regulator 
Posttranslational modifications of lysine residues can strongly interfere with protein 
function (Merrick and Duraisingh, 2007). In general, acetylation changes the electrostatic 
state of lysine from positive to neutral, increasing the hydrophobicity and the size of the 
amino acid side chain. Via such alterations, acetylation can affect enzymatic activity. 
Secondly, acetylated lysines exhibit slightly different preferences for secondary structures 
than unacetylated lysines. Thirdly, the different modifications like acetylation, sumoylation, 
ubiquitination and methylation can compete for the same lysines important for signalling 
pathways. Fourthly, a modification within localisation signals can change the subcellular 
distribution of a protein (Kim et al., 2006). Additionally, the acetylation of lysines can create 
a new docking site for protein-protein interactions, for example recognition by 
bromodomains. In sum, acetylation can determine protein function, including protein 
stability, protein structure, DNA binding capacity and protein-protein interactions. 
In eukaryotic cells, acetylation is among the most common covalent modifications and 
ranks almost equivalently to the important master switch phosphorylation (Kouzarides, 
2000). Up to now, thousands of acetylated proteins have been identified even though far 
fewer acetylases than kinases have been described. Acetylation apparently shows a broader 
substrate spectrum than phosphorylation. Therefore, its targets cover transcription factors 
and many other proteins involved in DNA repair and replication, metabolism, cytoskeletal 
dynamics, apoptosis, nuclear import, protein folding and cellular signalling (Choudhary et al., 
2009; Cohen and Yao, 2004; Kouzarides, 2000; Sterner and Berger, 2000; Yang and Gregoire, 
2007).  
In sum, these modified proteins are called the acetylome. Acetylation can affect 
signalling pathways and thereby alter cell fate and function. Acetylation can activate 
transcription independent from histone acetylation by orchestration of transcription factors 
and the transcriptional machinery. Moreover, mRNA splicing, mRNA transport, mRNA 
integrity, translation, protein activity, protein localisation, protein stability and interactions 
are regulated by acetylation.  
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Figure 11 
Effects of acetylation on 
signalling, transcription 
and posttranscriptional 
events.  
(A) p300/CBP-
mediated site-specific 
acetylation of p65 or p50 
has a major impact on 
the transcriptional 
activity of NF-κB in vitro. 
Hereby, sitespecific 
acetylation can activate 
or inhibit transcription.  
(B) Acetylation 
of STAT1 induces its 
interaction with p65. 
The resulting complex 
dissociates from DNA, 
translocates into the 
cytoplasm and inhibits 
the activity of NF-κB. (C) 
Acetylation of 
transcription factors can 
affect dimerisation (e.g., STAT3), DNA binding affinity (e.g., p53) or subcellular localisation (e.g., HNF-4) and thereby transcriptional activity. 
(D) HDACi alters the cellular acetylation state of various proteins including factors needed for pre-mRNA processing or translation. 
Additionally HDACi have been shown to alter mRNA stability (Spange et al., 2009). 
 
In short: Acetylation can interfere with every step of regulatory processes from 
signalling to transcription to protein degradation. The proper regulation of deacetylases 
appears to be critical for the maintenance of homeostasis, which is exemplified by 
deregulated HDAC activity in certain severe human malignancies (Bolden et al., 2006; Glozak 
and Seto, 2007; Marks and Xu, 2009). 
4.2 HDACi affect SIRT1 by targeting HuR 
The long way from newly synthesised RNA to its translation into a protein is a multi-
step process. Posttranscriptional control is mainly mediated by cis-acting RNA elements 
located in the 5'- and 3'-untranslated regions of mRNAs (5'-UTRs and 3'-UTRs) that can be 
targeted by trans-acting RNA binding proteins (Grzybowska et al., 2001; Pesole et al., 2001). 
The control of mRNA stability is often under-rated as a mechanism for the regulation of gene 
Discussion 
Modulation of regulatory processes by HDACi 
25 
 
expression. In fact, the initiation of transcription is just one side of the medal. The other side 
includes pre-mRNA processing, mRNA transport, mRNA stability and finally translation into 
protein. In the end, transcriptional activation does not necessarily result in increased protein 
levels.  
HDACs are known to crucially regulate eukaryotic gene expression via deacetylation of 
histones and other proteins targeting transcription. The addition of HDACi is thought to 
enhance transcriptionally active chromatin, which is hyperacetylated. Consequently, access 
of the transcriptional machinery to DNA target sequences is simplified (Kouzarides, 2007; 
Rosenfeld et al., 2006). Nevertheless, inhibiting HDACs does not simply result in a net 
increase in gene expression {Glozak, 2007 #27; Spange et al., 2009). Their inhibition by 
HDACi alters the expression of 2–10 % of human genes significantly, with almost equal 
numbers of genes up- and down regulated (Daly and Shirazi-Beechey, 2006; Gray et al., 
2004). To which extent posttranscriptional events contribute to the changes in gene 
expression is unknown. It is estimated that about 50% of all changes in gene expression 
actually are alterations in mRNA stability rather than “direct” transcriptional control 
(Cheadle et al., 2005). Actions of HDACi towards such posttranscriptional control 
mechanisms have not been the focus of research so far, whereas other proteins like eNOS, 
p21, ERα, Brm, DNMT-1, -3B, GATA3 and now also SIRT1 have been shown to be 
posttranscriptionally regulated by HDACi (Licata et al., 2009; Spange et al., 2009) (Figure 11 
D). 
As a key regulator of cellular signalling, SIRT1 is tightly controlled. In recent years, a 
complex network regulating SIRT1 action emerged including its transcription, co-factors, 
binding proteins and posttranslational modifications modulating SIRT1 function. 
Additionally, HuR posttranscriptionally regulates its expression levels. An siRNA-mediated 
knockdown of HuR resulted in a complete loss of SIRT1 protein expression. This and the fact 
that the RNA-Polymerase II inhibitor DRB drastically reduces SIRT1 mRNA half life suggests 
that SIRT1 mRNA is subject to high turnover rates. The stabilising action of HuR depends on 
its subcellular distribution as well as on its ability to bind mRNA tightly. Many different 
transport mechanisms as well as HuR binding partners affect the cellular distribution of the 
mainly nuclear protein. The cytoplasmic fraction of HuR is thought to protect mRNA from the 
cytosolic mRNA degradation machinery by binding to the 3´-UTR. Exposing cells to HDACi 
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decreases cytoplasmic HuR levels. The change in HuR localisation mediated by HDACi alone 
or in combination with aza-cytidine has already been described (Pryzbylkowski et al., 2008; 
Wang et al., 2004). In this context, the AMP-activated protein kinase (AMPK) is critically 
involved in the subcellular distribution of HuR. Upon AMPK activation p300 becomes 
phosphorylated. This enhances p300 activity, triggering acetylation of importin-α1(K22). This 
in turn favours the binding to its nuclear import factor importin-β. Additionally, AMPK 
phosphorylates importin-α1(S105) creating a binding site for HuR. The posttranslational 
modification-dependent complex of importin-β/ importin-α1/HuR translocates into the 
nucleus (see Figure 12). Regarding the effect of HDACi, they are thought to enhance 
CBP/p300-dependent acetylation of importin-α1(K22). Hence, this promotes the binding to 
its cofactor importin-β by neutralising an unusual basic residue within the IBB interaction 
domain (Bannister et al., 2000). Additionally, phosphorylation on importin-α1(S105) is 
equally important as acetylation of importin-α in the nuclear import process of HuR. It is 
unclear whether acetylation alone or only in combination with phosphorylation of importin-
α can trigger its nuclear localisation. The binding affinity of importin-α1 towards HuR is 
enhanced upon phosphorylation of serine 105 (Wang et al., 2004). An importin-α mutant of 
S105 was not able to locate HuR to the nucleus.  
Moreover, phosphorylation at either HuR(maybe S202) or importin-α(S105), which 
increases their binding affinity towards each other, can be discussed. Nevertheless, HDACi 
alone triggered HuR nuclear localisation without increasing AMPK enzymatic activity after 6h 
treatment (Wang et al., 2004). The basal activity of AMPK without further activation may be 
sufficient to phosphorylate a certain cytosolic HuR fraction, which in turn translocates to the 
nucleus. Eventually, this points to an HDACi-induced shift in the cellular HuR distribution 
independent from AMPK activation.  
Another mechanism triggering nuclear localisation of HuR is the CDK1 dependent 
phosphorylation of HuR(S202). In a cell cycle-dependent manner – the phosphorylation at 
site 202 of HuR enhances the binding of 14-3-3 protein which leads to a nuclear retention of 
HuR during the G2/M-Phase (Kim et al., 2008a) (see Figure 12). Our mass spectrometric 
analysis revealed that in control cells HuR(S202) is phosphorylated, whereas Butyrate-
treated cells showed no phosphorylation at this site. The phosphorylation at HuR(S202) was 
observed only in untreated cells, which consist of a mix of asynchronously growing cells in 
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different cell cycle stages with activated CDK1 in the G2/M-phase. HDACi like Butyrate or 
VPA have been shown to induce G1-cell cycle arrest via p21 induction preventing CDK1 
activity (Krämer et al., 2008). This could explain why there is no detectable HuR(S202) 
phosphorylation in HDACi treated cells. Therefore, the HDACi effect is independent of the 
G2/M-induced phosphorylation at HuR(S202). Additional transport mechanisms depicted in 
Figure 12 comprise the PKCα/δ-dependent phosphorylation at HuR(S221) triggering a 
cytoplasmic localisation. 
 
 
Figure 12 HuR – regulation of the subcellular HuR Transport Depicted are several transport mechanisms 
targeting the subcellular localization of HuR. The main export factor is CRM1 which exports HuR in combination 
with different cargo proteins (APRIL, pp32, SETα and SETβ). Importin α1 and β serve as import factors. These 
transport mechanisms can be further stimulated or abrogated by distinct signalling pathways that target the 
posttranslational modification of HuR or its transport factors. The green and red arrows depict whether certain 
pathways trigger a cytosolic or nuclear localisation of HuR.  
 
Moreover, phosphorylation at HuR(S197) which we identified, is located close to 
HuR(S202) and could interfere with mRNA binding or localisation. Kim et al. mutated 
different phosphorylatable amino acids in the hinge region of HuR. There was no significant 
shift in the basal subcellular localisation of the HuR(S197A) mutant (Kim et al., 2008b). It is 
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possible that under conditions of cellular stress this phosphorylation site can interfere with 
HuR localisation. 
In addition to localisation, posttranslational modifications interfere with HuR RNA 
binding capacity (Abdelmohsen et al., 2007b). As mentioned, phosphorylation of HuR(S202) 
not only enhances nuclear retention, it also shows an increased association of target 
transcripts with HuR (Kim et al., 2008a). Moreover, H2O2-induced DNA damage activates the 
kinase Chk2, which in turn phosphorylates HuR at distinct sites (S88, S100 & T118) resulting 
in a loss of HuR-SIRT1 mRNA binding affinity. This SIRT1-specific mechanism leads to a strong 
decline in SIRT1 levels (Abdelmohsen et al., 2007b). HDACi do not affect these sites in our 
approach. Hence, it is likely that other posttranslational modifications of HuR are responsible 
for the decline of mRNA binding. Presumably, the additional phosphorylation at HuR(S41 & 
S142) within the RNA binding domains could be responsible for the loss of HuR affinity 
towards SIRT1 mRNA upon HDACi treatment. The posttranslational modifications could also 
indirectly affect mRNA binding by creating novel surfaces for protein interactions modulating 
protein or RNA binding. 
 
 
Figure 13 HuR - phosphorylated sites HuR phosphorylation sites above the domain structure indicate published 
phosphorylation sites, the associated kinases and functional consequences. The Sites underneath the domain structure 
represent phosphorylation sites identified in our mass spectrometrical approach of 24 h incubated (3 mM But) Hela cells. 
 
How HDACi induce the phosphorylation of different sites in HuR (see Figure 13 – sites 
under domain structure) is still unknown. HDACi do not directly target kinases. Therefore, 
indirect pathways activated by HDACi are probably causing a kinase activation or 
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phosphatase inactivation triggering HuR phosphorylation. All 3 sites have so far not been 
described as phosphorylated or targeted by specific kinases. 
HuR has so far not been described to be targeted by HDACs. Immunoprecipitated 
cytosolic HuR shows HDAC activity in a RNA dependent way. This suggests that HuR 
indirectly binds an RNA-associated deacetylase. They suggested HDAC6 because it is the 
major HDAC in the cytosol (Scott et al., 2008). Our effect is detectable under conditions not 
inhibiting HDAC6. Therefore, we can rule out that the co-immunoprecipitated, putative 
HDAC6 plays a role in our system. Nevertheless, there are correlations between an increase 
in claudin-1 and HDAC-2 mRNA expression throughout all stages in colon cancer patients. 
Inhibition of claudin-1 expression by HDAC-2-specific small interfering RNA further 
supported the role of HDAC-2 in this regulation. In this context, HDAC inhibitors decrease 
claudin-1 mRNA stability mediated by its 3′-UTR (Krishnan et al., 2010). 
HuR protects and assures expression of SIRT1 mRNA by binding to its 3´-UTR. Under 
HDACi treatment HuR dissociates from the mRNA and becomes phosphorylated.  
4.3 Further possible HDACi-mediated posttranscriptional regulation scenarios 
Together with proteins, small noncoding RNAs can control the fate of mRNA. The role 
of miRNAs (micro RNAs) in this regulatory network is under intensive investigation. These 
endogenous highly conserved RNAs (21 – 23nt) primarily bind within the 3´-UTR of mRNAs. 
Their extent of complementarity causes siRNA-like mRNA degradation or inhibition of 
translation of the targeted mRNA. 
HDACi can modulate the expression of proteins as well as regulatory RNAs. Nearly a 
third of all human genes are estimated to be regulated by miRNAs (Bartel, 2004). By 
modulating the expression of miRNAs, HDACi may also effect protein expression in a more 
indirect way. Only a very limited number of studies focused on miRNA expression under 
HDACi treatment. HDACi can change the miRNA expression pattern similar to other protein 
coding genes (Bandres et al., 2009; Lee et al., 2009; Scott et al., 2006). A profile of miRNA 
expression in LAQ824-treated SKBr3 cells showed that the expression of the SIRT1 targeting 
miR-34a slightly decreases, whereas expression of miR-200c increases (Scott et al., 2006). 
SAHA incubation induces miR-132 expression drastically in A549 cells (Lee et al., 2009). 
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Therefore, this specific miRNA should be analysed in further investigations in the SIRT1 
HDACi regulation process. 
Additionally, SIRT1 expression can be changed upon HDACi-induced downstream 
effects like cell cycle arrest. This is the case for the SIRT1-targeting miR-34a, which is 
cyclically expressed in Hela cells, with the lowest levels in the G1/S-phase (Zhou et al., 2009). 
Therefore, it does not seem to play a major role in our system. Hela cells showed no increase 
in miR-34a while NB4 cells upregulated miR-34a. Moreover, this shows that HDACi can target 
miRNAs in a cell type-specific context (see Supplementary Figure 1).  
Further investigations need focus on the interdependent regulation of genes by 3´UTR 
binding proteins and miRNAs. HuR has been shown to repress c-Myc through an 
interdependent mechanism with let7 miRNA. Both binding sites are located next to each 
other. This suggests a regulatory model wherein HuR inhibits c-Myc expression by recruiting 
let-7-loaded RISC (RNA miRNA-induced silencing complex) to the c-Myc 3'UTR (Kim et al., 
2009).  
4.4 HDACi affect BIM 
As mentioned, BIM is a crucial regulator of apoptosis. Therefore, its expression and 
activity is tightly controlled in normal and cancer cells preventing cell death. BIM activity is 
repressed by growth factor signalling pathways, especially the extracellular signal-regulated 
kinase 1/2 (ERK1/2) and protein kinase B (PKB) pathways. In tumour cells these oncogene-
regulated pathways inhibit BIM action, thereby promoting tumour cell survival. 
Transcription of the BIM gene is normally repressed by serum, growth factors and 
cytokines, and increases upon the withdrawal of these factors (Bouillet et al., 1999; Ewings 
et al., 2007; Whitfield et al., 2001). In this context, FOXO3A, inhibited by ERK1/2 and PKB, 
induces BIM transcription (Gilley et al., 2003). Hence, the inhibition of either the ERK1/2 or 
PKB pathway is sufficient to increase BIM mRNA in many cell types. The expression and 
activation of BIM seems to be a common response to some chemotherapeutics. Indeed, BIM 
emerged as an important mediator of tumour cell death in response to chemotherapeutics 
(Gillings et al., 2009).  
Increased BIM levels could be the consequence of reduced proteasomal degradation 
or enhanced transcriptional activation, mRNA stability or translation (Hendrickson et al., 
Discussion 
Modulation of regulatory processes by HDACi 
31 
 
2008; Youle and Strasser, 2008)). We found that VPA and HU activate BIM at the 
transcriptional level. To date, several transcription factors, including p53, E2F, c-JUN/FOS 
(AP1), MYB, FOXO1/3A, and RUNX3 have been reported to regulate BIM transcription 
(Biswas et al., 2007; Hendrickson et al., 2008). Our data collectively support a crucial role of 
AP1 for VPA/HU-mediated transcriptional activation of BIM in HNSCC. This finding seems to 
be of clinical relevance as in contrast to p53, which is mutated in the majority of HNSCC 
(Poeta et al., 2007), the AP1 system appears to be intact also in cancer patients (Mishra et 
al., 2010; Weber et al., 2007). S-phase-dependent induction of c-JUN could be a mechanism 
enhancing BIM expression (Yogev et al., 2006). Of note, the HDAC3-NCoR complex 
(12853483), which is particularly sensitive to inhibition by VPA, represses the activity of c-
JUN (see Figure 5). Phosphorylation of c-JUN by JUN kinase (JNK) permits dissociation of 
HDAC3 and c-JUN-dependent transcription (Weiss et al., 2003). HU has been shown to 
activate JNK in vivo (Yan and Hales, 2008), which thereby could contribute to c-JUN-
dependent BIM induction. Also the VPA/HU combination treatment of HNSCC cells enhances 
BIM expression via AP1-dependent transcriptional activation (Biswas et al., 2007; Cragg et 
al., 2008). Although ERK signalling was reported to be critical for BIM expression VPA/HU did 
not affect ERK levels in our cell models.  
4.5 HDACi target cancer cells in parallel ways by SIRT1 and BIM 
4.5.1 HDACi therapy 
Treatment of malignant cells with HDACi can induce a wide range of anticancer effects 
including apoptosis, cell cycle arrest, and differentiation targeting tumour cells at different 
stages of cancer development (Bolden et al., 2006; Frew et al., 2009).  
Hence, numerous HDACi have been tested in the clinic or are currently the subject of 
ongoing clinical trials, including HNSCC (Blumenschein et al., 2008; Bots and Johnstone, 
2009; Prince et al., 2009; Schrump, 2009). Since HDACi monotherapies do not seem to be 
effective against solid tumours, their full therapeutic potential would be best realised 
through combination with other anticancer agents (Bolden et al., 2006; Krämer et al., 2008). 
However, most reports do not provide a well-defined molecular rationale for combining an 
HDACi with a given agent. Moreover, the molecular and biological events that underpin any 
observed additive or synergistic combination effects are largely lacking (Bolden et al., 2006; 
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Krämer et al., 2008). HDACi modulate various signal transduction pathways. Probably, the 
crosstalk of all these pathways in sum contributes to cancer cell sensitisation and apoptosis 
induction. The co-treatment of HDACi with other chemotherapeutics seems to be favoured 
above monotherapies. HDACi make cancer cells more vulnerable towards apoptosis and cell 
death (Hajji et al., 2010; Iacomino et al., 2008). This work provides two possible contributors 
to the effect of sensitisation established by the concurrent regulation of SIRT1 and BIM. 
4.5.2 SIRT1 
Although SIRT1 has been reported as a tumour suppressor in colon cancer by 
deacetylating the tumour promoter β-catenin (Firestein et al., 2008), most evidence 
supports a tumour-promoting role for SIRT1 (Ford et al., 2005). SIRT1 knockout mice showed 
no elevated tumour rates after induction of skin papillomas by the classical two-stage 
carcinogenesis protocol. Therefore, SIRT1 does not act like a like a classical tumour-
suppressor gene. Strikingly, tumour tissue very often shows elevated SIRT1 levels (Stunkel et 
al., 2007), which correlate with poor survival prognosis (Jang et al., 2008). Deacetylation of 
the tumour suppressors p53, p73 and Ku70 likely contributes to the tumour-promoting 
functions of SIRT1 (Cohen et al., 2004a; Dai et al., 2007; Luo et al., 2001). Following the 
multi-hit model of cancer development, SIRT1 seems to be a tumour growth promoter 
coming into play after aberrant changes have taken place. 
SIRT1 is repressed in non-malignant cells by tumour suppressor proteins including p53, 
HIC1, DBC1, and Chk2. During ageing and cancer development, the HIC1 promoter can 
undergo hypermethylation and epigenetic silencing (Chen et al., 2005). In this cells SIRT1 
expression is expected to rise, where it might enhance the survival of damaged cells and 
cancer risk (Campisi and Yaswen, 2009). The simple increase of SIRT1 expression does not 
per se lead to tumorigenesis (Lavu et al., 2008; Zeng et al., 2009). Nevertheless, inhibition of 
SIRT1 as well as its siRNA-mediated knockdown have been shown to have growth inhibitory 
effects on multiple cancer cell lines (Kamel et al., 2006; Solomon et al., 2006; Stunkel et al., 
2007) and tumour growth (Chang et al., 2009; Kojima et al., 2008).  
Beside knockdown, the subcellular localisation of SIRT1 is important. The mainly 
nuclear protein can have a cytosolic localisation in normal cells as well as cancer cells 
(Moynihan et al., 2005; Stunkel et al., 2007; Tanno et al., 2007). While only a small 
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percentage stays in the nucleus targeting well-established factors, cytosolic SIRT1 may affect 
a completely different set of yet undiscovered functional proteins. In consequence, 
“carcinogenic” SIRT1 functions should be considered in the discussion of tumour suppressing 
or promoting actions of SIRT1 in tumour development. Indeed, deacetylation of cytosolic 
cortactin by SIRT1 has been shown to promote cell migration (Zhang et al., 2009). 
So far, classical HDACi have not been described to impair the catalytic activity of class 
III sirtuins (Müller and Krämer, 2010). We could clearly show that these inhibitors have a 
strong effect on SIRT1 expression levels in different cancer cell lines. Hence, decreased 
expression of SIRT1 may contribute to the anti-tumourigenic effects of HDACi (Hajji et al., 
2010). Transient or persistent attenuation of SIRT1 decreases the stress resistance of 
transformed cells. Such an observation may explain why HDACi are more effective in killing 
cancer cells when combined with chemotherapeutic drugs inducing cellular stress (Hajji et 
al., 2010; Müller and Krämer, 2010).  
4.5.3 BIM 
BIM has attracted increasing attention as a plausible target for tumour therapy. It 
promotes anoikis of many tumour cells, such as lung cancer, breast cancer, osteosarcoma, 
melanoma and HNSCC. Various chemotherapeutic agents mediate cell death via BIM 
activation. Hence, BIM suppression supports metastasis and chemoresistance. BIM-targeted 
therapies offer benefits including the selective of treatment for tumour cells (Akiyama et al., 
2009).  
The work in manuscript 3 provides convincing evidence that activation of the pro-
apoptotic protein BIM is essential for efficient VPA/HU-induced tumour cell death. This 
result is applicable to therapy conditions because freshly isolated tumour cells from HNSCC 
patients responded to VPA/HU administered at therapeutically achievable levels with BIM 
induction and apoptosis. Additionally, ectopic expression and RNAi experiments convincingly 
demonstrated that BIM is essential for VPA/HU-induced cancer cell death. Moreover, 
VPA/HU efficiently prevented progression of HNSCC tumours in nude mice correlating with 
enhanced BIM levels. BIM-evoked apoptosis is crucial for epithelial tumour cell death 
triggered by several anticancer therapeutics (Hendrickson et al., 2008; Tan et al., 2005). 
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HNSCC tumours are often characterised by deregulated EGFR signalling due to 
receptor overexpression, activating mutations in the receptor itself and/or downstream 
signalling cascades. In these cells survival is secured by the sequential phosphorylation and 
activation of MEK and ERK kinases, leading to stabilisation of MCL-1, activation of BCL-2, and 
degradation of BIM. Approaches interfering with EGFR signalling trigger apoptosis also by 
enhancing BIM expression (Hendrickson et al., 2008). Importantly, we demonstrate for the 
first time that VPA/HU treatment efficiently reduced not only EGFR levels, but also 
attenuated its cell surface localisation. The underlying mechanisms remain to be resolved in 
detail. These may include HU-induced replication arrest, known to attenuate oncogenic 
tyrosine kinase signalling (Shields et al., 2008), and/or the E3 ubiquitin ligase c-CBL, which 
controls EGFR ubiquitination and lysosomal degradation (Pennock and Wang, 2008).  
4.5.4 Perspectives 
BIM as well as SIRT1 are important regulators of cell fate and survival. Our findings and 
the literature suggest that inducing anti-apoptotic SIRT1 and lowering endogenous pro-
apoptotic factors like BIM is a common mechanism enhancing tumour cell survival and 
proliferation. Targeting both of these factors is of potential clinically relevance not only for 
HNSCC therapy.  
We described a so far completely new regulation mechanism for SIRT1. Our results add 
a new layer to the understanding how HuR regulates SIRT1 mRNA stability in response to 
protein acetylation. HDACi critically influence HuR phosphorylation and mRNA stability of 
SIRT1. Similar regulatory processes might apply to other enzymes and modulators. Hence, 
the view on whether HDACi target class III HDACs requires a re-evaluation. Additionally we 
found that the pro-apoptotic BIM is enhanced upon HDACi treatment especially by 
transcriptional induction in an AP1-dependent manner. 
Although we have shown that BIM plays a major role in apoptotic signalling, this does 
not rule out the additional participation of other BCL-2 family members and/or other 
apoptosis-regulating proteins like SIRT1 (Li et al., 2009; Lippert et al., 2007). The induction of 
BIM alone may not be sufficient for significant tumour cell death, as BIM is more likely to act 
in concert with other BH3-only proteins, or other death pathways, when new targeted 
therapeutics are used in combination with traditional chemotherapy agents (Gillings et al., 
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2009). Residual apoptosis rates of HU/VPA-treated cells with attenuated BIM expression are 
probably mediated via alternative pro-apoptotic proteins and/or the activation of the 
extrinsic pathway (Gillenwater et al., 2007; Inoue et al., 2008). However, the mechanisms of 
HDAC inhibitor-induced apoptosis are incompletely understood. Several pathways are 
accounted for this effect. Whose of their contributing factors or the interplay of all/subgroup 
factors concur to the apoptotic effects needs to be investigated further.  
Additionally, we show for the first time the potent tumour cell killing activity of 
combining the HDACi VPA with the ribonucleotide reductase inhibitor HU against HNSCC. 
Although VPA and HU individually have been shown to target cancer cells in various 
malignancies (Lane and Chabner, 2009; Seiwert et al., 2008), the (pre)clinical anti-tumour 
activity of the VPA/HU combination for HNSCC und the underlying molecular mechanisms 
have not been investigated so far.  
SIRT1 has been reported to be involved in the acetylation of FOXOs and the expression 
of BIM (Brunet et al., 2004; Motta et al., 2004; Yang et al., 2005). HDACi treatment, which 
decreases SIRT1, favours the acetylation of FOXO1 which in turn activates BIM expression. 
This pathway is able to induce apoptosis in response to treatment with the HDACi 
depsipeptide (Yang et al., 2009). BIM, a BH3-only pro-apoptotic protein, was significantly 
upregulated by depsipeptide in cancer cells, and BIM's function in depsipeptide-induced 
apoptosis was confirmed by knockdown of BIM with RNAi. Thus, it is important to clarify 
whether acetylation of FOXO1 is involved in HDAC inhibitor-induced apoptosis via SIRT1 and 
BIM. 
Both, SIRT1 and BIM, are critical regulators of apoptosis and cell fate. We showed that 
both of them can be targeted by HDACi. The underlying mechanisms that alter gene 
expression differ extremely. We could show that in the case of SIRT1, HDACi critically reduce 
mRNA stability by modulating the binding affinity and localisation of HuR. On the other 
hand, BIM expression is up-regulated at the transcriptional level in an AP1-dependent 
manner. The parallel change in expression favours conditions that enhance apoptosis 
especially of tumour cells (see Figure 14). This amplifies the cancer specific effects of HDACi 
treatment and is able to sensitise cancer cells towards the additional treatment with other 
chemotherapeutics providing a basis therapy with less side effects. 
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Figure 14 HDACi affect cancer cell death by a parallel regulation of SIRT1 and BIM 
HDACi down-regulate SIRT1 expression posttranscriptionally. In this case (left side), the shift in acetylation status of the cell 
alters the subcellular HuR localisation as well as its binding affinity towards SIRT1 mRNA. On the other hand (right side), 
HDACi increase BIM expression by enhancing BIM transcription in an AP1-dependent manner. Both proteins regulate 
apoptosis. Both changes in gene expression (SIRT1 = downregulated / BIM = upregulated) favour the induction of apoptosis 
– resulting in an enhanced apoptosis rate of cancer cells. 
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Supplementary Figure 1 Detection of miR34a after 24h HDACi and SIRTi inhibitor treatment of 293 and NB4 
cells. 
Whole RNA was isolated from 24h treated cells (3mM Butyrate, 3mM VPA, 100nM TSA and 5mM 
Nicotinamide). 30µg were separated on a denaturating Northern Blot gel for small RNAs. After semidryblotting 
onto a nitrocellulose membrane – the membrane was hybridised for 16h at 42°C with radiolabeled (P32) RNA 
probes to detect miR-34a. The same gel, stained with Ethidium bromide, served as loading control to ensure 
equal sample loading (lower panel). 
 
 
